_id,cohorts.0.id,cohorts.0.label,dataUseConditions.id,dataUseConditions.label,description,externalReferences.0.id,externalReferences.0.label,histologicalDiagnosis.id,histologicalDiagnosis.label,icdoMorphology.id,icdoMorphology.label,icdoTopography.id,icdoTopography.label,id,individualAgeAtCollection,individual_id,info.callsetIds.0,info.cnvstatistics.cnvcoverage,info.cnvstatistics.cnvfraction,info.cnvstatistics.delcoverage,info.cnvstatistics.delfraction,info.cnvstatistics.dupcoverage,info.cnvstatistics.dupfraction,info.legacyId.0,pathologicalStage,provenance.geoLocation.geometry.coordinates.0,provenance.geoLocation.geometry.coordinates.1,provenance.geoLocation.geometry.type,provenance.geoLocation.properties.ISO3166alpha3,provenance.geoLocation.properties.city,provenance.geoLocation.properties.country,provenance.geoLocation.properties.label,provenance.geoLocation.properties.latitude,provenance.geoLocation.properties.longitude,provenance.geoLocation.properties.precision,provenance.geoLocation.type,provenance.material.id,provenance.material.label,sampledTissue.id,sampledTissue.label,tumorGrade,updated,info.tnm,pathologicalStage.id,pathologicalStage.label,pathologicalTnmFindings.0.id,pathologicalTnmFindings.0.label,pathologicalTnmFindings.1.id,pathologicalTnmFindings.1.label,pathologicalTnmFindings.2.id,pathologicalTnmFindings.2.label,tumorGrade.id,tumorGrade.label,info.death,info.followupMonths,pathologicalTnmFindings.3.id,pathologicalTnmFindings.3.label,externalReferences.1.id,externalReferences.1.label,cohorts.1.id,cohorts.1.label,cohorts.2.id,cohorts.2.label,cohorts.3.id,cohorts.3.label,externalReferences.2.id,externalReferences.2.label,externalReferences.3.id,externalReferences.3.label,externalReferences.0.description,externalReferences.1.description,externalReferences.2.description,info.callsetIds.1,info.tumorStage,info.callsetIds.2,cohorts.4.id,cohorts.4.label,externalReferences.3.description,externalReferences.4.description,externalReferences.4.id,externalReferences.4.label,info.provenance,provenance.populations.0.confidence,provenance.populations.0.description,provenance.populations.0.type.id,provenance.populations.0.type.label,provenance.populations.1.confidence,provenance.populations.1.description,provenance.populations.1.type.id,provenance.populations.1.type.label,info.samplesource,info.seer,info.cellLine,provenance.geo.ISO3166alpha3,provenance.geo.city,provenance.geo.country,provenance.geo.geojson,provenance.geo.label,provenance.geo.latitude,provenance.geo.longitude,provenance.geo.precision,sex,biosample_id,group_id,group_label,callset_ids,external_references_id___PMID,external_references_label___PMID,external_references_id___arrayexpress,external_references_label___arrayexpress,external_references_id___cbioportal,external_references_label___cbioportal,external_references_id___cellosaurus,external_references_label___cellosaurus,legacy_ids,notes,histological_diagnosis_id,histological_diagnosis_label,icdo_morphology_id,icdo_morphology_label,icdo_topography_id,icdo_topography_label,pathological_stage_id,pathological_stage_label,biosample_status_id,biosample_status_label,sampled_tissue_id,sampled_tissue_label,tnm,stage,grade,age_iso,sex_id,sex_label,followup_state_id,followup_state_label,followup_time,geoprov_city,geoprov_country,geoprov_iso_alpha3,geoprov_long_lat,cnv_fraction,cnv_del_fraction,cnv_dup_fraction,cell_line,experiment_id,series_id,platform_id,cell_line_id,cell_line_label,gene_source
5bab56c4727983b2e00acaa0,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,hepatocellular carcinoma [hepatitis C liver cirrhosis],PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C3099,Hepatocellular Carcinoma,icdom-81703,"Hepatocellular carcinoma, NOS",icdot-C22.0,Liver,pgxbs-kftvgr20,P59Y,pgxind-kftx2j0u,pgxcs-kftvoo5e,675635647,0.235,426803231,0.148,248832416,0.087,PGX_AM_BS_HCC-CC-hom-28,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:17.425000,T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,,,,,0,84.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr20,,,pgxcs-kftvoo5e,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-28,hepatocellular carcinoma [hepatitis C liver cirrhosis],NCIT:C3099,Hepatocellular Carcinoma,pgx:icdom-81703,"Hepatocellular carcinoma, NOS",pgx:icdot-C22.0,Liver,NCIT:C27966,Stage I,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P59Y,,,EFO:0030041,alive (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,CDKN2A
5bab56c4727983b2e00acaa1,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,hepatocellular carcinoma [alcoholic cirrhosis],PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C3099,Hepatocellular Carcinoma,icdom-81703,"Hepatocellular carcinoma, NOS",icdot-C22.0,Liver,pgxbs-kftvgr21,P57Y,pgxind-kftx2j0w,pgxcs-kftvoo5v,531165596,0.185,337926766,0.118,193238830,0.067,PGX_AM_BS_HCC-CC-hom-29,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:17.426000,T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,,,,,0,105.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr21,,,pgxcs-kftvoo5v,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-29,hepatocellular carcinoma [alcoholic cirrhosis],NCIT:C3099,Hepatocellular Carcinoma,pgx:icdom-81703,"Hepatocellular carcinoma, NOS",pgx:icdot-C22.0,Liver,NCIT:C27966,Stage I,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P57Y,,,EFO:0030041,alive (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,CDKN2A
5bab56c4727983b2e00acaaa,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,hepatocellular carcinoma [alcoholic cirrhosis],PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C3099,Hepatocellular Carcinoma,icdom-81703,"Hepatocellular carcinoma, NOS",icdot-C22.0,Liver,pgxbs-kftvgr2g,P62Y,pgxind-kftx2j1f,pgxcs-kftvooa6,319888676,0.111,97000096,0.034,222888580,0.078,PGX_AM_BS_HCC-CC-hom-38,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:17.438000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,0,64.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr2g,,,pgxcs-kftvooa6,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-38,hepatocellular carcinoma [alcoholic cirrhosis],NCIT:C3099,Hepatocellular Carcinoma,pgx:icdom-81703,"Hepatocellular carcinoma, NOS",pgx:icdot-C22.0,Liver,NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P62Y,,,EFO:0030041,alive (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,CDKN2A
5bab56c4727983b2e00acab6,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,hepatocellular carcinoma,PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C3099,Hepatocellular Carcinoma,icdom-81703,"Hepatocellular carcinoma, NOS",icdot-C22.0,Liver,pgxbs-kftvgr2z,P58Y,pgxind-kftx2j23,pgxcs-kftvoofy,664391300,0.231,532041633,0.185,132349667,0.046,PGX_AM_BS_HCC-CC-hom-50,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:17.455000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,0,121.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr2z,,,pgxcs-kftvoofy,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-50,hepatocellular carcinoma,NCIT:C3099,Hepatocellular Carcinoma,pgx:icdom-81703,"Hepatocellular carcinoma, NOS",pgx:icdot-C22.0,Liver,NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P58Y,,,EFO:0030041,alive (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,CDKN2A
5bab56c4727983b2e00acaac,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,hepatocellular carcinoma,PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C3099,Hepatocellular Carcinoma,icdom-81703,"Hepatocellular carcinoma, NOS",icdot-C22.0,Liver,pgxbs-kftvgr2j,P71Y,pgxind-kftx2j1j,pgxcs-kftvoob5,890799053,0.31,700092712,0.244,190706341,0.066,PGX_AM_BS_HCC-CC-hom-40,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:17.441000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,1,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgr2j,,,pgxcs-kftvoob5,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-40,hepatocellular carcinoma,NCIT:C3099,Hepatocellular Carcinoma,pgx:icdom-81703,"Hepatocellular carcinoma, NOS",pgx:icdot-C22.0,Liver,NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P71Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,CDKN2A
5bab56c4727983b2e00acabb,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,hepatocellular carcinoma [hepatitis C liver cirrhosis],PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C3099,Hepatocellular Carcinoma,icdom-81703,"Hepatocellular carcinoma, NOS",icdot-C22.0,Liver,pgxbs-kftvgr37,P50Y,pgxind-kftx2j2e,pgxcs-kftvooic,908099431,0.316,908099431,0.316,0,0.0,PGX_AM_BS_HCC-CC-hom-55,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:17.462000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,1,45.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr37,,,pgxcs-kftvooic,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-55,hepatocellular carcinoma [hepatitis C liver cirrhosis],NCIT:C3099,Hepatocellular Carcinoma,pgx:icdom-81703,"Hepatocellular carcinoma, NOS",pgx:icdot-C22.0,Liver,NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P50Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,CDKN2A
5bab56c4727983b2e00acabf,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,hepatocellular carcinoma [hepatitis C liver cirrhosis],PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C3099,Hepatocellular Carcinoma,icdom-81703,"Hepatocellular carcinoma, NOS",icdot-C22.0,Liver,pgxbs-kftvgr3e,P69Y,pgxind-kftx2j2m,pgxcs-kftvookc,1218243640,0.424,963390994,0.335,254852646,0.089,PGX_AM_BS_HCC-CC-hom-59,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:17.467000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,1,27.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr3e,,,pgxcs-kftvookc,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-59,hepatocellular carcinoma [hepatitis C liver cirrhosis],NCIT:C3099,Hepatocellular Carcinoma,pgx:icdom-81703,"Hepatocellular carcinoma, NOS",pgx:icdot-C22.0,Liver,NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P69Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,CDKN2A
5bab56c4727983b2e00acac0,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,hepatocellular carcinoma,PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C3099,Hepatocellular Carcinoma,icdom-81703,"Hepatocellular carcinoma, NOS",icdot-C22.0,Liver,pgxbs-kftvgr3g,P52Y,pgxind-kftx2j2o,pgxcs-kftvookt,1713545214,0.596,1125009313,0.391,588535901,0.205,PGX_AM_BS_HCC-CC-hom-60,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:17.469000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,1,48.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr3g,,,pgxcs-kftvookt,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-60,hepatocellular carcinoma,NCIT:C3099,Hepatocellular Carcinoma,pgx:icdom-81703,"Hepatocellular carcinoma, NOS",pgx:icdot-C22.0,Liver,NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P52Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,CDKN2A
5bab56c4727983b2e00acac6,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,hepatocellular carcinoma [hepatitis B liver cirrhosis],PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C3099,Hepatocellular Carcinoma,icdom-81703,"Hepatocellular carcinoma, NOS",icdot-C22.0,Liver,pgxbs-kftvgr3p,P60Y,pgxind-kftx2j30,pgxcs-kftvoonr,536768118,0.187,351382248,0.122,185385870,0.064,PGX_AM_BS_HCC-CC-hom-66,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:17.477000,T4,NCITstage-C27971,Stage IV,TNM-C48732,T4 Stage Finding,,,,,,,1,3.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr3p,,,pgxcs-kftvoonr,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-66,hepatocellular carcinoma [hepatitis B liver cirrhosis],NCIT:C3099,Hepatocellular Carcinoma,pgx:icdom-81703,"Hepatocellular carcinoma, NOS",pgx:icdot-C22.0,Liver,NCIT:C27971,Stage IV,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P60Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,CDKN2A
5bab56c4727983b2e00acac9,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,hepatocellular carcinoma [hemochromatosis-related cirrhosis],PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C3099,Hepatocellular Carcinoma,icdom-81703,"Hepatocellular carcinoma, NOS",icdot-C22.0,Liver,pgxbs-kftvgr3u,P57Y,pgxind-kftx2j36,pgxcs-kftvoop9,917772362,0.319,685581108,0.238,232191254,0.081,PGX_AM_BS_HCC-CC-hom-69,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:17.481000,T4,NCITstage-C27971,Stage IV,TNM-C48732,T4 Stage Finding,,,,,,,1,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr3u,,,pgxcs-kftvoop9,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-69,hepatocellular carcinoma [hemochromatosis-related cirrhosis],NCIT:C3099,Hepatocellular Carcinoma,pgx:icdom-81703,"Hepatocellular carcinoma, NOS",pgx:icdot-C22.0,Liver,NCIT:C27971,Stage IV,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P57Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,CDKN2A
5bab56c4727983b2e00aca85,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,cholangiocarcinoma,PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C35417,Intrahepatic Cholangiocarcinoma,icdom-81603,Cholangiocarcinoma,icdot-C22.1,intrahepatic bile ducts,pgxbs-kftvgr0s,P71Y,pgxind-kftx2izb,pgxcs-kftvonq2,864256101,0.301,537058772,0.187,327197329,0.114,PGX_AM_BS_HCC-CC-hom-01,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,{},2020-09-10 17:44:17.386000,T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,,,,,1,7.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgr0s,,,pgxcs-kftvonq2,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-01,cholangiocarcinoma,NCIT:C35417,Intrahepatic Cholangiocarcinoma,pgx:icdom-81603,Cholangiocarcinoma,pgx:icdot-C22.1,Intrahepatic bile duct,NCIT:C27966,Stage I,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,,,,P71Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,CDKN2A
5bab56c4727983b2e00aca8a,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,cholangiocarcinoma,PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C35417,Intrahepatic Cholangiocarcinoma,icdom-81603,Cholangiocarcinoma,icdot-C22.1,intrahepatic bile ducts,pgxbs-kftvgr10,P40Y,pgxind-kftx2izl,pgxcs-kftvonur,735130079,0.256,576308496,0.2,158821583,0.055,PGX_AM_BS_HCC-CC-hom-06,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,{},2020-09-10 17:44:17.393000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,1,44.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr10,,,pgxcs-kftvonur,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-06,cholangiocarcinoma,NCIT:C35417,Intrahepatic Cholangiocarcinoma,pgx:icdom-81603,Cholangiocarcinoma,pgx:icdot-C22.1,Intrahepatic bile duct,NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,,,,P40Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,CDKN2A
5bab56c4727983b2e00aca8b,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,cholangiocarcinoma,PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C35417,Intrahepatic Cholangiocarcinoma,icdom-81603,Cholangiocarcinoma,icdot-C22.1,intrahepatic bile ducts,pgxbs-kftvgr12,P62Y,pgxind-kftx2izn,pgxcs-kftvonv8,1127228510,0.392,711757136,0.248,415471374,0.145,PGX_AM_BS_HCC-CC-hom-07,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,{},2020-09-10 17:44:17.395000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,1,10.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr12,,,pgxcs-kftvonv8,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-07,cholangiocarcinoma,NCIT:C35417,Intrahepatic Cholangiocarcinoma,pgx:icdom-81603,Cholangiocarcinoma,pgx:icdot-C22.1,Intrahepatic bile duct,NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,,,,P62Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,CDKN2A
5bab56c4727983b2e00aca8c,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,cholangiocarcinoma,PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C35417,Intrahepatic Cholangiocarcinoma,icdom-81603,Cholangiocarcinoma,icdot-C22.1,intrahepatic bile ducts,pgxbs-kftvgr14,P59Y,pgxind-kftx2izp,pgxcs-kftvonvp,1700678516,0.592,747651812,0.26,953026704,0.331,PGX_AM_BS_HCC-CC-hom-08,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,{},2020-09-10 17:44:17.396000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,1,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr14,,,pgxcs-kftvonvp,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-08,cholangiocarcinoma,NCIT:C35417,Intrahepatic Cholangiocarcinoma,pgx:icdom-81603,Cholangiocarcinoma,pgx:icdot-C22.1,Intrahepatic bile duct,NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,,,,P59Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,CDKN2A
5bab56c4727983b2e00aca8d,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,cholangiocarcinoma,PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C35417,Intrahepatic Cholangiocarcinoma,icdom-81603,Cholangiocarcinoma,icdot-C22.1,intrahepatic bile ducts,pgxbs-kftvgr15,P74Y,pgxind-kftx2izr,pgxcs-kftvonw8,1809115968,0.629,864292341,0.301,944823627,0.329,PGX_AM_BS_HCC-CC-hom-09,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,{},2020-09-10 17:44:17.398000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,1,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgr15,,,pgxcs-kftvonw8,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-09,cholangiocarcinoma,NCIT:C35417,Intrahepatic Cholangiocarcinoma,pgx:icdom-81603,Cholangiocarcinoma,pgx:icdot-C22.1,Intrahepatic bile duct,NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,,,,P74Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,CDKN2A
5bab56c4727983b2e00aca92,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,cholangiocarcinoma,PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C35417,Intrahepatic Cholangiocarcinoma,icdom-81603,Cholangiocarcinoma,icdot-C22.1,intrahepatic bile ducts,pgxbs-kftvgr1d,P78Y,pgxind-kftx2j01,pgxcs-kftvonym,1127745488,0.392,848282109,0.295,279463379,0.097,PGX_AM_BS_HCC-CC-hom-14,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,{},2020-09-10 17:44:17.405000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,1,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr1d,,,pgxcs-kftvonym,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-14,cholangiocarcinoma,NCIT:C35417,Intrahepatic Cholangiocarcinoma,pgx:icdom-81603,Cholangiocarcinoma,pgx:icdot-C22.1,Intrahepatic bile duct,NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,,,,P78Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,CDKN2A
5bab56c4727983b2e00aca93,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,cholangiocarcinoma,PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C35417,Intrahepatic Cholangiocarcinoma,icdom-81603,Cholangiocarcinoma,icdot-C22.1,intrahepatic bile ducts,pgxbs-kftvgr1f,P65Y,pgxind-kftx2j03,pgxcs-kftvonz4,1099519139,0.382,828566477,0.288,270952662,0.094,PGX_AM_BS_HCC-CC-hom-15,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,{},2020-09-10 17:44:17.406000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,1,12.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr1f,,,pgxcs-kftvonz4,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-15,cholangiocarcinoma,NCIT:C35417,Intrahepatic Cholangiocarcinoma,pgx:icdom-81603,Cholangiocarcinoma,pgx:icdot-C22.1,Intrahepatic bile duct,NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,,,,P65Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,CDKN2A
5bab56c4727983b2e00aca95,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,cholangiocarcinoma,PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C35417,Intrahepatic Cholangiocarcinoma,icdom-81603,Cholangiocarcinoma,icdot-C22.1,intrahepatic bile ducts,pgxbs-kftvgr1i,P65Y,pgxind-kftx2j07,pgxcs-kftvoo03,2034365127,0.708,988111601,0.344,1046253526,0.364,PGX_AM_BS_HCC-CC-hom-17,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,{},2020-09-10 17:44:17.409000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,1,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgr1i,,,pgxcs-kftvoo03,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-17,cholangiocarcinoma,NCIT:C35417,Intrahepatic Cholangiocarcinoma,pgx:icdom-81603,Cholangiocarcinoma,pgx:icdot-C22.1,Intrahepatic bile duct,NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,,,,P65Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,CDKN2A
5bab56c4727983b2e00aca96,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,cholangiocarcinoma,PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C35417,Intrahepatic Cholangiocarcinoma,icdom-81603,Cholangiocarcinoma,icdot-C22.1,intrahepatic bile ducts,pgxbs-kftvgr1k,P36Y,pgxind-kftx2j0a,pgxcs-kftvoo0l,633016973,0.22,498624480,0.173,134392493,0.047,PGX_AM_BS_HCC-CC-hom-18,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,{},2020-09-10 17:44:17.411000,T4,NCITstage-C27971,Stage IV,TNM-C48732,T4 Stage Finding,,,,,,,1,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgr1k,,,pgxcs-kftvoo0l,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-18,cholangiocarcinoma,NCIT:C35417,Intrahepatic Cholangiocarcinoma,pgx:icdom-81603,Cholangiocarcinoma,pgx:icdot-C22.1,Intrahepatic bile duct,NCIT:C27971,Stage IV,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,,,,P36Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,CDKN2A
5bab56c4727983b2e00aca97,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,cholangiocarcinoma,PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C35417,Intrahepatic Cholangiocarcinoma,icdom-81603,Cholangiocarcinoma,icdot-C22.1,intrahepatic bile ducts,pgxbs-kftvgr1l,P60Y,pgxind-kftx2j0c,pgxcs-kftvoo12,1141738146,0.397,786770918,0.274,354967228,0.123,PGX_AM_BS_HCC-CC-hom-19,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,{},2020-09-10 17:44:17.412000,T4,NCITstage-C27971,Stage IV,TNM-C48732,T4 Stage Finding,,,,,,,1,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr1l,,,pgxcs-kftvoo12,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-19,cholangiocarcinoma,NCIT:C35417,Intrahepatic Cholangiocarcinoma,pgx:icdom-81603,Cholangiocarcinoma,pgx:icdot-C22.1,Intrahepatic bile duct,NCIT:C27971,Stage IV,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,,,,P60Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,CDKN2A
5bab56c4727983b2e00aca99,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,cholangiocarcinoma,PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C35417,Intrahepatic Cholangiocarcinoma,icdom-81603,Cholangiocarcinoma,icdot-C22.1,intrahepatic bile ducts,pgxbs-kftvgr1p,P58Y,pgxind-kftx2j0g,pgxcs-kftvoo22,1320396122,0.459,1016588232,0.354,303807890,0.106,PGX_AM_BS_HCC-CC-hom-21,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,{},2020-09-10 17:44:17.415000,T4,NCITstage-C27971,Stage IV,TNM-C48732,T4 Stage Finding,,,,,,,1,16.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgr1p,,,pgxcs-kftvoo22,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-21,cholangiocarcinoma,NCIT:C35417,Intrahepatic Cholangiocarcinoma,pgx:icdom-81603,Cholangiocarcinoma,pgx:icdot-C22.1,Intrahepatic bile duct,NCIT:C27971,Stage IV,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,,,,P58Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,CDKN2A
5bab56c4727983b2e00aca9a,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,cholangiocarcinoma,PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C35417,Intrahepatic Cholangiocarcinoma,icdom-81603,Cholangiocarcinoma,icdot-C22.1,intrahepatic bile ducts,pgxbs-kftvgr1q,P62Y,pgxind-kftx2j0i,pgxcs-kftvoo2j,1263444464,0.439,830611806,0.289,432832658,0.151,PGX_AM_BS_HCC-CC-hom-22,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,{},2020-09-10 17:44:17.416000,T4,NCITstage-C27971,Stage IV,TNM-C48732,T4 Stage Finding,,,,,,,1,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr1q,,,pgxcs-kftvoo2j,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-22,cholangiocarcinoma,NCIT:C35417,Intrahepatic Cholangiocarcinoma,pgx:icdom-81603,Cholangiocarcinoma,pgx:icdot-C22.1,Intrahepatic bile duct,NCIT:C27971,Stage IV,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,,,,P62Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,CDKN2A
5bab56cc727983b2e00b07e8,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,hepatoblastoma [Embryonal],PMID:11509117,"Kumon K, Kobayashi H et al. (2001): Frequent increase of DNA copy number...",NCIT:C3728,Hepatoblastoma,icdom-89703,Hepatoblastoma,icdot-C22.0,Liver,pgxbs-kftvhb0v,P0Y7M,pgxind-kftx37k0,pgxcs-kftvuro9,717132114,0.249,0,0.0,717132114,0.249,PGX_AM_BS_HepBlast-kum-991,{},137.95,35.83,Point,JPN,Ina,Japan,"Ina, Japan",35.83,137.95,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:39.513000,,,,,,,,,,,,0,80.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvhb0v,,,pgxcs-kftvuro9,PMID:11509117,,,,,,,,PGX_AM_BS_HepBlast-kum-991,hepatoblastoma [Embryonal],NCIT:C3728,Hepatoblastoma,pgx:icdom-89703,Hepatoblastoma,pgx:icdot-C22.0,Liver,NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P0Y7M,,,EFO:0030041,alive (follow-up status),,Ina,Japan,JPN,137.95::35.83,,,,,,,,,,CDKN2A
5bab56c4727983b2e00acacf,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,combined hepatocellular carcinoma and cholangiocarcinoma,PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C3828,Combined Hepatocellular Carcinoma and Cholangiocarcinoma,icdom-81803,Combined hepatocellular carcinoma and cholangiocarcinoma,icdot-C22.1,intrahepatic bile ducts,pgxbs-kftvgr44,P54Y,pgxind-kftx2j3i,pgxcs-kftvoos8,1740523173,0.605,927580133,0.323,812943040,0.283,PGX_AM_BS_HCC-CC-hom-75,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,{},2020-09-10 17:44:17.490000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,0,10.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr44,,,pgxcs-kftvoos8,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-75,combined hepatocellular carcinoma and cholangiocarcinoma,NCIT:C3828,Combined Hepatocellular Carcinoma and Cholangiocarcinoma,pgx:icdom-81803,Combined hepatocellular carcinoma and cholangiocarcinoma,pgx:icdot-C22.1,Intrahepatic bile duct,NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,,,,P54Y,,,EFO:0030041,alive (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,CDKN2A
5bab56c6727983b2e00adaf6,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Squamous cell carcinoma [esophagus],PMID:17470683,"Hirasaki S, Noguchi T et al. (2007): BAC clones related to prognosis in...",NCIT:C4024,Esophageal Squamous Cell Carcinoma,icdom-80703,"Squamous cell carcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvgwah,,pgxind-kftx2pkh,pgxcs-kftvqang,2947212661,1.0,0,0.0,2947212661,1.0,PGX_AM_BS_EsSCC-hir-5,,131.5,33.28,Point,JPN,Beppu,Japan,"Beppu, Japan",33.28,131.5,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:23.211000,T1N1M0,NCITstage-C27966,Stage I,TNM-C48706,N1 Stage Finding,TNM-C48714,N3 Stage Finding,TNM-C48720,T1 Stage Finding,,,0,60.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pgxbs-kftvgwah,,,pgxcs-kftvqang,PMID:17470683,,,,,,,,PGX_AM_BS_EsSCC-hir-5,Squamous cell carcinoma [esophagus],NCIT:C4024,Esophageal Squamous Cell Carcinoma,pgx:icdom-80703,"Squamous cell carcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27966,Stage I,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,,,,EFO:0030041,alive (follow-up status),,Beppu,Japan,JPN,131.5::33.28,,,,,,,,,,CDKN2A
5bab56c6727983b2e00adaf9,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Squamous cell carcinoma [esophagus],PMID:17470683,"Hirasaki S, Noguchi T et al. (2007): BAC clones related to prognosis in...",NCIT:C4024,Esophageal Squamous Cell Carcinoma,icdom-80703,"Squamous cell carcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvgwam,,pgxind-kftx2pkn,pgxcs-kftvqaow,671618962,0.234,582984677,0.203,88634285,0.031,PGX_AM_BS_EsSCC-hir-9,,131.5,33.28,Point,JPN,Beppu,Japan,"Beppu, Japan",33.28,131.5,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:23.216000,T3N1M0,NCITstage-C27970,Stage III,TNM-C48706,N1 Stage Finding,TNM-C48714,N3 Stage Finding,TNM-C48728,T3 Stage Finding,,,0,60.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pgxbs-kftvgwam,,,pgxcs-kftvqaow,PMID:17470683,,,,,,,,PGX_AM_BS_EsSCC-hir-9,Squamous cell carcinoma [esophagus],NCIT:C4024,Esophageal Squamous Cell Carcinoma,pgx:icdom-80703,"Squamous cell carcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,,,,EFO:0030041,alive (follow-up status),,Beppu,Japan,JPN,131.5::33.28,,,,,,,,,,CDKN2A
5bab56c6727983b2e00adc69,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,squamous cell carcinoma [esophagus],PMID:17298740,"Wu SS, Liu JF et al. (2007): [Analyzing chromosomal abnormality in primary esophageal...",NCIT:C4024,Esophageal Squamous Cell Carcinoma,icdom-80703,"Squamous cell carcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvgwrb,,pgxind-kftx2q5j,pgxcs-kftvqft8,885343925,0.308,253694970,0.088,631648955,0.22,PGX_AM_BS_17298740_ESCC-wu-13,{},116.4,39.91,Point,CHN,Beijing,China,"Beijing, China",39.91,116.4,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:23.724000,,,,,,,,,,,,0,36.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pgxbs-kftvgwrb,,,pgxcs-kftvqft8,PMID:17298740,,,,,,,,PGX_AM_BS_17298740_ESCC-wu-13,squamous cell carcinoma [esophagus],NCIT:C4024,Esophageal Squamous Cell Carcinoma,pgx:icdom-80703,"Squamous cell carcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,,,,EFO:0030041,alive (follow-up status),,Beijing,China,CHN,116.4::39.91,,,,,,,,,,CDKN2A
5bab56c6727983b2e00adc6c,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,squamous cell carcinoma [esophagus],PMID:17298740,"Wu SS, Liu JF et al. (2007): [Analyzing chromosomal abnormality in primary esophageal...",NCIT:C4024,Esophageal Squamous Cell Carcinoma,icdom-80703,"Squamous cell carcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvgwrg,,pgxind-kftx2q5p,pgxcs-kftvqfw9,294190571,0.102,0,0.0,294190571,0.102,PGX_AM_BS_17298740_ESCC-wu-16,{},116.4,39.91,Point,CHN,Beijing,China,"Beijing, China",39.91,116.4,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:23.729000,,,,,,,,,,,,0,36.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pgxbs-kftvgwrg,,,pgxcs-kftvqfw9,PMID:17298740,,,,,,,,PGX_AM_BS_17298740_ESCC-wu-16,squamous cell carcinoma [esophagus],NCIT:C4024,Esophageal Squamous Cell Carcinoma,pgx:icdom-80703,"Squamous cell carcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,,,,EFO:0030041,alive (follow-up status),,Beijing,China,CHN,116.4::39.91,,,,,,,,,,CDKN2A
5bab56c6727983b2e00adae4,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Squamous cell carcinoma [esophagus],PMID:17470683,"Hirasaki S, Noguchi T et al. (2007): BAC clones related to prognosis in...",NCIT:C4024,Esophageal Squamous Cell Carcinoma,icdom-80703,"Squamous cell carcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvgw9n,,pgxind-kftx2pjg,pgxcs-kftvqaev,507328474,0.176,401414614,0.14,105913860,0.037,PGX_AM_BS_EsSCC-hir-12,,131.5,33.28,Point,JPN,Beppu,Japan,"Beppu, Japan",33.28,131.5,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:23.187000,T2N1M0,NCITstage-C28054,Stage II,TNM-C48706,N1 Stage Finding,TNM-C48714,N3 Stage Finding,TNM-C48724,T2 Stage Finding,,,1,3.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pgxbs-kftvgw9n,,,pgxcs-kftvqaev,PMID:17470683,,,,,,,,PGX_AM_BS_EsSCC-hir-12,Squamous cell carcinoma [esophagus],NCIT:C4024,Esophageal Squamous Cell Carcinoma,pgx:icdom-80703,"Squamous cell carcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,,,,EFO:0030049,dead (follow-up status),,Beppu,Japan,JPN,131.5::33.28,,,,,,,,,,CDKN2A
5bab56c6727983b2e00adaec,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Squamous cell carcinoma [esophagus],PMID:17470683,"Hirasaki S, Noguchi T et al. (2007): BAC clones related to prognosis in...",NCIT:C4024,Esophageal Squamous Cell Carcinoma,icdom-80703,"Squamous cell carcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvgwa1,,pgxind-kftx2pjx,pgxcs-kftvqain,670764696,0.233,624226012,0.217,46538684,0.016,PGX_AM_BS_EsSCC-hir-22,,131.5,33.28,Point,JPN,Beppu,Japan,"Beppu, Japan",33.28,131.5,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:23.197000,T2N0M0,NCITstage-C28054,Stage II,TNM-C48705,N0 Stage Finding,TNM-C48724,T2 Stage Finding,,,,,1,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pgxbs-kftvgwa1,,,pgxcs-kftvqain,PMID:17470683,,,,,,,,PGX_AM_BS_EsSCC-hir-22,Squamous cell carcinoma [esophagus],NCIT:C4024,Esophageal Squamous Cell Carcinoma,pgx:icdom-80703,"Squamous cell carcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,,,,EFO:0030049,dead (follow-up status),,Beppu,Japan,JPN,131.5::33.28,,,,,,,,,,CDKN2A
5bab56c6727983b2e00adaed,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Squamous cell carcinoma [esophagus],PMID:17470683,"Hirasaki S, Noguchi T et al. (2007): BAC clones related to prognosis in...",NCIT:C4024,Esophageal Squamous Cell Carcinoma,icdom-80703,"Squamous cell carcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvgwa2,,pgxind-kftx2pjz,pgxcs-kftvqaj4,260969797,0.091,228569766,0.08,32400031,0.011,PGX_AM_BS_EsSCC-hir-23,,131.5,33.28,Point,JPN,Beppu,Japan,"Beppu, Japan",33.28,131.5,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:23.199000,T4N1M0,NCITstage-C27971,Stage IV,TNM-C48706,N1 Stage Finding,TNM-C48714,N3 Stage Finding,TNM-C48732,T4 Stage Finding,,,1,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pgxbs-kftvgwa2,,,pgxcs-kftvqaj4,PMID:17470683,,,,,,,,PGX_AM_BS_EsSCC-hir-23,Squamous cell carcinoma [esophagus],NCIT:C4024,Esophageal Squamous Cell Carcinoma,pgx:icdom-80703,"Squamous cell carcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27971,Stage IV,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,,,,EFO:0030049,dead (follow-up status),,Beppu,Japan,JPN,131.5::33.28,,,,,,,,,,CDKN2A
5bab56c6727983b2e00adaf2,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Squamous cell carcinoma [esophagus],PMID:17470683,"Hirasaki S, Noguchi T et al. (2007): BAC clones related to prognosis in...",NCIT:C4024,Esophageal Squamous Cell Carcinoma,icdom-80703,"Squamous cell carcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvgwaa,,pgxind-kftx2pk9,pgxcs-kftvqali,679754120,0.236,433314986,0.151,246439134,0.086,PGX_AM_BS_EsSCC-hir-28,,131.5,33.28,Point,JPN,Beppu,Japan,"Beppu, Japan",33.28,131.5,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:23.205000,T3N1M0,NCITstage-C27970,Stage III,TNM-C48706,N1 Stage Finding,TNM-C48714,N3 Stage Finding,TNM-C48728,T3 Stage Finding,,,1,7.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pgxbs-kftvgwaa,,,pgxcs-kftvqali,PMID:17470683,,,,,,,,PGX_AM_BS_EsSCC-hir-28,Squamous cell carcinoma [esophagus],NCIT:C4024,Esophageal Squamous Cell Carcinoma,pgx:icdom-80703,"Squamous cell carcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,,,,EFO:0030049,dead (follow-up status),,Beppu,Japan,JPN,131.5::33.28,,,,,,,,,,CDKN2A
5bab56c6727983b2e00adc60,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,squamous cell carcinoma [esophagus],PMID:17298740,"Wu SS, Liu JF et al. (2007): [Analyzing chromosomal abnormality in primary esophageal...",NCIT:C4024,Esophageal Squamous Cell Carcinoma,icdom-80703,"Squamous cell carcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvgwqw,,pgxind-kftx2q51,pgxcs-kftvqfox,837182526,0.291,581990054,0.202,255192472,0.089,PGX_AM_BS_17298740_ESCC-wu-04,{},116.4,39.91,Point,CHN,Beijing,China,"Beijing, China",39.91,116.4,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:23.711000,,,,,,,,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pgxbs-kftvgwqw,,,pgxcs-kftvqfox,PMID:17298740,,,,,,,,PGX_AM_BS_17298740_ESCC-wu-04,squamous cell carcinoma [esophagus],NCIT:C4024,Esophageal Squamous Cell Carcinoma,pgx:icdom-80703,"Squamous cell carcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,,,,EFO:0030049,dead (follow-up status),,Beijing,China,CHN,116.4::39.91,,,,,,,,,,CDKN2A
5bab56cb727983b2e00afcb5,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Esophageal squamous cell carcinoma,PMID:12419583,"Wei F, Ni J, Wu SS et al. (2002): Cytogenetic studies of esophageal squamous cell...",NCIT:C4024,Esophageal Squamous Cell Carcinoma,icdom-80703,"Squamous cell carcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvh7fj,,pgxind-kftx3326,pgxcs-kftvtnho,456451805,0.159,216217369,0.075,240234436,0.084,PGX_AM_BS_EsSCC-03,,116.4,39.91,Point,CHN,Beijing,China,"Beijing, China",39.91,116.4,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:35.555000,T3N1M0,NCITstage-C27970,Stage III,TNM-C48706,N1 Stage Finding,TNM-C48714,N3 Stage Finding,TNM-C48728,T3 Stage Finding,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvh7fj,,,pgxcs-kftvtnho,PMID:12419583,,,,,,,,PGX_AM_BS_EsSCC-03,Esophageal squamous cell carcinoma,NCIT:C4024,Esophageal Squamous Cell Carcinoma,pgx:icdom-80703,"Squamous cell carcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,,,,EFO:0030049,dead (follow-up status),,Beijing,China,CHN,116.4::39.91,,,,,,,,,,CDKN2A
5bab56cb727983b2e00afcbb,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Esophageal squamous cell carcinoma,PMID:12419583,"Wei F, Ni J, Wu SS et al. (2002): Cytogenetic studies of esophageal squamous cell...",NCIT:C4024,Esophageal Squamous Cell Carcinoma,icdom-80703,"Squamous cell carcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvh7ft,,pgxind-kftx332i,pgxcs-kftvtnkl,450356352,0.157,204060545,0.071,246295807,0.086,PGX_AM_BS_EsSCC-09,,116.4,39.91,Point,CHN,Beijing,China,"Beijing, China",39.91,116.4,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:35.564000,T3N0M0,NCITstage-C27970,Stage III,TNM-C48705,N0 Stage Finding,TNM-C48728,T3 Stage Finding,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvh7ft,,,pgxcs-kftvtnkl,PMID:12419583,,,,,,,,PGX_AM_BS_EsSCC-09,Esophageal squamous cell carcinoma,NCIT:C4024,Esophageal Squamous Cell Carcinoma,pgx:icdom-80703,"Squamous cell carcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,,,,EFO:0030049,dead (follow-up status),,Beijing,China,CHN,116.4::39.91,,,,,,,,,,CDKN2A
5bab56cb727983b2e00afcc4,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Esophageal squamous cell carcinoma,PMID:12419583,"Wei F, Ni J, Wu SS et al. (2002): Cytogenetic studies of esophageal squamous cell...",NCIT:C4024,Esophageal Squamous Cell Carcinoma,icdom-80703,"Squamous cell carcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvh7g7,,pgxind-kftx3330,pgxcs-kftvtnqy,1100263856,0.383,526678385,0.183,573585471,0.2,PGX_AM_BS_EsSCC-18,,116.4,39.91,Point,CHN,Beijing,China,"Beijing, China",39.91,116.4,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:35.576000,T2N0M0,NCITstage-C28054,Stage II,TNM-C48705,N0 Stage Finding,TNM-C48724,T2 Stage Finding,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvh7g7,,,pgxcs-kftvtnqy,PMID:12419583,,,,,,,,PGX_AM_BS_EsSCC-18,Esophageal squamous cell carcinoma,NCIT:C4024,Esophageal Squamous Cell Carcinoma,pgx:icdom-80703,"Squamous cell carcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,,,,EFO:0030049,dead (follow-up status),,Beijing,China,CHN,116.4::39.91,,,,,,,,,,CDKN2A
5bab56cb727983b2e00afcc5,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Esophageal squamous cell carcinoma,PMID:12419583,"Wei F, Ni J, Wu SS et al. (2002): Cytogenetic studies of esophageal squamous cell...",NCIT:C4024,Esophageal Squamous Cell Carcinoma,icdom-80703,"Squamous cell carcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvh7g9,,pgxind-kftx3332,pgxcs-kftvtnrf,1377000844,0.479,669167683,0.233,707833161,0.246,PGX_AM_BS_EsSCC-19,,116.4,39.91,Point,CHN,Beijing,China,"Beijing, China",39.91,116.4,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:35.578000,T3N1M0,NCITstage-C27970,Stage III,TNM-C48706,N1 Stage Finding,TNM-C48714,N3 Stage Finding,TNM-C48728,T3 Stage Finding,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvh7g9,,,pgxcs-kftvtnrf,PMID:12419583,,,,,,,,PGX_AM_BS_EsSCC-19,Esophageal squamous cell carcinoma,NCIT:C4024,Esophageal Squamous Cell Carcinoma,pgx:icdom-80703,"Squamous cell carcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,,,,EFO:0030049,dead (follow-up status),,Beijing,China,CHN,116.4::39.91,,,,,,,,,,CDKN2A
5bab56cb727983b2e00afcc7,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Esophageal squamous cell carcinoma,PMID:12419583,"Wei F, Ni J, Wu SS et al. (2002): Cytogenetic studies of esophageal squamous cell...",NCIT:C4024,Esophageal Squamous Cell Carcinoma,icdom-80703,"Squamous cell carcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvh7gc,,pgxind-kftx3336,pgxcs-kftvtnse,1059223676,0.368,225885965,0.079,833337711,0.29,PGX_AM_BS_EsSCC-21,,116.4,39.91,Point,CHN,Beijing,China,"Beijing, China",39.91,116.4,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:35.581000,T3N1M0,NCITstage-C27970,Stage III,TNM-C48706,N1 Stage Finding,TNM-C48714,N3 Stage Finding,TNM-C48728,T3 Stage Finding,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvh7gc,,,pgxcs-kftvtnse,PMID:12419583,,,,,,,,PGX_AM_BS_EsSCC-21,Esophageal squamous cell carcinoma,NCIT:C4024,Esophageal Squamous Cell Carcinoma,pgx:icdom-80703,"Squamous cell carcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,,,,EFO:0030049,dead (follow-up status),,Beijing,China,CHN,116.4::39.91,,,,,,,,,,CDKN2A
5bab56cb727983b2e00afcc8,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Esophageal squamous cell carcinoma,PMID:12419583,"Wei F, Ni J, Wu SS et al. (2002): Cytogenetic studies of esophageal squamous cell...",NCIT:C4024,Esophageal Squamous Cell Carcinoma,icdom-80703,"Squamous cell carcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvh7ge,,pgxind-kftx3338,pgxcs-kftvtnsw,754034079,0.262,143437542,0.05,610596537,0.212,PGX_AM_BS_EsSCC-22,,116.4,39.91,Point,CHN,Beijing,China,"Beijing, China",39.91,116.4,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:35.582000,T3N0M0,NCITstage-C27970,Stage III,TNM-C48705,N0 Stage Finding,TNM-C48728,T3 Stage Finding,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvh7ge,,,pgxcs-kftvtnsw,PMID:12419583,,,,,,,,PGX_AM_BS_EsSCC-22,Esophageal squamous cell carcinoma,NCIT:C4024,Esophageal Squamous Cell Carcinoma,pgx:icdom-80703,"Squamous cell carcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,,,,EFO:0030049,dead (follow-up status),,Beijing,China,CHN,116.4::39.91,,,,,,,,,,CDKN2A
5bab56cb727983b2e00afcc9,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Esophageal squamous cell carcinoma,PMID:12419583,"Wei F, Ni J, Wu SS et al. (2002): Cytogenetic studies of esophageal squamous cell...",NCIT:C4024,Esophageal Squamous Cell Carcinoma,icdom-80703,"Squamous cell carcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvh7gf,,pgxind-kftx333a,pgxcs-kftvtntd,1398202200,0.486,1049681830,0.365,348520370,0.121,PGX_AM_BS_EsSCC-23,,116.4,39.91,Point,CHN,Beijing,China,"Beijing, China",39.91,116.4,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:35.584000,T3N1M0,NCITstage-C27970,Stage III,TNM-C48706,N1 Stage Finding,TNM-C48714,N3 Stage Finding,TNM-C48728,T3 Stage Finding,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvh7gf,,,pgxcs-kftvtntd,PMID:12419583,,,,,,,,PGX_AM_BS_EsSCC-23,Esophageal squamous cell carcinoma,NCIT:C4024,Esophageal Squamous Cell Carcinoma,pgx:icdom-80703,"Squamous cell carcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,,,,EFO:0030049,dead (follow-up status),,Beijing,China,CHN,116.4::39.91,,,,,,,,,,CDKN2A
5bab56ce727983b2e00b197a,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,adenocarcinoma [esophagus],geo:GPL5711,,NCIT:C4025,Esophageal Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvhgyw,P73Y,pgxind-kftx3ekb,pgxcs-kftvwj3e,319338493,0.111,261241352,0.091,58097141,0.02,PGX_AM_BS_GSM265501,,153.02,-27.45,Point,AUS,Herston,Australia,"Herston, Australia",-27.45,153.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:45.732000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,0,38.0,,,geo:GSM265501,,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),pgxcohort-2021progenetix,Version at Progenetix Update 2021,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:GSE10506,,PMID:18519675,"Nancarrow DJ, Handoko HY et al. (2008): Genome-wide copy number analysis in esophageal...",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvhgyw,,,pgxcs-kftvwj3e,PMID:18519675,,,,,,,,PGX_AM_BS_GSM265501,adenocarcinoma [esophagus],NCIT:C4025,Esophageal Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,P73Y,,,EFO:0030041,alive (follow-up status),,Herston,Australia,AUS,153.02::-27.45,,,,,geo:GSM265501,geo:GSE10506,geo:GPL5711,,,CDKN2A
5bab56ce727983b2e00b197c,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,adenocarcinoma [esophagus],geo:GPL5711,,NCIT:C4025,Esophageal Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvhgyz,P62Y,pgxind-kftx3ekf,pgxcs-kftvwj4d,1050479893,0.365,690877763,0.24,359602130,0.125,PGX_AM_BS_GSM265808,,153.02,-27.45,Point,AUS,Herston,Australia,"Herston, Australia",-27.45,153.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:45.735000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,0,23.0,,,PMID:18519675,"Nancarrow DJ, Handoko HY et al. (2008): Genome-wide copy number analysis in esophageal...",pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),pgxcohort-2021progenetix,Version at Progenetix Update 2021,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:GSE10506,,geo:GSM265808,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvhgyz,,,pgxcs-kftvwj4d,PMID:18519675,,,,,,,,PGX_AM_BS_GSM265808,adenocarcinoma [esophagus],NCIT:C4025,Esophageal Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27968,Stage IIb,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,P62Y,,,EFO:0030041,alive (follow-up status),,Herston,Australia,AUS,153.02::-27.45,,,,,geo:GSM265808,geo:GSE10506,geo:GPL5711,,,CDKN2A
5bab56ce727983b2e00b197f,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,adenocarcinoma [esophagus],geo:GSM266119,,NCIT:C4025,Esophageal Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvhgz4,P55Y,pgxind-kftx3ekm,pgxcs-kftvwj5u,544614041,0.189,428561292,0.149,116052749,0.04,PGX_AM_BS_GSM266119,,153.02,-27.45,Point,AUS,Herston,Australia,"Herston, Australia",-27.45,153.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:45.739000,T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,,,,,0,19.0,,,geo:GSE10506,,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),pgxcohort-2021progenetix,Version at Progenetix Update 2021,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),PMID:18519675,"Nancarrow DJ, Handoko HY et al. (2008): Genome-wide copy number analysis in esophageal...",geo:GPL5711,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvhgz4,,,pgxcs-kftvwj5u,PMID:18519675,,,,,,,,PGX_AM_BS_GSM266119,adenocarcinoma [esophagus],NCIT:C4025,Esophageal Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27966,Stage I,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,P55Y,,,EFO:0030041,alive (follow-up status),,Herston,Australia,AUS,153.02::-27.45,,,,,geo:GSM266119,geo:GSE10506,geo:GPL5711,,,CDKN2A
5bab56ce727983b2e00b1980,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,adenocarcinoma [esophagus],geo:GPL5711,,NCIT:C4025,Esophageal Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvhgz5,P74Y,pgxind-kftx3eko,pgxcs-kftvwj6d,554221366,0.193,394588487,0.137,159632879,0.056,PGX_AM_BS_GSM266586,,153.02,-27.45,Point,AUS,Herston,Australia,"Herston, Australia",-27.45,153.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:45.741000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,0,21.0,,,geo:GSM266586,,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),pgxcohort-2021progenetix,Version at Progenetix Update 2021,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),PMID:18519675,"Nancarrow DJ, Handoko HY et al. (2008): Genome-wide copy number analysis in esophageal...",geo:GSE10506,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvhgz5,,,pgxcs-kftvwj6d,PMID:18519675,,,,,,,,PGX_AM_BS_GSM266586,adenocarcinoma [esophagus],NCIT:C4025,Esophageal Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27967,Stage IIa,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,P74Y,,,EFO:0030041,alive (follow-up status),,Herston,Australia,AUS,153.02::-27.45,,,,,geo:GSM266586,geo:GSE10506,geo:GPL5711,,,CDKN2A
5bab56ce727983b2e00b1983,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,adenocarcinoma [esophagus],geo:GPL5711,,NCIT:C4025,Esophageal Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvhgza,P69Y,pgxind-kftx3eku,pgxcs-kftvwj7u,830858339,0.289,480482392,0.167,350375947,0.122,PGX_AM_BS_GSM266661,,153.02,-27.45,Point,AUS,Herston,Australia,"Herston, Australia",-27.45,153.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:45.745000,T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,,,,,0,15.0,,,PMID:18519675,"Nancarrow DJ, Handoko HY et al. (2008): Genome-wide copy number analysis in esophageal...",pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),pgxcohort-2021progenetix,Version at Progenetix Update 2021,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:GSE10506,,geo:GSM266661,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvhgza,,,pgxcs-kftvwj7u,PMID:18519675,,,,,,,,PGX_AM_BS_GSM266661,adenocarcinoma [esophagus],NCIT:C4025,Esophageal Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27966,Stage I,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,P69Y,,,EFO:0030041,alive (follow-up status),,Herston,Australia,AUS,153.02::-27.45,,,,,geo:GSM266661,geo:GSE10506,geo:GPL5711,,,CDKN2A
5bab56ce727983b2e00b1984,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,adenocarcinoma [esophagus],geo:GPL5711,,NCIT:C4025,Esophageal Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvhgzc,P70Y,pgxind-kftx3ekw,pgxcs-kftvwj8c,1320407228,0.459,779640766,0.271,540766462,0.188,PGX_AM_BS_GSM266703,,153.02,-27.45,Point,AUS,Herston,Australia,"Herston, Australia",-27.45,153.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:45.747000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,0,38.0,,,geo:GSE10506,,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),pgxcohort-2021progenetix,Version at Progenetix Update 2021,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),PMID:18519675,"Nancarrow DJ, Handoko HY et al. (2008): Genome-wide copy number analysis in esophageal...",geo:GSM266703,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvhgzc,,,pgxcs-kftvwj8c,PMID:18519675,,,,,,,,PGX_AM_BS_GSM266703,adenocarcinoma [esophagus],NCIT:C4025,Esophageal Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,P70Y,,,EFO:0030041,alive (follow-up status),,Herston,Australia,AUS,153.02::-27.45,,,,,geo:GSM266703,geo:GSE10506,geo:GPL5711,,,CDKN2A
5bab56ce727983b2e00b1987,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,adenocarcinoma [esophagus],geo:GSM266707,,NCIT:C4025,Esophageal Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvhgzh,P78Y,pgxind-kftx3el2,pgxcs-kftvwj9t,1586895216,0.552,736921827,0.256,849973389,0.296,PGX_AM_BS_GSM266707,,153.02,-27.45,Point,AUS,Herston,Australia,"Herston, Australia",-27.45,153.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:45.751000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,0,15.0,,,PMID:18519675,"Nancarrow DJ, Handoko HY et al. (2008): Genome-wide copy number analysis in esophageal...",pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),pgxcohort-2021progenetix,Version at Progenetix Update 2021,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:GSE10506,,geo:GPL5711,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvhgzh,,,pgxcs-kftvwj9t,PMID:18519675,,,,,,,,PGX_AM_BS_GSM266707,adenocarcinoma [esophagus],NCIT:C4025,Esophageal Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27967,Stage IIa,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,P78Y,,,EFO:0030041,alive (follow-up status),,Herston,Australia,AUS,153.02::-27.45,,,,,geo:GSM266707,geo:GSE10506,geo:GPL5711,,,CDKN2A
5bab56ce727983b2e00b1989,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,adenocarcinoma [esophagus],geo:GSE10506,,NCIT:C4025,Esophageal Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvhgzk,P52Y,pgxind-kftx3el6,pgxcs-kftvwjas,1220457045,0.425,662770209,0.231,557686836,0.194,PGX_AM_BS_GSM266715,,153.02,-27.45,Point,AUS,Herston,Australia,"Herston, Australia",-27.45,153.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:45.754000,T4,NCITstage-C27971,Stage IV,TNM-C48732,T4 Stage Finding,,,,,,,0,29.0,,,PMID:18519675,"Nancarrow DJ, Handoko HY et al. (2008): Genome-wide copy number analysis in esophageal...",pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),pgxcohort-2021progenetix,Version at Progenetix Update 2021,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:GSM266715,,geo:GPL5711,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvhgzk,,,pgxcs-kftvwjas,PMID:18519675,,,,,,,,PGX_AM_BS_GSM266715,adenocarcinoma [esophagus],NCIT:C4025,Esophageal Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27966,Stage I,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,P52Y,,,EFO:0030041,alive (follow-up status),,Herston,Australia,AUS,153.02::-27.45,,,,,geo:GSM266715,geo:GSE10506,geo:GPL5711,,,CDKN2A
5bab56ce727983b2e00b1979,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,adenocarcinoma [esophagus],PMID:18519675,"Nancarrow DJ, Handoko HY et al. (2008): Genome-wide copy number analysis in esophageal...",NCIT:C4025,Esophageal Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvhgyu,P80Y,pgxind-kftx3ek9,pgxcs-kftvwj2w,961675959,0.334,542187873,0.189,419488086,0.146,PGX_AM_BS_GSM265500,{},153.02,-27.45,Point,AUS,Herston,Australia,"Herston, Australia",-27.45,153.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:45.731000,,,,,,,,,,,,1,12.0,,,geo:GSE10506,,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),pgxcohort-2021progenetix,Version at Progenetix Update 2021,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:GSM265500,,geo:GPL5711,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvhgyu,,,pgxcs-kftvwj2w,PMID:18519675,,,,,,,,PGX_AM_BS_GSM265500,adenocarcinoma [esophagus],NCIT:C4025,Esophageal Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,P80Y,,,EFO:0030049,dead (follow-up status),,Herston,Australia,AUS,153.02::-27.45,,,,,geo:GSM265500,geo:GSE10506,geo:GPL5711,,,CDKN2A
5bab56ce727983b2e00b197b,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,adenocarcinoma [esophagus],PMID:18519675,"Nancarrow DJ, Handoko HY et al. (2008): Genome-wide copy number analysis in esophageal...",NCIT:C4025,Esophageal Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvhgyx,P72Y,pgxind-kftx3ekd,pgxcs-kftvwj3w,1580009098,0.55,884423576,0.308,695585522,0.242,PGX_AM_BS_GSM265787,,153.02,-27.45,Point,AUS,Herston,Australia,"Herston, Australia",-27.45,153.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:45.733000,T4,NCITstage-C27971,Stage IV,TNM-C48732,T4 Stage Finding,,,,,,,1,2.0,,,geo:GSE10506,,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),pgxcohort-2021progenetix,Version at Progenetix Update 2021,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:GSM265787,,geo:GPL5711,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvhgyx,,,pgxcs-kftvwj3w,PMID:18519675,,,,,,,,PGX_AM_BS_GSM265787,adenocarcinoma [esophagus],NCIT:C4025,Esophageal Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27980,Stage IVb,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,P72Y,,,EFO:0030049,dead (follow-up status),,Herston,Australia,AUS,153.02::-27.45,,,,,geo:GSM265787,geo:GSE10506,geo:GPL5711,,,CDKN2A
5bab56ce727983b2e00b1981,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,adenocarcinoma [esophagus],geo:GPL5711,,NCIT:C4025,Esophageal Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvhgz7,P75Y,pgxind-kftx3ekq,pgxcs-kftvwj6u,1210003192,0.421,770821343,0.268,439181849,0.153,PGX_AM_BS_GSM266659,,153.02,-27.45,Point,AUS,Herston,Australia,"Herston, Australia",-27.45,153.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:45.742000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,1,9.0,,,geo:GSM266659,,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),pgxcohort-2021progenetix,Version at Progenetix Update 2021,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:GSE10506,,PMID:18519675,"Nancarrow DJ, Handoko HY et al. (2008): Genome-wide copy number analysis in esophageal...",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvhgz7,,,pgxcs-kftvwj6u,PMID:18519675,,,,,,,,PGX_AM_BS_GSM266659,adenocarcinoma [esophagus],NCIT:C4025,Esophageal Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,P75Y,,,EFO:0030049,dead (follow-up status),,Herston,Australia,AUS,153.02::-27.45,,,,,geo:GSM266659,geo:GSE10506,geo:GPL5711,,,CDKN2A
5bab56ce727983b2e00b1982,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,adenocarcinoma [esophagus],geo:GPL5711,,NCIT:C4025,Esophageal Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvhgz9,P65Y,pgxind-kftx3eks,pgxcs-kftvwj7c,931363932,0.324,496954362,0.173,434409570,0.151,PGX_AM_BS_GSM266660,,153.02,-27.45,Point,AUS,Herston,Australia,"Herston, Australia",-27.45,153.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:45.744000,T4,NCITstage-C27971,Stage IV,TNM-C48732,T4 Stage Finding,,,,,,,1,6.0,,,geo:GSM266660,,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),pgxcohort-2021progenetix,Version at Progenetix Update 2021,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:GSE10506,,PMID:18519675,"Nancarrow DJ, Handoko HY et al. (2008): Genome-wide copy number analysis in esophageal...",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvhgz9,,,pgxcs-kftvwj7c,PMID:18519675,,,,,,,,PGX_AM_BS_GSM266660,adenocarcinoma [esophagus],NCIT:C4025,Esophageal Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27979,Stage IVa,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,P65Y,,,EFO:0030049,dead (follow-up status),,Herston,Australia,AUS,153.02::-27.45,,,,,geo:GSM266660,geo:GSE10506,geo:GPL5711,,,CDKN2A
5bab56ce727983b2e00b1985,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,adenocarcinoma [esophagus],PMID:18519675,"Nancarrow DJ, Handoko HY et al. (2008): Genome-wide copy number analysis in esophageal...",NCIT:C4025,Esophageal Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvhgze,P79Y,pgxind-kftx3eky,pgxcs-kftvwj8u,1133265781,0.394,556089386,0.193,577176395,0.201,PGX_AM_BS_GSM266705,,153.02,-27.45,Point,AUS,Herston,Australia,"Herston, Australia",-27.45,153.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:45.748000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,1,16.0,,,geo:GSE10506,,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),pgxcohort-2021progenetix,Version at Progenetix Update 2021,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:GSM266705,,geo:GPL5711,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvhgze,,,pgxcs-kftvwj8u,PMID:18519675,,,,,,,,PGX_AM_BS_GSM266705,adenocarcinoma [esophagus],NCIT:C4025,Esophageal Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,P79Y,,,EFO:0030049,dead (follow-up status),,Herston,Australia,AUS,153.02::-27.45,,,,,geo:GSM266705,geo:GSE10506,geo:GPL5711,,,CDKN2A
5bab56ce727983b2e00b1986,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,adenocarcinoma [esophagus],geo:GSE10506,,NCIT:C4025,Esophageal Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvhgzf,P56Y,pgxind-kftx3el0,pgxcs-kftvwj9b,1106784670,0.385,590582266,0.205,516202404,0.18,PGX_AM_BS_GSM266706,,153.02,-27.45,Point,AUS,Herston,Australia,"Herston, Australia",-27.45,153.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:45.750000,T4,NCITstage-C27971,Stage IV,TNM-C48732,T4 Stage Finding,,,,,,,1,14.0,,,PMID:18519675,"Nancarrow DJ, Handoko HY et al. (2008): Genome-wide copy number analysis in esophageal...",pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),pgxcohort-2021progenetix,Version at Progenetix Update 2021,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:GSM266706,,geo:GPL5711,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvhgzf,,,pgxcs-kftvwj9b,PMID:18519675,,,,,,,,PGX_AM_BS_GSM266706,adenocarcinoma [esophagus],NCIT:C4025,Esophageal Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27979,Stage IVa,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,P56Y,,,EFO:0030049,dead (follow-up status),,Herston,Australia,AUS,153.02::-27.45,,,,,geo:GSM266706,geo:GSE10506,geo:GPL5711,,,CDKN2A
5bab56ce727983b2e00b1988,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,adenocarcinoma [esophagus],geo:GPL5711,,NCIT:C4025,Esophageal Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvhgzj,P71Y,pgxind-kftx3el4,pgxcs-kftvwjab,1420469696,0.494,800137678,0.278,620332018,0.216,PGX_AM_BS_GSM266708,,153.02,-27.45,Point,AUS,Herston,Australia,"Herston, Australia",-27.45,153.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:45.752000,T4,NCITstage-C27971,Stage IV,TNM-C48732,T4 Stage Finding,,,,,,,1,10.0,,,PMID:18519675,"Nancarrow DJ, Handoko HY et al. (2008): Genome-wide copy number analysis in esophageal...",pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),pgxcohort-2021progenetix,Version at Progenetix Update 2021,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:GSE10506,,geo:GSM266708,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvhgzj,,,pgxcs-kftvwjab,PMID:18519675,,,,,,,,PGX_AM_BS_GSM266708,adenocarcinoma [esophagus],NCIT:C4025,Esophageal Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27979,Stage IVa,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,P71Y,,,EFO:0030049,dead (follow-up status),,Herston,Australia,AUS,153.02::-27.45,,,,,geo:GSM266708,geo:GSE10506,geo:GPL5711,,,CDKN2A
5bab56c7727983b2e00ae073,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,adenocarcinoma [colorectal; liver metastasis],PMID:17044061,"Habermann JK, Paulsen U et al. (2007): Stage-specific alterations of the genome, transcriptome,...",NCIT:C4349,Colon Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C18.9,"large intestine, excl. rectum and rectosigmoid junction",pgxbs-kftvgydc,P84Y,pgxind-kftx2rrd,pgxcs-kftvquas,1164222946,0.405,561494839,0.195,602728107,0.21,PGX_AM_BS_NCBISKYCGH-3736,{},-77.1,38.98,Point,USA,Bethesda,United States of America,"Bethesda, United States",38.98,-77.1,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001155,colon,{},2020-09-10 17:44:25.151000,T0N0M1,,,TNM-C48699,M0 Stage Finding,TNM-C48700,M1 Stage Finding,TNM-C48705,N0 Stage Finding,,,0,48.0,TNM-C48719,T0 Stage Finding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgydc,,,pgxcs-kftvquas,PMID:17044061,,,,,,,,PGX_AM_BS_NCBISKYCGH-3736,adenocarcinoma [colorectal; liver metastasis],NCIT:C4349,Colon Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C18.9,"Colon, NOS",NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0001155,colon,,,,P84Y,,,EFO:0030041,alive (follow-up status),,Bethesda,United States of America,USA,-77.1::38.98,,,,,,,,,,CDKN2A
5bab56c7727983b2e00ae07a,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,adenocarcinoma [colorectal; liver metastasis],PMID:17044061,"Habermann JK, Paulsen U et al. (2007): Stage-specific alterations of the genome, transcriptome,...",NCIT:C4349,Colon Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C18.9,"large intestine, excl. rectum and rectosigmoid junction",pgxbs-kftvgydn,P58Y,pgxind-kftx2rrs,pgxcs-kftvque4,389848225,0.136,198412070,0.069,191436155,0.067,PGX_AM_BS_NCBISKYCGH-3743,{},-77.1,38.98,Point,USA,Bethesda,United States of America,"Bethesda, United States",38.98,-77.1,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001155,colon,{},2020-09-10 17:44:25.161000,T0N0M1,,,TNM-C48699,M0 Stage Finding,TNM-C48700,M1 Stage Finding,TNM-C48705,N0 Stage Finding,,,0,34.0,TNM-C48719,T0 Stage Finding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgydn,,,pgxcs-kftvque4,PMID:17044061,,,,,,,,PGX_AM_BS_NCBISKYCGH-3743,adenocarcinoma [colorectal; liver metastasis],NCIT:C4349,Colon Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C18.9,"Colon, NOS",NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0001155,colon,,,,P58Y,,,EFO:0030041,alive (follow-up status),,Bethesda,United States of America,USA,-77.1::38.98,,,,,,,,,,CDKN2A
5bab56c7727983b2e00ae063,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,adenocarcinoma [colon ascendens],PMID:17044061,"Habermann JK, Paulsen U et al. (2007): Stage-specific alterations of the genome, transcriptome,...",NCIT:C4349,Colon Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C18.9,"large intestine, excl. rectum and rectosigmoid junction",pgxbs-kftvgycm,P65Y,pgxind-kftx2rqh,pgxcs-kftvqu2t,1465371574,0.51,762822628,0.265,702548946,0.244,PGX_AM_BS_NCBISKYCGH-3718,,-77.1,38.98,Point,USA,Bethesda,United States of America,"Bethesda, United States",38.98,-77.1,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001155,colon,{},2020-09-10 17:44:25.129000,T3N2M1,NCITstage-C27970,Stage III,TNM-C48700,M1 Stage Finding,TNM-C48786,N2 Stage Finding,TNM-C48728,T3 Stage Finding,,,1,7.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgycm,,,pgxcs-kftvqu2t,PMID:17044061,,,,,,,,PGX_AM_BS_NCBISKYCGH-3718,adenocarcinoma [colon ascendens],NCIT:C4349,Colon Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C18.9,"Colon, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001155,colon,,,,P65Y,,,EFO:0030049,dead (follow-up status),,Bethesda,United States of America,USA,-77.1::38.98,,,,,,,,,,CDKN2A
5c865b3b09d374f2dc2b8e43,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,"colorectal carcinoma [right, mucinous, lymph node metastasis]",geo:GSM288135,,NCIT:C4349,Colon Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C18.9,"Colon, NOS",pgxbs-kftvia6y,P54Y6M,pgxind-kftx3wyp,pgxcs-kftw5o0s,693083075,0.241,423682992,0.147,269400083,0.094,PGX_AM_BS_GSM288135,,139.85,36.4,Point,JPN,Shimotsuke-shi,Japan,"Shimotsuke-shi, Japan",36.4,139.85,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001155,colon,{},2020-09-10 17:45:18.430000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,1,35.2,,,PMID:18564138,"Kurashina K, Yamashita Y et al. (2008): Chromosome copy number analysis in screening...",pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),pgxcohort-2021progenetix,Version at Progenetix Update 2021,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:GSE11417,,geo:GPL2005,,geo:gsm,pubmed,geo:gse,,,,,,geo:gpl,,,,arraymap import,0.1,SNP2pop 1000 Genomes population,HANCESTRO:0027,Han Chinese,0.56,SNP2pop 1000 Genomes superpopulation,HANCESTRO:0009,East Asian,,,,,,,,,,,,F,pgxbs-kftvia6y,,,pgxcs-kftw5o0s,PMID:18564138,,,,,,,,PGX_AM_BS_GSM288135,"colorectal carcinoma [right, mucinous, lymph node metastasis]",NCIT:C4349,Colon Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C18.9,"Colon, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001155,colon,,,,P54Y6M,,,EFO:0030039,no followup status,,Shimotsuke-shi,Japan,JPN,139.85::36.4,,,,,geo:GSM288135,geo:GSE11417,geo:GPL2005,,,CDKN2A
5c865b3b09d374f2dc2b8e4f,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,"colorectal carcinoma [left, well differentiated, lymph node metastasis]",PMID:18564138,"Kurashina K, Yamashita Y et al. (2008): Chromosome copy number analysis in screening...",NCIT:C4349,Colon Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C18.9,"Colon, NOS",pgxbs-kftvia7j,P86Y6M,pgxind-kftx3wzb,pgxcs-kftw5o6l,883968574,0.307,546023174,0.19,337945400,0.118,PGX_AM_BS_GSM288147,,139.85,36.4,Point,JPN,Shimotsuke-shi,Japan,"Shimotsuke-shi, Japan",36.4,139.85,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001155,colon,{},2020-09-10 17:45:18.447000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,1,17.37,,,geo:GPL2005,,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),pgxcohort-2021progenetix,Version at Progenetix Update 2021,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:GSE11417,,geo:GSM288147,,pubmed,geo:gpl,geo:gse,,,,,,geo:gsm,,,,arraymap import,0.12,SNP2pop 1000 Genomes population,HANCESTRO:0027,Han Chinese,0.52,SNP2pop 1000 Genomes superpopulation,HANCESTRO:0009,East Asian,,,,,,,,,,,,F,pgxbs-kftvia7j,,,pgxcs-kftw5o6l,PMID:18564138,,,,,,,,PGX_AM_BS_GSM288147,"colorectal carcinoma [left, well differentiated, lymph node metastasis]",NCIT:C4349,Colon Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C18.9,"Colon, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001155,colon,,,,P86Y6M,,,EFO:0030039,no followup status,,Shimotsuke-shi,Japan,JPN,139.85::36.4,,,,,geo:GSM288147,geo:GSE11417,geo:GPL2005,,,CDKN2A
5bab56cb727983b2e00afcdf,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"Enteropathy-Type T-Cell Lymphoma [pleomorphic, medium and large cells]",PMID:12414511,"Zettl A, Ott G, Makulik A et al. (2002): Chromosomal gains at 9q characterize enteropathy-type...",NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,icdom-97173,Intestinal T-cell lymphoma,icdot-C26.9,unspecified digest. Organs,pgxbs-kftvh7hf,P50Y,pgxind-kftx334k,pgxcs-kftvto3v,123821548,0.043,32800032,0.011,91021516,0.032,PGX_AM_BS_EP-T-NHL-03,{},9.95,49.79,Point,DEU,Wuerzburg,Germany,"Wuerzburg, Germany",49.79,9.95,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001007,digestive system,{},2020-09-10 17:44:35.614000,,,,,,,,,,,,0,48.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvh7hf,,,pgxcs-kftvto3v,PMID:12414511,,,,,,,,PGX_AM_BS_EP-T-NHL-03,"Enteropathy-Type T-Cell Lymphoma [pleomorphic, medium and large cells]",NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,pgx:icdom-97173,Intestinal T-cell lymphoma,pgx:icdot-C26.9,"Gastrointestinal tract, NOS",NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0001007,digestive system,,,,P50Y,,,EFO:0030041,alive (follow-up status),,Wuerzburg,Germany,DEU,9.95::49.79,,,,,,,,,,CDKN2A
5bab56cb727983b2e00afcfe,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Enteropathy-Type T-Cell Lymphoma [monomorphic with small- to medium-sized cells],PMID:12414511,"Zettl A, Ott G, Makulik A et al. (2002): Chromosomal gains at 9q characterize enteropathy-type...",NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,icdom-97173,Intestinal T-cell lymphoma,icdot-C26.9,unspecified digest. Organs,pgxbs-kftvh7iu,P43Y,pgxind-kftx336b,pgxcs-kftvtoio,421858430,0.147,335514090,0.117,86344340,0.03,PGX_AM_BS_EP-T-NHL-31,,9.95,49.79,Point,DEU,Wuerzburg,Germany,"Wuerzburg, Germany",49.79,9.95,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001007,digestive system,{},2020-09-10 17:44:35.656000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,0,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvh7iu,,,pgxcs-kftvtoio,PMID:12414511,,,,,,,,PGX_AM_BS_EP-T-NHL-31,Enteropathy-Type T-Cell Lymphoma [monomorphic with small- to medium-sized cells],NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,pgx:icdom-97173,Intestinal T-cell lymphoma,pgx:icdot-C26.9,"Gastrointestinal tract, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001007,digestive system,,,,P43Y,,,EFO:0030041,alive (follow-up status),,Wuerzburg,Germany,DEU,9.95::49.79,,,,,,,,,,CDKN2A
5bab56c6727983b2e00ada99,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Enteropathy type T-cell lymphoma,PMID:17484883,"Deleeuw RJ, Zettl A et al. (2007): Whole-genome analysis and HLA genotyping of...",NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,icdom-97173,Intestinal T-cell lymphoma,icdot-C17.9,small intestine,pgxbs-kftvgw6a,P51Y,pgxind-kftx2pf8,pgxcs-kftvq9d3,531651103,0.185,185443169,0.065,346207934,0.12,PGX_AM_BS_EntTNHL-del-07,{},-123.12,49.25,Point,CAN,Vancouver,Canada,"Vancouver, Canada",49.25,-123.12,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002108,small intestine,{},2020-09-10 17:44:23.084000,,,,,,,,,,,,1,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgw6a,,,pgxcs-kftvq9d3,PMID:17484883,,,,,,,,PGX_AM_BS_EntTNHL-del-07,Enteropathy type T-cell lymphoma,NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,pgx:icdom-97173,Intestinal T-cell lymphoma,pgx:icdot-C17.9,"Small intestine, NOS",NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0002108,small intestine,,,,P51Y,,,EFO:0030049,dead (follow-up status),,Vancouver,Canada,CAN,-123.12::49.25,,,,,,,,,,CDKN2A
5bab56c6727983b2e00adaae,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Enteropathy type T-cell lymphoma,PMID:17484883,"Deleeuw RJ, Zettl A et al. (2007): Whole-genome analysis and HLA genotyping of...",NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,icdom-97173,Intestinal T-cell lymphoma,icdot-C17.9,small intestine,pgxbs-kftvgw77,P81Y,pgxind-kftx2pge,pgxcs-kftvq9n5,691379046,0.24,366664120,0.128,324714926,0.113,PGX_AM_BS_EntTNHL-del-28,{},-123.12,49.25,Point,CAN,Vancouver,Canada,"Vancouver, Canada",49.25,-123.12,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002108,small intestine,{},2020-09-10 17:44:23.112000,,,,,,,,,,,,1,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgw77,,,pgxcs-kftvq9n5,PMID:17484883,,,,,,,,PGX_AM_BS_EntTNHL-del-28,Enteropathy type T-cell lymphoma,NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,pgx:icdom-97173,Intestinal T-cell lymphoma,pgx:icdot-C17.9,"Small intestine, NOS",NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0002108,small intestine,,,,P81Y,,,EFO:0030049,dead (follow-up status),,Vancouver,Canada,CAN,-123.12::49.25,,,,,,,,,,CDKN2A
5bab56c6727983b2e00adab4,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Enteropathy type T-cell lymphoma,PMID:17484883,"Deleeuw RJ, Zettl A et al. (2007): Whole-genome analysis and HLA genotyping of...",NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,icdom-97173,Intestinal T-cell lymphoma,icdot-C17.9,small intestine,pgxbs-kftvgw7h,P43Y,pgxind-kftx2pgq,pgxcs-kftvq9q1,590185329,0.205,309146412,0.108,281038917,0.098,PGX_AM_BS_EntTNHL-del-11,{},-123.12,49.25,Point,CAN,Vancouver,Canada,"Vancouver, Canada",49.25,-123.12,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002108,small intestine,{},2020-09-10 17:44:23.121000,,,,,,,,,,,,1,18.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgw7h,,,pgxcs-kftvq9q1,PMID:17484883,,,,,,,,PGX_AM_BS_EntTNHL-del-11,Enteropathy type T-cell lymphoma,NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,pgx:icdom-97173,Intestinal T-cell lymphoma,pgx:icdot-C17.9,"Small intestine, NOS",NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0002108,small intestine,,,,P43Y,,,EFO:0030049,dead (follow-up status),,Vancouver,Canada,CAN,-123.12::49.25,,,,,,,,,,CDKN2A
5bab56c6727983b2e00adab8,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Enteropathy type T-cell lymphoma,PMID:17484883,"Deleeuw RJ, Zettl A et al. (2007): Whole-genome analysis and HLA genotyping of...",NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,icdom-97173,Intestinal T-cell lymphoma,icdot-C17.9,small intestine,pgxbs-kftvgw7n,P50Y,pgxind-kftx2pgy,pgxcs-kftvq9tu,524816259,0.183,265002246,0.092,259814013,0.09,PGX_AM_BS_EntTNHL-del-15,{},-123.12,49.25,Point,CAN,Vancouver,Canada,"Vancouver, Canada",49.25,-123.12,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002108,small intestine,{},2020-09-10 17:44:23.126000,,,,,,,,,,,,1,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgw7n,,,pgxcs-kftvq9tu,PMID:17484883,,,,,,,,PGX_AM_BS_EntTNHL-del-15,Enteropathy type T-cell lymphoma,NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,pgx:icdom-97173,Intestinal T-cell lymphoma,pgx:icdot-C17.9,"Small intestine, NOS",NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0002108,small intestine,,,,P50Y,,,EFO:0030049,dead (follow-up status),,Vancouver,Canada,CAN,-123.12::49.25,,,,,,,,,,CDKN2A
5bab56c6727983b2e00adab9,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Enteropathy type T-cell lymphoma,PMID:17484883,"Deleeuw RJ, Zettl A et al. (2007): Whole-genome analysis and HLA genotyping of...",NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,icdom-97173,Intestinal T-cell lymphoma,icdot-C17.9,small intestine,pgxbs-kftvgw7p,P66Y,pgxind-kftx2ph0,pgxcs-kftvq9uc,579712895,0.202,113427530,0.039,466285365,0.162,PGX_AM_BS_EntTNHL-del-16,{},-123.12,49.25,Point,CAN,Vancouver,Canada,"Vancouver, Canada",49.25,-123.12,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002108,small intestine,{},2020-09-10 17:44:23.128000,,,,,,,,,,,,1,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgw7p,,,pgxcs-kftvq9uc,PMID:17484883,,,,,,,,PGX_AM_BS_EntTNHL-del-16,Enteropathy type T-cell lymphoma,NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,pgx:icdom-97173,Intestinal T-cell lymphoma,pgx:icdot-C17.9,"Small intestine, NOS",NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0002108,small intestine,,,,P66Y,,,EFO:0030049,dead (follow-up status),,Vancouver,Canada,CAN,-123.12::49.25,,,,,,,,,,CDKN2A
5bab56c6727983b2e00adac3,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Enteropathy type T-cell lymphoma,PMID:17484883,"Deleeuw RJ, Zettl A et al. (2007): Whole-genome analysis and HLA genotyping of...",NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,icdom-97173,Intestinal T-cell lymphoma,icdot-C17.9,small intestine,pgxbs-kftvgw85,P59Y,pgxind-kftx2phl,pgxcs-kftvq9z5,680101440,0.237,431355243,0.15,248746197,0.087,PGX_AM_BS_EntTNHL-del-26,{},-123.12,49.25,Point,CAN,Vancouver,Canada,"Vancouver, Canada",49.25,-123.12,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002108,small intestine,{},2020-09-10 17:44:23.141000,,,,,,,,,,,,1,10.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgw85,,,pgxcs-kftvq9z5,PMID:17484883,,,,,,,,PGX_AM_BS_EntTNHL-del-26,Enteropathy type T-cell lymphoma,NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,pgx:icdom-97173,Intestinal T-cell lymphoma,pgx:icdot-C17.9,"Small intestine, NOS",NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0002108,small intestine,,,,P59Y,,,EFO:0030049,dead (follow-up status),,Vancouver,Canada,CAN,-123.12::49.25,,,,,,,,,,CDKN2A
5bab56c6727983b2e00adac6,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Enteropathy type T-cell lymphoma,PMID:17484883,"Deleeuw RJ, Zettl A et al. (2007): Whole-genome analysis and HLA genotyping of...",NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,icdom-97173,Intestinal T-cell lymphoma,icdot-C17.9,small intestine,pgxbs-kftvgw8a,P65Y,pgxind-kftx2phr,pgxcs-kftvqa0k,503373409,0.175,196615237,0.068,306758172,0.107,PGX_AM_BS_EntTNHL-del-29,{},-123.12,49.25,Point,CAN,Vancouver,Canada,"Vancouver, Canada",49.25,-123.12,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002108,small intestine,{},2020-09-10 17:44:23.146000,,,,,,,,,,,,1,7.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgw8a,,,pgxcs-kftvqa0k,PMID:17484883,,,,,,,,PGX_AM_BS_EntTNHL-del-29,Enteropathy type T-cell lymphoma,NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,pgx:icdom-97173,Intestinal T-cell lymphoma,pgx:icdot-C17.9,"Small intestine, NOS",NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0002108,small intestine,,,,P65Y,,,EFO:0030049,dead (follow-up status),,Vancouver,Canada,CAN,-123.12::49.25,,,,,,,,,,CDKN2A
5bab56cb727983b2e00afcde,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"Enteropathy-Type T-Cell Lymphoma [pleomorphic, medium and large cells]",PMID:12414511,"Zettl A, Ott G, Makulik A et al. (2002): Chromosomal gains at 9q characterize enteropathy-type...",NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,icdom-97173,Intestinal T-cell lymphoma,icdot-C26.9,unspecified digest. Organs,pgxbs-kftvh7hd,P53Y,pgxind-kftx334i,pgxcs-kftvto3e,83494801,0.029,32800032,0.011,50694769,0.018,PGX_AM_BS_EP-T-NHL-02,,9.95,49.79,Point,DEU,Wuerzburg,Germany,"Wuerzburg, Germany",49.79,9.95,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001007,digestive system,{},2020-09-10 17:44:35.612000,T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,,,,,1,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvh7hd,,,pgxcs-kftvto3e,PMID:12414511,,,,,,,,PGX_AM_BS_EP-T-NHL-02,"Enteropathy-Type T-Cell Lymphoma [pleomorphic, medium and large cells]",NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,pgx:icdom-97173,Intestinal T-cell lymphoma,pgx:icdot-C26.9,"Gastrointestinal tract, NOS",NCIT:C27966,Stage I,EFO:0009656,neoplastic sample,UBERON:0001007,digestive system,,,,P53Y,,,EFO:0030049,dead (follow-up status),,Wuerzburg,Germany,DEU,9.95::49.79,,,,,,,,,,CDKN2A
5bab56cb727983b2e00afce7,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"Enteropathy-Type T-Cell Lymphoma [pleomorphic, medium and large cells]",PMID:12414511,"Zettl A, Ott G, Makulik A et al. (2002): Chromosomal gains at 9q characterize enteropathy-type...",NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,icdom-97173,Intestinal T-cell lymphoma,icdot-C26.9,unspecified digest. Organs,pgxbs-kftvh7hs,P61Y,pgxind-kftx3350,pgxcs-kftvto7o,256915403,0.089,213540617,0.074,43374786,0.015,PGX_AM_BS_EP-T-NHL-10,,9.95,49.79,Point,DEU,Wuerzburg,Germany,"Wuerzburg, Germany",49.79,9.95,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001007,digestive system,{},2020-09-10 17:44:35.624000,T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,,,,,1,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvh7hs,,,pgxcs-kftvto7o,PMID:12414511,,,,,,,,PGX_AM_BS_EP-T-NHL-10,"Enteropathy-Type T-Cell Lymphoma [pleomorphic, medium and large cells]",NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,pgx:icdom-97173,Intestinal T-cell lymphoma,pgx:icdot-C26.9,"Gastrointestinal tract, NOS",NCIT:C27966,Stage I,EFO:0009656,neoplastic sample,UBERON:0001007,digestive system,,,,P61Y,,,EFO:0030049,dead (follow-up status),,Wuerzburg,Germany,DEU,9.95::49.79,,,,,,,,,,CDKN2A
5bab56cb727983b2e00afcee,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Enteropathy-Type T-Cell Lymphoma [ALCL],PMID:12414511,"Zettl A, Ott G, Makulik A et al. (2002): Chromosomal gains at 9q characterize enteropathy-type...",NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,icdom-97173,Intestinal T-cell lymphoma,icdot-C26.9,Unspecified digestive organs,pgxbs-kftvh7i4,P65Y,pgxind-kftx335e,pgxcs-kftvtob0,684458609,0.238,167595727,0.058,516862882,0.18,PGX_AM_BS_EP-T-NHL-17,{},9.95,49.79,Point,DEU,Wuerzburg,Germany,"Wuerzburg, Germany",49.79,9.95,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001007,digestive system,{},2020-09-10 17:44:35.634000,,,,,,,,,,,,1,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvh7i4,,,pgxcs-kftvtob0,PMID:12414511,,,,,,,,PGX_AM_BS_EP-T-NHL-17,Enteropathy-Type T-Cell Lymphoma [ALCL],NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,pgx:icdom-97173,Intestinal T-cell lymphoma,pgx:icdot-C26.9,"Gastrointestinal tract, NOS",NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0001007,digestive system,,,,P65Y,,,EFO:0030049,dead (follow-up status),,Wuerzburg,Germany,DEU,9.95::49.79,,,,,,,,,,CDKN2A
5bab56cb727983b2e00afcf5,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Enteropathy-Type T-Cell Lymphoma [monomorphic with small- to medium-sized cells],PMID:12414511,"Zettl A, Ott G, Makulik A et al. (2002): Chromosomal gains at 9q characterize enteropathy-type...",NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,icdom-97173,Intestinal T-cell lymphoma,icdot-C26.9,unspecified digest. Organs,pgxbs-kftvh7if,P51Y,pgxind-kftx335t,pgxcs-kftvtoed,142737841,0.05,74843055,0.026,67894786,0.024,PGX_AM_BS_EP-T-NHL-24,,9.95,49.79,Point,DEU,Wuerzburg,Germany,"Wuerzburg, Germany",49.79,9.95,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001007,digestive system,{},2020-09-10 17:44:35.643000,T4,NCITstage-C27971,Stage IV,TNM-C48732,T4 Stage Finding,,,,,,,1,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvh7if,,,pgxcs-kftvtoed,PMID:12414511,,,,,,,,PGX_AM_BS_EP-T-NHL-24,Enteropathy-Type T-Cell Lymphoma [monomorphic with small- to medium-sized cells],NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,pgx:icdom-97173,Intestinal T-cell lymphoma,pgx:icdot-C26.9,"Gastrointestinal tract, NOS",NCIT:C27971,Stage IV,EFO:0009656,neoplastic sample,UBERON:0001007,digestive system,,,,P51Y,,,EFO:0030049,dead (follow-up status),,Wuerzburg,Germany,DEU,9.95::49.79,,,,,,,,,,CDKN2A
5bab56c9727983b2e00aef89,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"Mucinous colorectal carcinoma [Rectum [above], pT3N1M0, stage II]",PMID:15289862,"Liu XP, Sato T, Oga A et al. (2004): Two subtypes of mucinous colorectal carcinoma...",NCIT:C7966,Colon Mucinous Adenocarcinoma,icdom-84803,Mucinous adenocarcinoma,icdot-C18.9,"large intestine, excl. rectum and rectosigmoid junction",pgxbs-kftvh37n,P75Y,pgxind-kftx2xsk,pgxcs-kftvscd1,1291929548,0.449,685440588,0.238,606488960,0.211,PGX_AM_BS_MucCoCa-liu-16,,131.47,34.19,Point,JPN,Yamaguchi-shi,Japan,"Yamaguchi-shi, Japan",34.19,131.47,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001155,colon,{},2020-09-10 17:44:30.892000,T3N1M0,NCITstage-C28054,Stage II,TNM-C48706,N1 Stage Finding,TNM-C48714,N3 Stage Finding,TNM-C48728,T3 Stage Finding,,,0,107.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvh37n,,,pgxcs-kftvscd1,PMID:15289862,,,,,,,,PGX_AM_BS_MucCoCa-liu-16,"Mucinous colorectal carcinoma [Rectum [above], pT3N1M0, stage II]",NCIT:C7966,Colon Mucinous Adenocarcinoma,pgx:icdom-84803,Mucinous adenocarcinoma,pgx:icdot-C18.9,"Colon, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001155,colon,,,,P75Y,,,EFO:0030041,alive (follow-up status),,Yamaguchi-shi,Japan,JPN,131.47::34.19,,,,,,,,,,CDKN2A
5bab56c9727983b2e00aef8d,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"Mucinous colorectal carcinoma [Rectum [above], pT3N1M0, stage II]",PMID:15289862,"Liu XP, Sato T, Oga A et al. (2004): Two subtypes of mucinous colorectal carcinoma...",NCIT:C7966,Colon Mucinous Adenocarcinoma,icdom-84803,Mucinous adenocarcinoma,icdot-C18.9,"large intestine, excl. rectum and rectosigmoid junction",pgxbs-kftvh37u,P65Y,pgxind-kftx2xss,pgxcs-kftvscey,1495035193,0.52,699395763,0.243,795639430,0.277,PGX_AM_BS_MucCoCa-liu-20,,131.47,34.19,Point,JPN,Yamaguchi-shi,Japan,"Yamaguchi-shi, Japan",34.19,131.47,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001155,colon,{},2020-09-10 17:44:30.898000,T3N1M0,NCITstage-C28054,Stage II,TNM-C48706,N1 Stage Finding,TNM-C48714,N3 Stage Finding,TNM-C48728,T3 Stage Finding,,,0,100.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvh37u,,,pgxcs-kftvscey,PMID:15289862,,,,,,,,PGX_AM_BS_MucCoCa-liu-20,"Mucinous colorectal carcinoma [Rectum [above], pT3N1M0, stage II]",NCIT:C7966,Colon Mucinous Adenocarcinoma,pgx:icdom-84803,Mucinous adenocarcinoma,pgx:icdot-C18.9,"Colon, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001155,colon,,,,P65Y,,,EFO:0030041,alive (follow-up status),,Yamaguchi-shi,Japan,JPN,131.47::34.19,,,,,,,,,,CDKN2A
5bab56c9727983b2e00aef8e,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"Mucinous colorectal carcinoma [Ascending colon, pT3N0M0, stage I]",PMID:15289862,"Liu XP, Sato T, Oga A et al. (2004): Two subtypes of mucinous colorectal carcinoma...",NCIT:C7966,Colon Mucinous Adenocarcinoma,icdom-84803,Mucinous adenocarcinoma,icdot-C18.9,"large intestine, excl. rectum and rectosigmoid junction",pgxbs-kftvh37w,P91Y,pgxind-kftx2xsu,pgxcs-kftvscfg,991861570,0.345,416560996,0.145,575300574,0.2,PGX_AM_BS_MucCoCa-liu-21,,131.47,34.19,Point,JPN,Yamaguchi-shi,Japan,"Yamaguchi-shi, Japan",34.19,131.47,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001155,colon,{},2020-09-10 17:44:30.899000,T3N0M0,NCITstage-C27966,Stage I,TNM-C48705,N0 Stage Finding,TNM-C48728,T3 Stage Finding,,,,,0,101.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvh37w,,,pgxcs-kftvscfg,PMID:15289862,,,,,,,,PGX_AM_BS_MucCoCa-liu-21,"Mucinous colorectal carcinoma [Ascending colon, pT3N0M0, stage I]",NCIT:C7966,Colon Mucinous Adenocarcinoma,pgx:icdom-84803,Mucinous adenocarcinoma,pgx:icdot-C18.9,"Colon, NOS",NCIT:C27966,Stage I,EFO:0009656,neoplastic sample,UBERON:0001155,colon,,,,P91Y,,,EFO:0030041,alive (follow-up status),,Yamaguchi-shi,Japan,JPN,131.47::34.19,,,,,,,,,,CDKN2A
5bab56c9727983b2e00aef8c,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"Mucinous colorectal carcinoma [Cecum, pT3N1M1, stage V]",PMID:15289862,"Liu XP, Sato T, Oga A et al. (2004): Two subtypes of mucinous colorectal carcinoma...",NCIT:C7966,Colon Mucinous Adenocarcinoma,icdom-84803,Mucinous adenocarcinoma,icdot-C18.0,cecum,pgxbs-kftvh37s,P57Y,pgxind-kftx2xsq,pgxcs-kftvsceh,674810044,0.235,127417281,0.044,547392763,0.19,PGX_AM_BS_MucCoCa-liu-19,,131.47,34.19,Point,JPN,Yamaguchi-shi,Japan,"Yamaguchi-shi, Japan",34.19,131.47,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000314,cecum mucosa,{},2020-09-10 17:44:30.896000,T3N1M1,NCITstage-C27970,Stage III,TNM-C48700,M1 Stage Finding,TNM-C48706,N1 Stage Finding,TNM-C48714,N3 Stage Finding,,,1,11.0,TNM-C48728,T3 Stage Finding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvh37s,,,pgxcs-kftvsceh,PMID:15289862,,,,,,,,PGX_AM_BS_MucCoCa-liu-19,"Mucinous colorectal carcinoma [Cecum, pT3N1M1, stage V]",NCIT:C7966,Colon Mucinous Adenocarcinoma,pgx:icdom-84803,Mucinous adenocarcinoma,pgx:icdot-C18.0,Cecum,NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0000314,cecum mucosa,,,,P57Y,,,EFO:0030049,dead (follow-up status),,Yamaguchi-shi,Japan,JPN,131.47::34.19,,,,,,,,,,CDKN2A
5bab56c1727983b2e00ab6c9,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgknh,P49Y,pgxind-kftx2b4g,pgxcs-kftvmqmc,724756462,0.252,395806320,0.138,328950142,0.114,PGX_AM_BS_PDAC-sto-09,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.305000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,0,28.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgknh,,,pgxcs-kftvmqmc,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-09,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P49Y,,,EFO:0030041,alive (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,CDKN2A
5bab56c1727983b2e00ab6ca,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgknj,P48Y,pgxind-kftx2b4i,pgxcs-kftvmqms,938015686,0.326,699651973,0.243,238363713,0.083,PGX_AM_BS_PDAC-sto-10,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.307000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgknj,,,pgxcs-kftvmqms,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-10,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P48Y,,,EFO:0030041,alive (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,CDKN2A
5bab56c1727983b2e00ab6d5,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgko1,P50Y,pgxind-kftx2b54,pgxcs-kftvmqrx,1235069614,0.43,541193772,0.188,693875842,0.241,PGX_AM_BS_PDAC-sto-21,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.323000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgko1,,,pgxcs-kftvmqrx,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-21,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P50Y,,,EFO:0030041,alive (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,CDKN2A
5bab56c1727983b2e00ab6ea,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgkoz,P75Y,pgxind-kftx2b6a,pgxcs-kftvmr1p,1180879782,0.411,773840865,0.269,407038917,0.142,PGX_AM_BS_PDAC-sto-42,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.353000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,0,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgkoz,,,pgxcs-kftvmr1p,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-42,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P75Y,,,EFO:0030041,alive (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,CDKN2A
5bab56c1727983b2e00ab6f2,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgkpc,P60Y,pgxind-kftx2b6p,pgxcs-kftvmr7e,468361000,0.163,435560967,0.151,32800033,0.011,PGX_AM_BS_PDAC-sto-50,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.364000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,0,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgkpc,,,pgxcs-kftvmr7e,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-50,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P60Y,,,EFO:0030041,alive (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,CDKN2A
5bab56c1727983b2e00ab6f4,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgkpf,P75Y,pgxind-kftx2b6t,pgxcs-kftvmr8c,737247429,0.256,317301731,0.11,419945698,0.146,PGX_AM_BS_PDAC-sto-52,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.367000,T4,NCITstage-C27971,Stage IV,TNM-C48732,T4 Stage Finding,,,,,,,0,7.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgkpf,,,pgxcs-kftvmr8c,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-52,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C27971,Stage IV,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P75Y,,,EFO:0030041,alive (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,CDKN2A
5bab56c1727983b2e00ab6c3,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgkn7,P53Y,pgxind-kftx2b44,pgxcs-kftvmqjk,285300282,0.099,112300110,0.039,173000172,0.06,PGX_AM_BS_PDAC-sto-03,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.297000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,1,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgkn7,,,pgxcs-kftvmqjk,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-03,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P53Y,,,EFO:0030049,dead (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,CDKN2A
5bab56c1727983b2e00ab6cb,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgknk,P75Y,pgxind-kftx2b4k,pgxcs-kftvmqn9,463415715,0.161,434915687,0.151,28500028,0.01,PGX_AM_BS_PDAC-sto-11,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.308000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,1,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgknk,,,pgxcs-kftvmqn9,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-11,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P75Y,,,EFO:0030049,dead (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,CDKN2A
5bab56c1727983b2e00ab6d1,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgknu,P33Y,pgxind-kftx2b4w,pgxcs-kftvmqq2,930201938,0.324,353048690,0.123,577153248,0.201,PGX_AM_BS_PDAC-sto-17,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.317000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,1,10.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgknu,,,pgxcs-kftvmqq2,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-17,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P33Y,,,EFO:0030049,dead (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,CDKN2A
5bab56c1727983b2e00ab6d6,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgko2,P60Y,pgxind-kftx2b56,pgxcs-kftvmqse,608243566,0.212,447781954,0.156,160461612,0.056,PGX_AM_BS_PDAC-sto-22,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.325000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,1,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgko2,,,pgxcs-kftvmqse,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-22,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P60Y,,,EFO:0030049,dead (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,CDKN2A
5bab56c1727983b2e00ab6dc,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgkoc,P59Y,pgxind-kftx2b5i,pgxcs-kftvmqv7,926355064,0.322,392458973,0.137,533896091,0.186,PGX_AM_BS_PDAC-sto-28,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.333000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,1,17.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgkoc,,,pgxcs-kftvmqv7,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-28,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P59Y,,,EFO:0030049,dead (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,CDKN2A
5bab56c1727983b2e00ab6df,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgkoh,P53Y,pgxind-kftx2b5o,pgxcs-kftvmqwl,1209663424,0.421,1011717945,0.352,197945479,0.069,PGX_AM_BS_PDAC-sto-31,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.337000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,1,16.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgkoh,,,pgxcs-kftvmqwl,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-31,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P53Y,,,EFO:0030049,dead (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,CDKN2A
5bab56c1727983b2e00ab6e1,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgkok,P54Y,pgxind-kftx2b5s,pgxcs-kftvmqxj,918386292,0.319,446532627,0.155,471853665,0.164,PGX_AM_BS_PDAC-sto-33,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.340000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,1,11.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgkok,,,pgxcs-kftvmqxj,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-33,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P54Y,,,EFO:0030049,dead (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,CDKN2A
5bab56c1727983b2e00ab6e4,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgkop,P49Y,pgxind-kftx2b5y,pgxcs-kftvmqyx,388864561,0.135,252010997,0.088,136853564,0.048,PGX_AM_BS_PDAC-sto-36,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.344000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,1,12.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgkop,,,pgxcs-kftvmqyx,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-36,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P49Y,,,EFO:0030049,dead (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,CDKN2A
5bab56c1727983b2e00ab6ed,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgkp4,P63Y,pgxind-kftx2b6g,pgxcs-kftvmr51,658419457,0.229,530633644,0.185,127785813,0.044,PGX_AM_BS_PDAC-sto-45,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.357000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,1,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgkp4,,,pgxcs-kftvmr51,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-45,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P63Y,,,EFO:0030049,dead (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,CDKN2A
5bab56c1727983b2e00ab6f3,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgkpe,P71Y,pgxind-kftx2b6r,pgxcs-kftvmr7v,1429106309,0.497,262818701,0.091,1166287608,0.406,PGX_AM_BS_PDAC-sto-51,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.366000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,1,14.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgkpe,,,pgxcs-kftvmr7v,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-51,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P71Y,,,EFO:0030049,dead (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,CDKN2A
5bab56c7727983b2e00ae069,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,adenocarcinoma [rectum],PMID:17044061,"Habermann JK, Paulsen U et al. (2007): Stage-specific alterations of the genome, transcriptome,...",NCIT:C9383,Rectal Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C20.9,"Rectum, NOS",pgxbs-kftvgycw,P71Y,pgxind-kftx2rqt,pgxcs-kftvqu5s,954534975,0.332,501795515,0.175,452739460,0.157,PGX_AM_BS_NCBISKYCGH-3724,,-77.1,38.98,Point,USA,Bethesda,United States of America,"Bethesda, United States",38.98,-77.1,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001052,rectum,{},2020-09-10 17:44:25.137000,T3N1M0,NCITstage-C27970,Stage III,TNM-C48706,N1 Stage Finding,TNM-C48714,N3 Stage Finding,TNM-C48728,T3 Stage Finding,,,0,52.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgycw,,,pgxcs-kftvqu5s,PMID:17044061,,,,,,,,PGX_AM_BS_NCBISKYCGH-3724,adenocarcinoma [rectum],NCIT:C9383,Rectal Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C20.9,"Rectum, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001052,rectum,,,,P71Y,,,EFO:0030041,alive (follow-up status),,Bethesda,United States of America,USA,-77.1::38.98,,,,,,,,,,CDKN2A
5bab56c4727983b2e00acaa2,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,hepatocellular carcinoma,PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C3099,Hepatocellular Carcinoma,icdom-81703,"Hepatocellular carcinoma, NOS",icdot-C22.0,Liver,pgxbs-kftvgr23,P75Y,pgxind-kftx2j0y,pgxcs-kftvoo6d,1194333344,0.415,881329622,0.307,313003722,0.109,PGX_AM_BS_HCC-CC-hom-30,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:17.427000,T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,,,,,0,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr23,,,pgxcs-kftvoo6d,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-30,hepatocellular carcinoma,NCIT:C3099,Hepatocellular Carcinoma,pgx:icdom-81703,"Hepatocellular carcinoma, NOS",pgx:icdot-C22.0,Liver,NCIT:C27966,Stage I,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P75Y,,,EFO:0030041,alive (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,ERBB2
5bab56c4727983b2e00acabc,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,hepatocellular carcinoma,PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C3099,Hepatocellular Carcinoma,icdom-81703,"Hepatocellular carcinoma, NOS",icdot-C22.0,Liver,pgxbs-kftvgr39,P73Y,pgxind-kftx2j2g,pgxcs-kftvooiv,962977633,0.335,728107938,0.253,234869695,0.082,PGX_AM_BS_HCC-CC-hom-56,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:17.463000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgr39,,,pgxcs-kftvooiv,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-56,hepatocellular carcinoma,NCIT:C3099,Hepatocellular Carcinoma,pgx:icdom-81703,"Hepatocellular carcinoma, NOS",pgx:icdot-C22.0,Liver,NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P73Y,,,EFO:0030041,alive (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,ERBB2
5bab56c4727983b2e00acaac,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,hepatocellular carcinoma,PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C3099,Hepatocellular Carcinoma,icdom-81703,"Hepatocellular carcinoma, NOS",icdot-C22.0,Liver,pgxbs-kftvgr2j,P71Y,pgxind-kftx2j1j,pgxcs-kftvoob5,890799053,0.31,700092712,0.244,190706341,0.066,PGX_AM_BS_HCC-CC-hom-40,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:17.441000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,1,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgr2j,,,pgxcs-kftvoob5,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-40,hepatocellular carcinoma,NCIT:C3099,Hepatocellular Carcinoma,pgx:icdom-81703,"Hepatocellular carcinoma, NOS",pgx:icdot-C22.0,Liver,NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P71Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,ERBB2
5bab56c4727983b2e00acaad,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,hepatocellular carcinoma,PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C3099,Hepatocellular Carcinoma,icdom-81703,"Hepatocellular carcinoma, NOS",icdot-C22.0,Liver,pgxbs-kftvgr2k,P67Y,pgxind-kftx2j1l,pgxcs-kftvoobm,1163283887,0.405,853453044,0.297,309830843,0.108,PGX_AM_BS_HCC-CC-hom-41,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:17.442000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,1,18.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr2k,,,pgxcs-kftvoobm,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-41,hepatocellular carcinoma,NCIT:C3099,Hepatocellular Carcinoma,pgx:icdom-81703,"Hepatocellular carcinoma, NOS",pgx:icdot-C22.0,Liver,NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P67Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,ERBB2
5bab56c4727983b2e00acaaf,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"hepatocellular carcinoma [cirrhosis, cryptogenic]",PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C3099,Hepatocellular Carcinoma,icdom-81703,"Hepatocellular carcinoma, NOS",icdot-C22.0,Liver,pgxbs-kftvgr2o,P78Y,pgxind-kftx2j1p,pgxcs-kftvoocl,1379385783,0.48,1000522305,0.348,378863478,0.132,PGX_AM_BS_HCC-CC-hom-43,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:17.445000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,1,3.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr2o,,,pgxcs-kftvoocl,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-43,"hepatocellular carcinoma [cirrhosis, cryptogenic]",NCIT:C3099,Hepatocellular Carcinoma,pgx:icdom-81703,"Hepatocellular carcinoma, NOS",pgx:icdot-C22.0,Liver,NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P78Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,ERBB2
5bab56c4727983b2e00acab7,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,hepatocellular carcinoma [hepatitis C pos.],PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C3099,Hepatocellular Carcinoma,icdom-81703,"Hepatocellular carcinoma, NOS",icdot-C22.0,Liver,pgxbs-kftvgr31,P68Y,pgxind-kftx2j25,pgxcs-kftvoogf,566677314,0.197,155506135,0.054,411171179,0.143,PGX_AM_BS_HCC-CC-hom-51,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:17.456000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,1,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr31,,,pgxcs-kftvoogf,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-51,hepatocellular carcinoma [hepatitis C pos.],NCIT:C3099,Hepatocellular Carcinoma,pgx:icdom-81703,"Hepatocellular carcinoma, NOS",pgx:icdot-C22.0,Liver,NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P68Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,ERBB2
5bab56c4727983b2e00acabb,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,hepatocellular carcinoma [hepatitis C liver cirrhosis],PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C3099,Hepatocellular Carcinoma,icdom-81703,"Hepatocellular carcinoma, NOS",icdot-C22.0,Liver,pgxbs-kftvgr37,P50Y,pgxind-kftx2j2e,pgxcs-kftvooic,908099431,0.316,908099431,0.316,0,0.0,PGX_AM_BS_HCC-CC-hom-55,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:17.462000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,1,45.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr37,,,pgxcs-kftvooic,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-55,hepatocellular carcinoma [hepatitis C liver cirrhosis],NCIT:C3099,Hepatocellular Carcinoma,pgx:icdom-81703,"Hepatocellular carcinoma, NOS",pgx:icdot-C22.0,Liver,NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P50Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,ERBB2
5bab56c4727983b2e00acabe,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,hepatocellular carcinoma,PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C3099,Hepatocellular Carcinoma,icdom-81703,"Hepatocellular carcinoma, NOS",icdot-C22.0,Liver,pgxbs-kftvgr3c,P64Y,pgxind-kftx2j2k,pgxcs-kftvooju,1107365509,0.385,453075144,0.158,654290365,0.228,PGX_AM_BS_HCC-CC-hom-58,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:17.466000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,1,26.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr3c,,,pgxcs-kftvooju,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-58,hepatocellular carcinoma,NCIT:C3099,Hepatocellular Carcinoma,pgx:icdom-81703,"Hepatocellular carcinoma, NOS",pgx:icdot-C22.0,Liver,NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P64Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,ERBB2
5bab56c4727983b2e00acac4,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,hepatocellular carcinoma [hepatitis C liver cirrhosis],PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C3099,Hepatocellular Carcinoma,icdom-81703,"Hepatocellular carcinoma, NOS",icdot-C22.0,Liver,pgxbs-kftvgr3m,P63Y,pgxind-kftx2j2w,pgxcs-kftvoomr,201713581,0.07,45200045,0.016,156513536,0.054,PGX_AM_BS_HCC-CC-hom-64,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:17.474000,T4,NCITstage-C27971,Stage IV,TNM-C48732,T4 Stage Finding,,,,,,,1,35.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr3m,,,pgxcs-kftvoomr,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-64,hepatocellular carcinoma [hepatitis C liver cirrhosis],NCIT:C3099,Hepatocellular Carcinoma,pgx:icdom-81703,"Hepatocellular carcinoma, NOS",pgx:icdot-C22.0,Liver,NCIT:C27971,Stage IV,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P63Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,ERBB2
5bab56c4727983b2e00aca92,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,cholangiocarcinoma,PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C35417,Intrahepatic Cholangiocarcinoma,icdom-81603,Cholangiocarcinoma,icdot-C22.1,intrahepatic bile ducts,pgxbs-kftvgr1d,P78Y,pgxind-kftx2j01,pgxcs-kftvonym,1127745488,0.392,848282109,0.295,279463379,0.097,PGX_AM_BS_HCC-CC-hom-14,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,{},2020-09-10 17:44:17.405000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,1,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr1d,,,pgxcs-kftvonym,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-14,cholangiocarcinoma,NCIT:C35417,Intrahepatic Cholangiocarcinoma,pgx:icdom-81603,Cholangiocarcinoma,pgx:icdot-C22.1,Intrahepatic bile duct,NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,,,,P78Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,ERBB2
5bab56c4727983b2e00aca96,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,cholangiocarcinoma,PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C35417,Intrahepatic Cholangiocarcinoma,icdom-81603,Cholangiocarcinoma,icdot-C22.1,intrahepatic bile ducts,pgxbs-kftvgr1k,P36Y,pgxind-kftx2j0a,pgxcs-kftvoo0l,633016973,0.22,498624480,0.173,134392493,0.047,PGX_AM_BS_HCC-CC-hom-18,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,{},2020-09-10 17:44:17.411000,T4,NCITstage-C27971,Stage IV,TNM-C48732,T4 Stage Finding,,,,,,,1,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgr1k,,,pgxcs-kftvoo0l,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-18,cholangiocarcinoma,NCIT:C35417,Intrahepatic Cholangiocarcinoma,pgx:icdom-81603,Cholangiocarcinoma,pgx:icdot-C22.1,Intrahepatic bile duct,NCIT:C27971,Stage IV,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,,,,P36Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,ERBB2
5bab56c4727983b2e00aca9a,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,cholangiocarcinoma,PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C35417,Intrahepatic Cholangiocarcinoma,icdom-81603,Cholangiocarcinoma,icdot-C22.1,intrahepatic bile ducts,pgxbs-kftvgr1q,P62Y,pgxind-kftx2j0i,pgxcs-kftvoo2j,1263444464,0.439,830611806,0.289,432832658,0.151,PGX_AM_BS_HCC-CC-hom-22,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,{},2020-09-10 17:44:17.416000,T4,NCITstage-C27971,Stage IV,TNM-C48732,T4 Stage Finding,,,,,,,1,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr1q,,,pgxcs-kftvoo2j,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-22,cholangiocarcinoma,NCIT:C35417,Intrahepatic Cholangiocarcinoma,pgx:icdom-81603,Cholangiocarcinoma,pgx:icdot-C22.1,Intrahepatic bile duct,NCIT:C27971,Stage IV,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,,,,P62Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,ERBB2
5bab56cc727983b2e00b07e8,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,hepatoblastoma [Embryonal],PMID:11509117,"Kumon K, Kobayashi H et al. (2001): Frequent increase of DNA copy number...",NCIT:C3728,Hepatoblastoma,icdom-89703,Hepatoblastoma,icdot-C22.0,Liver,pgxbs-kftvhb0v,P0Y7M,pgxind-kftx37k0,pgxcs-kftvuro9,717132114,0.249,0,0.0,717132114,0.249,PGX_AM_BS_HepBlast-kum-991,{},137.95,35.83,Point,JPN,Ina,Japan,"Ina, Japan",35.83,137.95,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:39.513000,,,,,,,,,,,,0,80.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvhb0v,,,pgxcs-kftvuro9,PMID:11509117,,,,,,,,PGX_AM_BS_HepBlast-kum-991,hepatoblastoma [Embryonal],NCIT:C3728,Hepatoblastoma,pgx:icdom-89703,Hepatoblastoma,pgx:icdot-C22.0,Liver,NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P0Y7M,,,EFO:0030041,alive (follow-up status),,Ina,Japan,JPN,137.95::35.83,,,,,,,,,,ERBB2
5bab56cc727983b2e00b07c6,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,hepatoblastoma [Unclassifiable],PMID:11509117,"Kumon K, Kobayashi H et al. (2001): Frequent increase of DNA copy number...",NCIT:C3728,Hepatoblastoma,icdom-89703,Hepatoblastoma,icdot-C22.0,Liver,pgxbs-kftvhazc,P2Y,pgxind-kftx37i3,pgxcs-kftvur7q,426516644,0.148,129017282,0.045,297499362,0.103,PGX_AM_BS_HepBlast-kum-1107,{},137.95,35.83,Point,JPN,Ina,Japan,"Ina, Japan",35.83,137.95,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:39.465000,,,,,,,,,,,,1,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvhazc,,,pgxcs-kftvur7q,PMID:11509117,,,,,,,,PGX_AM_BS_HepBlast-kum-1107,hepatoblastoma [Unclassifiable],NCIT:C3728,Hepatoblastoma,pgx:icdom-89703,Hepatoblastoma,pgx:icdot-C22.0,Liver,NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P2Y,,,EFO:0030049,dead (follow-up status),,Ina,Japan,JPN,137.95::35.83,,,,,,,,,,ERBB2
5bab56c6727983b2e00adaf6,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Squamous cell carcinoma [esophagus],PMID:17470683,"Hirasaki S, Noguchi T et al. (2007): BAC clones related to prognosis in...",NCIT:C4024,Esophageal Squamous Cell Carcinoma,icdom-80703,"Squamous cell carcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvgwah,,pgxind-kftx2pkh,pgxcs-kftvqang,2947212661,1.0,0,0.0,2947212661,1.0,PGX_AM_BS_EsSCC-hir-5,,131.5,33.28,Point,JPN,Beppu,Japan,"Beppu, Japan",33.28,131.5,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:23.211000,T1N1M0,NCITstage-C27966,Stage I,TNM-C48706,N1 Stage Finding,TNM-C48714,N3 Stage Finding,TNM-C48720,T1 Stage Finding,,,0,60.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pgxbs-kftvgwah,,,pgxcs-kftvqang,PMID:17470683,,,,,,,,PGX_AM_BS_EsSCC-hir-5,Squamous cell carcinoma [esophagus],NCIT:C4024,Esophageal Squamous Cell Carcinoma,pgx:icdom-80703,"Squamous cell carcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27966,Stage I,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,,,,EFO:0030041,alive (follow-up status),,Beppu,Japan,JPN,131.5::33.28,,,,,,,,,,ERBB2
5bab56c6727983b2e00adc66,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,squamous cell carcinoma [esophagus],PMID:17298740,"Wu SS, Liu JF et al. (2007): [Analyzing chromosomal abnormality in primary esophageal...",NCIT:C4024,Esophageal Squamous Cell Carcinoma,icdom-80703,"Squamous cell carcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvgwr6,,pgxind-kftx2q5d,pgxcs-kftvqfrs,846925028,0.295,345128655,0.12,501796373,0.175,PGX_AM_BS_17298740_ESCC-wu-10,{},116.4,39.91,Point,CHN,Beijing,China,"Beijing, China",39.91,116.4,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:23.720000,,,,,,,,,,,,0,36.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pgxbs-kftvgwr6,,,pgxcs-kftvqfrs,PMID:17298740,,,,,,,,PGX_AM_BS_17298740_ESCC-wu-10,squamous cell carcinoma [esophagus],NCIT:C4024,Esophageal Squamous Cell Carcinoma,pgx:icdom-80703,"Squamous cell carcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,,,,EFO:0030041,alive (follow-up status),,Beijing,China,CHN,116.4::39.91,,,,,,,,,,ERBB2
5bab56c6727983b2e00adc6a,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,squamous cell carcinoma [esophagus],PMID:17298740,"Wu SS, Liu JF et al. (2007): [Analyzing chromosomal abnormality in primary esophageal...",NCIT:C4024,Esophageal Squamous Cell Carcinoma,icdom-80703,"Squamous cell carcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvgwrc,,pgxind-kftx2q5l,pgxcs-kftvqftq,1021059741,0.355,58617675,0.02,962442066,0.335,PGX_AM_BS_17298740_ESCC-wu-14,{},116.4,39.91,Point,CHN,Beijing,China,"Beijing, China",39.91,116.4,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:23.726000,,,,,,,,,,,,0,36.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pgxbs-kftvgwrc,,,pgxcs-kftvqftq,PMID:17298740,,,,,,,,PGX_AM_BS_17298740_ESCC-wu-14,squamous cell carcinoma [esophagus],NCIT:C4024,Esophageal Squamous Cell Carcinoma,pgx:icdom-80703,"Squamous cell carcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,,,,EFO:0030041,alive (follow-up status),,Beijing,China,CHN,116.4::39.91,,,,,,,,,,ERBB2
5bab56c6727983b2e00adc6b,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,squamous cell carcinoma [esophagus],PMID:17298740,"Wu SS, Liu JF et al. (2007): [Analyzing chromosomal abnormality in primary esophageal...",NCIT:C4024,Esophageal Squamous Cell Carcinoma,icdom-80703,"Squamous cell carcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvgwre,,pgxind-kftx2q5n,pgxcs-kftvqfu8,283513568,0.099,0,0.0,283513568,0.099,PGX_AM_BS_17298740_ESCC-wu-15,{},116.4,39.91,Point,CHN,Beijing,China,"Beijing, China",39.91,116.4,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:23.727000,,,,,,,,,,,,0,36.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pgxbs-kftvgwre,,,pgxcs-kftvqfu8,PMID:17298740,,,,,,,,PGX_AM_BS_17298740_ESCC-wu-15,squamous cell carcinoma [esophagus],NCIT:C4024,Esophageal Squamous Cell Carcinoma,pgx:icdom-80703,"Squamous cell carcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,,,,EFO:0030041,alive (follow-up status),,Beijing,China,CHN,116.4::39.91,,,,,,,,,,ERBB2
5bab56c6727983b2e00adaef,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Squamous cell carcinoma [esophagus],PMID:17470683,"Hirasaki S, Noguchi T et al. (2007): BAC clones related to prognosis in...",NCIT:C4024,Esophageal Squamous Cell Carcinoma,icdom-80703,"Squamous cell carcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvgwa5,,pgxind-kftx2pk3,pgxcs-kftvqak2,1185569250,0.412,1107282179,0.385,78287071,0.027,PGX_AM_BS_EsSCC-hir-25,,131.5,33.28,Point,JPN,Beppu,Japan,"Beppu, Japan",33.28,131.5,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:23.201000,T3N1M1,NCITstage-C27970,Stage III,TNM-C48700,M1 Stage Finding,TNM-C48706,N1 Stage Finding,TNM-C48714,N3 Stage Finding,,,1,9.0,TNM-C48728,T3 Stage Finding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pgxbs-kftvgwa5,,,pgxcs-kftvqak2,PMID:17470683,,,,,,,,PGX_AM_BS_EsSCC-hir-25,Squamous cell carcinoma [esophagus],NCIT:C4024,Esophageal Squamous Cell Carcinoma,pgx:icdom-80703,"Squamous cell carcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,,,,EFO:0030049,dead (follow-up status),,Beppu,Japan,JPN,131.5::33.28,,,,,,,,,,ERBB2
5bab56c6727983b2e00adc5d,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,squamous cell carcinoma [esophagus],PMID:17298740,"Wu SS, Liu JF et al. (2007): [Analyzing chromosomal abnormality in primary esophageal...",NCIT:C4024,Esophageal Squamous Cell Carcinoma,icdom-80703,"Squamous cell carcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvgwqr,,pgxind-kftx2q4v,pgxcs-kftvqfnh,461859299,0.161,123531834,0.043,338327465,0.118,PGX_AM_BS_17298740_ESCC-wu-01,{},116.4,39.91,Point,CHN,Beijing,China,"Beijing, China",39.91,116.4,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:23.707000,,,,,,,,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pgxbs-kftvgwqr,,,pgxcs-kftvqfnh,PMID:17298740,,,,,,,,PGX_AM_BS_17298740_ESCC-wu-01,squamous cell carcinoma [esophagus],NCIT:C4024,Esophageal Squamous Cell Carcinoma,pgx:icdom-80703,"Squamous cell carcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,,,,EFO:0030049,dead (follow-up status),,Beijing,China,CHN,116.4::39.91,,,,,,,,,,ERBB2
5bab56c6727983b2e00adc61,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,squamous cell carcinoma [esophagus],PMID:17298740,"Wu SS, Liu JF et al. (2007): [Analyzing chromosomal abnormality in primary esophageal...",NCIT:C4024,Esophageal Squamous Cell Carcinoma,icdom-80703,"Squamous cell carcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvgwqx,,pgxind-kftx2q53,pgxcs-kftvqfpe,612223025,0.213,124817278,0.043,487405747,0.17,PGX_AM_BS_17298740_ESCC-wu-05,{},116.4,39.91,Point,CHN,Beijing,China,"Beijing, China",39.91,116.4,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:23.713000,,,,,,,,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pgxbs-kftvgwqx,,,pgxcs-kftvqfpe,PMID:17298740,,,,,,,,PGX_AM_BS_17298740_ESCC-wu-05,squamous cell carcinoma [esophagus],NCIT:C4024,Esophageal Squamous Cell Carcinoma,pgx:icdom-80703,"Squamous cell carcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,,,,EFO:0030049,dead (follow-up status),,Beijing,China,CHN,116.4::39.91,,,,,,,,,,ERBB2
5bab56c6727983b2e00adc62,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,squamous cell carcinoma [esophagus],PMID:17298740,"Wu SS, Liu JF et al. (2007): [Analyzing chromosomal abnormality in primary esophageal...",NCIT:C4024,Esophageal Squamous Cell Carcinoma,icdom-80703,"Squamous cell carcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvgwqz,,pgxind-kftx2q55,pgxcs-kftvqfpw,665397116,0.231,59500059,0.021,605897057,0.211,PGX_AM_BS_17298740_ESCC-wu-06,{},116.4,39.91,Point,CHN,Beijing,China,"Beijing, China",39.91,116.4,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:23.714000,,,,,,,,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pgxbs-kftvgwqz,,,pgxcs-kftvqfpw,PMID:17298740,,,,,,,,PGX_AM_BS_17298740_ESCC-wu-06,squamous cell carcinoma [esophagus],NCIT:C4024,Esophageal Squamous Cell Carcinoma,pgx:icdom-80703,"Squamous cell carcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,,,,EFO:0030049,dead (follow-up status),,Beijing,China,CHN,116.4::39.91,,,,,,,,,,ERBB2
5bab56cb727983b2e00afcc2,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Esophageal squamous cell carcinoma,PMID:12419583,"Wei F, Ni J, Wu SS et al. (2002): Cytogenetic studies of esophageal squamous cell...",NCIT:C4024,Esophageal Squamous Cell Carcinoma,icdom-80703,"Squamous cell carcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvh7g4,,pgxind-kftx332w,pgxcs-kftvtnpy,1275822477,0.444,425326170,0.148,850496307,0.296,PGX_AM_BS_EsSCC-16,,116.4,39.91,Point,CHN,Beijing,China,"Beijing, China",39.91,116.4,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:35.573000,T3N0M0,NCITstage-C27970,Stage III,TNM-C48705,N0 Stage Finding,TNM-C48728,T3 Stage Finding,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvh7g4,,,pgxcs-kftvtnpy,PMID:12419583,,,,,,,,PGX_AM_BS_EsSCC-16,Esophageal squamous cell carcinoma,NCIT:C4024,Esophageal Squamous Cell Carcinoma,pgx:icdom-80703,"Squamous cell carcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,,,,EFO:0030049,dead (follow-up status),,Beijing,China,CHN,116.4::39.91,,,,,,,,,,ERBB2
5bab56cb727983b2e00afcc5,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Esophageal squamous cell carcinoma,PMID:12419583,"Wei F, Ni J, Wu SS et al. (2002): Cytogenetic studies of esophageal squamous cell...",NCIT:C4024,Esophageal Squamous Cell Carcinoma,icdom-80703,"Squamous cell carcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvh7g9,,pgxind-kftx3332,pgxcs-kftvtnrf,1377000844,0.479,669167683,0.233,707833161,0.246,PGX_AM_BS_EsSCC-19,,116.4,39.91,Point,CHN,Beijing,China,"Beijing, China",39.91,116.4,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:35.578000,T3N1M0,NCITstage-C27970,Stage III,TNM-C48706,N1 Stage Finding,TNM-C48714,N3 Stage Finding,TNM-C48728,T3 Stage Finding,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvh7g9,,,pgxcs-kftvtnrf,PMID:12419583,,,,,,,,PGX_AM_BS_EsSCC-19,Esophageal squamous cell carcinoma,NCIT:C4024,Esophageal Squamous Cell Carcinoma,pgx:icdom-80703,"Squamous cell carcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,,,,EFO:0030049,dead (follow-up status),,Beijing,China,CHN,116.4::39.91,,,,,,,,,,ERBB2
5bab56cb727983b2e00afcc7,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Esophageal squamous cell carcinoma,PMID:12419583,"Wei F, Ni J, Wu SS et al. (2002): Cytogenetic studies of esophageal squamous cell...",NCIT:C4024,Esophageal Squamous Cell Carcinoma,icdom-80703,"Squamous cell carcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvh7gc,,pgxind-kftx3336,pgxcs-kftvtnse,1059223676,0.368,225885965,0.079,833337711,0.29,PGX_AM_BS_EsSCC-21,,116.4,39.91,Point,CHN,Beijing,China,"Beijing, China",39.91,116.4,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:35.581000,T3N1M0,NCITstage-C27970,Stage III,TNM-C48706,N1 Stage Finding,TNM-C48714,N3 Stage Finding,TNM-C48728,T3 Stage Finding,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvh7gc,,,pgxcs-kftvtnse,PMID:12419583,,,,,,,,PGX_AM_BS_EsSCC-21,Esophageal squamous cell carcinoma,NCIT:C4024,Esophageal Squamous Cell Carcinoma,pgx:icdom-80703,"Squamous cell carcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,,,,EFO:0030049,dead (follow-up status),,Beijing,China,CHN,116.4::39.91,,,,,,,,,,ERBB2
5bab56ce727983b2e00b197c,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,adenocarcinoma [esophagus],geo:GPL5711,,NCIT:C4025,Esophageal Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvhgyz,P62Y,pgxind-kftx3ekf,pgxcs-kftvwj4d,1050479893,0.365,690877763,0.24,359602130,0.125,PGX_AM_BS_GSM265808,,153.02,-27.45,Point,AUS,Herston,Australia,"Herston, Australia",-27.45,153.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:45.735000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,0,23.0,,,PMID:18519675,"Nancarrow DJ, Handoko HY et al. (2008): Genome-wide copy number analysis in esophageal...",pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),pgxcohort-2021progenetix,Version at Progenetix Update 2021,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:GSE10506,,geo:GSM265808,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvhgyz,,,pgxcs-kftvwj4d,PMID:18519675,,,,,,,,PGX_AM_BS_GSM265808,adenocarcinoma [esophagus],NCIT:C4025,Esophageal Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27968,Stage IIb,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,P62Y,,,EFO:0030041,alive (follow-up status),,Herston,Australia,AUS,153.02::-27.45,,,,,geo:GSM265808,geo:GSE10506,geo:GPL5711,,,ERBB2
5bab56ce727983b2e00b197e,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,adenocarcinoma [esophagus],geo:GSM266075,,NCIT:C4025,Esophageal Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvhgz2,P65Y,pgxind-kftx3ekk,pgxcs-kftvwj5d,1001163624,0.348,592904485,0.206,408259139,0.142,PGX_AM_BS_GSM266075,,153.02,-27.45,Point,AUS,Herston,Australia,"Herston, Australia",-27.45,153.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:45.738000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,0,20.0,,,geo:GSE10506,,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),pgxcohort-2021progenetix,Version at Progenetix Update 2021,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),PMID:18519675,"Nancarrow DJ, Handoko HY et al. (2008): Genome-wide copy number analysis in esophageal...",geo:GPL5711,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvhgz2,,,pgxcs-kftvwj5d,PMID:18519675,,,,,,,,PGX_AM_BS_GSM266075,adenocarcinoma [esophagus],NCIT:C4025,Esophageal Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,P65Y,,,EFO:0030041,alive (follow-up status),,Herston,Australia,AUS,153.02::-27.45,,,,,geo:GSM266075,geo:GSE10506,geo:GPL5711,,,ERBB2
5bab56ce727983b2e00b1983,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,adenocarcinoma [esophagus],geo:GPL5711,,NCIT:C4025,Esophageal Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvhgza,P69Y,pgxind-kftx3eku,pgxcs-kftvwj7u,830858339,0.289,480482392,0.167,350375947,0.122,PGX_AM_BS_GSM266661,,153.02,-27.45,Point,AUS,Herston,Australia,"Herston, Australia",-27.45,153.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:45.745000,T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,,,,,0,15.0,,,PMID:18519675,"Nancarrow DJ, Handoko HY et al. (2008): Genome-wide copy number analysis in esophageal...",pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),pgxcohort-2021progenetix,Version at Progenetix Update 2021,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:GSE10506,,geo:GSM266661,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvhgza,,,pgxcs-kftvwj7u,PMID:18519675,,,,,,,,PGX_AM_BS_GSM266661,adenocarcinoma [esophagus],NCIT:C4025,Esophageal Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27966,Stage I,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,P69Y,,,EFO:0030041,alive (follow-up status),,Herston,Australia,AUS,153.02::-27.45,,,,,geo:GSM266661,geo:GSE10506,geo:GPL5711,,,ERBB2
5bab56ce727983b2e00b1987,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,adenocarcinoma [esophagus],geo:GSM266707,,NCIT:C4025,Esophageal Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvhgzh,P78Y,pgxind-kftx3el2,pgxcs-kftvwj9t,1586895216,0.552,736921827,0.256,849973389,0.296,PGX_AM_BS_GSM266707,,153.02,-27.45,Point,AUS,Herston,Australia,"Herston, Australia",-27.45,153.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:45.751000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,0,15.0,,,PMID:18519675,"Nancarrow DJ, Handoko HY et al. (2008): Genome-wide copy number analysis in esophageal...",pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),pgxcohort-2021progenetix,Version at Progenetix Update 2021,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:GSE10506,,geo:GPL5711,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvhgzh,,,pgxcs-kftvwj9t,PMID:18519675,,,,,,,,PGX_AM_BS_GSM266707,adenocarcinoma [esophagus],NCIT:C4025,Esophageal Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27967,Stage IIa,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,P78Y,,,EFO:0030041,alive (follow-up status),,Herston,Australia,AUS,153.02::-27.45,,,,,geo:GSM266707,geo:GSE10506,geo:GPL5711,,,ERBB2
5bab56ce727983b2e00b197b,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,adenocarcinoma [esophagus],PMID:18519675,"Nancarrow DJ, Handoko HY et al. (2008): Genome-wide copy number analysis in esophageal...",NCIT:C4025,Esophageal Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvhgyx,P72Y,pgxind-kftx3ekd,pgxcs-kftvwj3w,1580009098,0.55,884423576,0.308,695585522,0.242,PGX_AM_BS_GSM265787,,153.02,-27.45,Point,AUS,Herston,Australia,"Herston, Australia",-27.45,153.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:45.733000,T4,NCITstage-C27971,Stage IV,TNM-C48732,T4 Stage Finding,,,,,,,1,2.0,,,geo:GSE10506,,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),pgxcohort-2021progenetix,Version at Progenetix Update 2021,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:GSM265787,,geo:GPL5711,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvhgyx,,,pgxcs-kftvwj3w,PMID:18519675,,,,,,,,PGX_AM_BS_GSM265787,adenocarcinoma [esophagus],NCIT:C4025,Esophageal Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27980,Stage IVb,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,P72Y,,,EFO:0030049,dead (follow-up status),,Herston,Australia,AUS,153.02::-27.45,,,,,geo:GSM265787,geo:GSE10506,geo:GPL5711,,,ERBB2
5bab56ce727983b2e00b197d,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,adenocarcinoma [esophagus],PMID:18519675,"Nancarrow DJ, Handoko HY et al. (2008): Genome-wide copy number analysis in esophageal...",NCIT:C4025,Esophageal Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvhgz1,P62Y,pgxind-kftx3eki,pgxcs-kftvwj4v,621290996,0.216,439452456,0.153,181838540,0.063,PGX_AM_BS_GSM266074,,153.02,-27.45,Point,AUS,Herston,Australia,"Herston, Australia",-27.45,153.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:45.736000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,1,22.0,,,geo:GSE10506,,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),pgxcohort-2021progenetix,Version at Progenetix Update 2021,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:GSM266074,,geo:GPL5711,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvhgz1,,,pgxcs-kftvwj4v,PMID:18519675,,,,,,,,PGX_AM_BS_GSM266074,adenocarcinoma [esophagus],NCIT:C4025,Esophageal Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27967,Stage IIa,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,P62Y,,,EFO:0030049,dead (follow-up status),,Herston,Australia,AUS,153.02::-27.45,,,,,geo:GSM266074,geo:GSE10506,geo:GPL5711,,,ERBB2
5bab56ce727983b2e00b1982,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,adenocarcinoma [esophagus],geo:GPL5711,,NCIT:C4025,Esophageal Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvhgz9,P65Y,pgxind-kftx3eks,pgxcs-kftvwj7c,931363932,0.324,496954362,0.173,434409570,0.151,PGX_AM_BS_GSM266660,,153.02,-27.45,Point,AUS,Herston,Australia,"Herston, Australia",-27.45,153.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:45.744000,T4,NCITstage-C27971,Stage IV,TNM-C48732,T4 Stage Finding,,,,,,,1,6.0,,,geo:GSM266660,,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),pgxcohort-2021progenetix,Version at Progenetix Update 2021,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:GSE10506,,PMID:18519675,"Nancarrow DJ, Handoko HY et al. (2008): Genome-wide copy number analysis in esophageal...",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvhgz9,,,pgxcs-kftvwj7c,PMID:18519675,,,,,,,,PGX_AM_BS_GSM266660,adenocarcinoma [esophagus],NCIT:C4025,Esophageal Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27979,Stage IVa,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,P65Y,,,EFO:0030049,dead (follow-up status),,Herston,Australia,AUS,153.02::-27.45,,,,,geo:GSM266660,geo:GSE10506,geo:GPL5711,,,ERBB2
5bab56ce727983b2e00b1985,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,adenocarcinoma [esophagus],PMID:18519675,"Nancarrow DJ, Handoko HY et al. (2008): Genome-wide copy number analysis in esophageal...",NCIT:C4025,Esophageal Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvhgze,P79Y,pgxind-kftx3eky,pgxcs-kftvwj8u,1133265781,0.394,556089386,0.193,577176395,0.201,PGX_AM_BS_GSM266705,,153.02,-27.45,Point,AUS,Herston,Australia,"Herston, Australia",-27.45,153.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:45.748000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,1,16.0,,,geo:GSE10506,,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),pgxcohort-2021progenetix,Version at Progenetix Update 2021,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:GSM266705,,geo:GPL5711,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvhgze,,,pgxcs-kftvwj8u,PMID:18519675,,,,,,,,PGX_AM_BS_GSM266705,adenocarcinoma [esophagus],NCIT:C4025,Esophageal Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,P79Y,,,EFO:0030049,dead (follow-up status),,Herston,Australia,AUS,153.02::-27.45,,,,,geo:GSM266705,geo:GSE10506,geo:GPL5711,,,ERBB2
5bab56ce727983b2e00b1986,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,adenocarcinoma [esophagus],geo:GSE10506,,NCIT:C4025,Esophageal Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvhgzf,P56Y,pgxind-kftx3el0,pgxcs-kftvwj9b,1106784670,0.385,590582266,0.205,516202404,0.18,PGX_AM_BS_GSM266706,,153.02,-27.45,Point,AUS,Herston,Australia,"Herston, Australia",-27.45,153.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:45.750000,T4,NCITstage-C27971,Stage IV,TNM-C48732,T4 Stage Finding,,,,,,,1,14.0,,,PMID:18519675,"Nancarrow DJ, Handoko HY et al. (2008): Genome-wide copy number analysis in esophageal...",pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),pgxcohort-2021progenetix,Version at Progenetix Update 2021,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:GSM266706,,geo:GPL5711,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvhgzf,,,pgxcs-kftvwj9b,PMID:18519675,,,,,,,,PGX_AM_BS_GSM266706,adenocarcinoma [esophagus],NCIT:C4025,Esophageal Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27979,Stage IVa,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,P56Y,,,EFO:0030049,dead (follow-up status),,Herston,Australia,AUS,153.02::-27.45,,,,,geo:GSM266706,geo:GSE10506,geo:GPL5711,,,ERBB2
5bab56ce727983b2e00b1988,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,adenocarcinoma [esophagus],geo:GPL5711,,NCIT:C4025,Esophageal Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvhgzj,P71Y,pgxind-kftx3el4,pgxcs-kftvwjab,1420469696,0.494,800137678,0.278,620332018,0.216,PGX_AM_BS_GSM266708,,153.02,-27.45,Point,AUS,Herston,Australia,"Herston, Australia",-27.45,153.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:45.752000,T4,NCITstage-C27971,Stage IV,TNM-C48732,T4 Stage Finding,,,,,,,1,10.0,,,PMID:18519675,"Nancarrow DJ, Handoko HY et al. (2008): Genome-wide copy number analysis in esophageal...",pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),pgxcohort-2021progenetix,Version at Progenetix Update 2021,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:GSE10506,,geo:GSM266708,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvhgzj,,,pgxcs-kftvwjab,PMID:18519675,,,,,,,,PGX_AM_BS_GSM266708,adenocarcinoma [esophagus],NCIT:C4025,Esophageal Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27979,Stage IVa,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,P71Y,,,EFO:0030049,dead (follow-up status),,Herston,Australia,AUS,153.02::-27.45,,,,,geo:GSM266708,geo:GSE10506,geo:GPL5711,,,ERBB2
5bab56c7727983b2e00ae073,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,adenocarcinoma [colorectal; liver metastasis],PMID:17044061,"Habermann JK, Paulsen U et al. (2007): Stage-specific alterations of the genome, transcriptome,...",NCIT:C4349,Colon Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C18.9,"large intestine, excl. rectum and rectosigmoid junction",pgxbs-kftvgydc,P84Y,pgxind-kftx2rrd,pgxcs-kftvquas,1164222946,0.405,561494839,0.195,602728107,0.21,PGX_AM_BS_NCBISKYCGH-3736,{},-77.1,38.98,Point,USA,Bethesda,United States of America,"Bethesda, United States",38.98,-77.1,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001155,colon,{},2020-09-10 17:44:25.151000,T0N0M1,,,TNM-C48699,M0 Stage Finding,TNM-C48700,M1 Stage Finding,TNM-C48705,N0 Stage Finding,,,0,48.0,TNM-C48719,T0 Stage Finding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgydc,,,pgxcs-kftvquas,PMID:17044061,,,,,,,,PGX_AM_BS_NCBISKYCGH-3736,adenocarcinoma [colorectal; liver metastasis],NCIT:C4349,Colon Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C18.9,"Colon, NOS",NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0001155,colon,,,,P84Y,,,EFO:0030041,alive (follow-up status),,Bethesda,United States of America,USA,-77.1::38.98,,,,,,,,,,ERBB2
5bab56c7727983b2e00ae063,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,adenocarcinoma [colon ascendens],PMID:17044061,"Habermann JK, Paulsen U et al. (2007): Stage-specific alterations of the genome, transcriptome,...",NCIT:C4349,Colon Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C18.9,"large intestine, excl. rectum and rectosigmoid junction",pgxbs-kftvgycm,P65Y,pgxind-kftx2rqh,pgxcs-kftvqu2t,1465371574,0.51,762822628,0.265,702548946,0.244,PGX_AM_BS_NCBISKYCGH-3718,,-77.1,38.98,Point,USA,Bethesda,United States of America,"Bethesda, United States",38.98,-77.1,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001155,colon,{},2020-09-10 17:44:25.129000,T3N2M1,NCITstage-C27970,Stage III,TNM-C48700,M1 Stage Finding,TNM-C48786,N2 Stage Finding,TNM-C48728,T3 Stage Finding,,,1,7.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgycm,,,pgxcs-kftvqu2t,PMID:17044061,,,,,,,,PGX_AM_BS_NCBISKYCGH-3718,adenocarcinoma [colon ascendens],NCIT:C4349,Colon Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C18.9,"Colon, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001155,colon,,,,P65Y,,,EFO:0030049,dead (follow-up status),,Bethesda,United States of America,USA,-77.1::38.98,,,,,,,,,,ERBB2
5c865b3a09d374f2dc2b8e27,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,"colorectal carcinoma [right, mucinous]",geo:GSM288107,,NCIT:C4349,Colon Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C18.9,"Colon, NOS",pgxbs-kftvia5o,P94Y10M,pgxind-kftx3wx3,pgxcs-kftw5nn9,314062432,0.109,123498142,0.043,190564290,0.066,PGX_AM_BS_GSM288107,,139.85,36.4,Point,JPN,Shimotsuke-shi,Japan,"Shimotsuke-shi, Japan",36.4,139.85,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001155,colon,{},2020-09-10 17:45:18.391000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,1,45.5,,,geo:GPL2005,,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),pgxcohort-2021progenetix,Version at Progenetix Update 2021,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:GSE11417,,PMID:18564138,"Kurashina K, Yamashita Y et al. (2008): Chromosome copy number analysis in screening...",geo:gsm,geo:gpl,geo:gse,,,,,,pubmed,,,,arraymap import,0.22,SNP2pop 1000 Genomes population,HANCESTRO:0027,Han Chinese,0.24,SNP2pop 1000 Genomes superpopulation,HANCESTRO:0009,East Asian,,,,,,,,,,,,M,pgxbs-kftvia5o,,,pgxcs-kftw5nn9,PMID:18564138,,,,,,,,PGX_AM_BS_GSM288107,"colorectal carcinoma [right, mucinous]",NCIT:C4349,Colon Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C18.9,"Colon, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001155,colon,,,,P94Y10M,,,EFO:0030039,no followup status,,Shimotsuke-shi,Japan,JPN,139.85::36.4,,,,,geo:GSM288107,geo:GSE11417,geo:GPL2005,,,ERBB2
5bab56cb727983b2e00afce7,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"Enteropathy-Type T-Cell Lymphoma [pleomorphic, medium and large cells]",PMID:12414511,"Zettl A, Ott G, Makulik A et al. (2002): Chromosomal gains at 9q characterize enteropathy-type...",NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,icdom-97173,Intestinal T-cell lymphoma,icdot-C26.9,unspecified digest. Organs,pgxbs-kftvh7hs,P61Y,pgxind-kftx3350,pgxcs-kftvto7o,256915403,0.089,213540617,0.074,43374786,0.015,PGX_AM_BS_EP-T-NHL-10,,9.95,49.79,Point,DEU,Wuerzburg,Germany,"Wuerzburg, Germany",49.79,9.95,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001007,digestive system,{},2020-09-10 17:44:35.624000,T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,,,,,1,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvh7hs,,,pgxcs-kftvto7o,PMID:12414511,,,,,,,,PGX_AM_BS_EP-T-NHL-10,"Enteropathy-Type T-Cell Lymphoma [pleomorphic, medium and large cells]",NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,pgx:icdom-97173,Intestinal T-cell lymphoma,pgx:icdot-C26.9,"Gastrointestinal tract, NOS",NCIT:C27966,Stage I,EFO:0009656,neoplastic sample,UBERON:0001007,digestive system,,,,P61Y,,,EFO:0030049,dead (follow-up status),,Wuerzburg,Germany,DEU,9.95::49.79,,,,,,,,,,ERBB2
5bab56cb727983b2e00afcf8,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Enteropathy-Type T-Cell Lymphoma [monomorphic with small- to medium-sized cells],PMID:12414511,"Zettl A, Ott G, Makulik A et al. (2002): Chromosomal gains at 9q characterize enteropathy-type...",NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,icdom-97173,Intestinal T-cell lymphoma,icdot-C26.9,unspecified digest. Organs,pgxbs-kftvh7ik,P39Y,pgxind-kftx335z,pgxcs-kftvtofs,372279815,0.129,82500082,0.029,289779733,0.101,PGX_AM_BS_EP-T-NHL-26,,9.95,49.79,Point,DEU,Wuerzburg,Germany,"Wuerzburg, Germany",49.79,9.95,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001007,digestive system,{},2020-09-10 17:44:35.648000,T4,NCITstage-C27971,Stage IV,TNM-C48732,T4 Stage Finding,,,,,,,1,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvh7ik,,,pgxcs-kftvtofs,PMID:12414511,,,,,,,,PGX_AM_BS_EP-T-NHL-26,Enteropathy-Type T-Cell Lymphoma [monomorphic with small- to medium-sized cells],NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,pgx:icdom-97173,Intestinal T-cell lymphoma,pgx:icdot-C26.9,"Gastrointestinal tract, NOS",NCIT:C27971,Stage IV,EFO:0009656,neoplastic sample,UBERON:0001007,digestive system,,,,P39Y,,,EFO:0030049,dead (follow-up status),,Wuerzburg,Germany,DEU,9.95::49.79,,,,,,,,,,ERBB2
5bab56c9727983b2e00aef89,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"Mucinous colorectal carcinoma [Rectum [above], pT3N1M0, stage II]",PMID:15289862,"Liu XP, Sato T, Oga A et al. (2004): Two subtypes of mucinous colorectal carcinoma...",NCIT:C7966,Colon Mucinous Adenocarcinoma,icdom-84803,Mucinous adenocarcinoma,icdot-C18.9,"large intestine, excl. rectum and rectosigmoid junction",pgxbs-kftvh37n,P75Y,pgxind-kftx2xsk,pgxcs-kftvscd1,1291929548,0.449,685440588,0.238,606488960,0.211,PGX_AM_BS_MucCoCa-liu-16,,131.47,34.19,Point,JPN,Yamaguchi-shi,Japan,"Yamaguchi-shi, Japan",34.19,131.47,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001155,colon,{},2020-09-10 17:44:30.892000,T3N1M0,NCITstage-C28054,Stage II,TNM-C48706,N1 Stage Finding,TNM-C48714,N3 Stage Finding,TNM-C48728,T3 Stage Finding,,,0,107.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvh37n,,,pgxcs-kftvscd1,PMID:15289862,,,,,,,,PGX_AM_BS_MucCoCa-liu-16,"Mucinous colorectal carcinoma [Rectum [above], pT3N1M0, stage II]",NCIT:C7966,Colon Mucinous Adenocarcinoma,pgx:icdom-84803,Mucinous adenocarcinoma,pgx:icdot-C18.9,"Colon, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001155,colon,,,,P75Y,,,EFO:0030041,alive (follow-up status),,Yamaguchi-shi,Japan,JPN,131.47::34.19,,,,,,,,,,ERBB2
5bab56c9727983b2e00aef8d,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"Mucinous colorectal carcinoma [Rectum [above], pT3N1M0, stage II]",PMID:15289862,"Liu XP, Sato T, Oga A et al. (2004): Two subtypes of mucinous colorectal carcinoma...",NCIT:C7966,Colon Mucinous Adenocarcinoma,icdom-84803,Mucinous adenocarcinoma,icdot-C18.9,"large intestine, excl. rectum and rectosigmoid junction",pgxbs-kftvh37u,P65Y,pgxind-kftx2xss,pgxcs-kftvscey,1495035193,0.52,699395763,0.243,795639430,0.277,PGX_AM_BS_MucCoCa-liu-20,,131.47,34.19,Point,JPN,Yamaguchi-shi,Japan,"Yamaguchi-shi, Japan",34.19,131.47,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001155,colon,{},2020-09-10 17:44:30.898000,T3N1M0,NCITstage-C28054,Stage II,TNM-C48706,N1 Stage Finding,TNM-C48714,N3 Stage Finding,TNM-C48728,T3 Stage Finding,,,0,100.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvh37u,,,pgxcs-kftvscey,PMID:15289862,,,,,,,,PGX_AM_BS_MucCoCa-liu-20,"Mucinous colorectal carcinoma [Rectum [above], pT3N1M0, stage II]",NCIT:C7966,Colon Mucinous Adenocarcinoma,pgx:icdom-84803,Mucinous adenocarcinoma,pgx:icdot-C18.9,"Colon, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001155,colon,,,,P65Y,,,EFO:0030041,alive (follow-up status),,Yamaguchi-shi,Japan,JPN,131.47::34.19,,,,,,,,,,ERBB2
5bab56c9727983b2e00aef8e,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"Mucinous colorectal carcinoma [Ascending colon, pT3N0M0, stage I]",PMID:15289862,"Liu XP, Sato T, Oga A et al. (2004): Two subtypes of mucinous colorectal carcinoma...",NCIT:C7966,Colon Mucinous Adenocarcinoma,icdom-84803,Mucinous adenocarcinoma,icdot-C18.9,"large intestine, excl. rectum and rectosigmoid junction",pgxbs-kftvh37w,P91Y,pgxind-kftx2xsu,pgxcs-kftvscfg,991861570,0.345,416560996,0.145,575300574,0.2,PGX_AM_BS_MucCoCa-liu-21,,131.47,34.19,Point,JPN,Yamaguchi-shi,Japan,"Yamaguchi-shi, Japan",34.19,131.47,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001155,colon,{},2020-09-10 17:44:30.899000,T3N0M0,NCITstage-C27966,Stage I,TNM-C48705,N0 Stage Finding,TNM-C48728,T3 Stage Finding,,,,,0,101.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvh37w,,,pgxcs-kftvscfg,PMID:15289862,,,,,,,,PGX_AM_BS_MucCoCa-liu-21,"Mucinous colorectal carcinoma [Ascending colon, pT3N0M0, stage I]",NCIT:C7966,Colon Mucinous Adenocarcinoma,pgx:icdom-84803,Mucinous adenocarcinoma,pgx:icdot-C18.9,"Colon, NOS",NCIT:C27966,Stage I,EFO:0009656,neoplastic sample,UBERON:0001155,colon,,,,P91Y,,,EFO:0030041,alive (follow-up status),,Yamaguchi-shi,Japan,JPN,131.47::34.19,,,,,,,,,,ERBB2
5bab56c1727983b2e00ab6ce,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgknp,P57Y,pgxind-kftx2b4q,pgxcs-kftvmqoo,375113607,0.13,261513494,0.091,113600113,0.04,PGX_AM_BS_PDAC-sto-14,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.313000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,0,23.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgknp,,,pgxcs-kftvmqoo,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-14,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P57Y,,,EFO:0030041,alive (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,ERBB2
5bab56c1727983b2e00ab6d5,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgko1,P50Y,pgxind-kftx2b54,pgxcs-kftvmqrx,1235069614,0.43,541193772,0.188,693875842,0.241,PGX_AM_BS_PDAC-sto-21,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.323000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgko1,,,pgxcs-kftvmqrx,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-21,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P50Y,,,EFO:0030041,alive (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,ERBB2
5bab56c1727983b2e00ab6ea,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgkoz,P75Y,pgxind-kftx2b6a,pgxcs-kftvmr1p,1180879782,0.411,773840865,0.269,407038917,0.142,PGX_AM_BS_PDAC-sto-42,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.353000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,0,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgkoz,,,pgxcs-kftvmr1p,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-42,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P75Y,,,EFO:0030041,alive (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,ERBB2
5bab56c1727983b2e00ab6ee,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgkp5,P62Y,pgxind-kftx2b6i,pgxcs-kftvmr5i,400557910,0.139,232355745,0.081,168202165,0.059,PGX_AM_BS_PDAC-sto-46,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.359000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,0,10.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgkp5,,,pgxcs-kftvmr5i,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-46,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P62Y,,,EFO:0030041,alive (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,ERBB2
5bab56c1727983b2e00ab6ef,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgkp7,P50Y,pgxind-kftx2b6k,pgxcs-kftvmr5z,454995441,0.158,202745470,0.071,252249971,0.088,PGX_AM_BS_PDAC-sto-47,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.360000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,0,17.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgkp7,,,pgxcs-kftvmr5z,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-47,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P50Y,,,EFO:0030041,alive (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,ERBB2
5bab56c1727983b2e00ab6f0,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgkp9,P68Y,pgxind-kftx2b6m,pgxcs-kftvmr6h,595273564,0.207,184545216,0.064,410728348,0.143,PGX_AM_BS_PDAC-sto-48,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.362000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,0,18.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgkp9,,,pgxcs-kftvmr6h,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-48,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P68Y,,,EFO:0030041,alive (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,ERBB2
5bab56c1727983b2e00ab6f1,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgkpa,P64Y,pgxind-kftx2b6o,pgxcs-kftvmr6x,1028256992,0.358,594551142,0.207,433705850,0.151,PGX_AM_BS_PDAC-sto-49,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.363000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,0,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgkpa,,,pgxcs-kftvmr6x,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-49,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P64Y,,,EFO:0030041,alive (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,ERBB2
5bab56c1727983b2e00ab6c4,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgkn9,P81Y,pgxind-kftx2b46,pgxcs-kftvmqk0,607308745,0.211,208133603,0.072,399175142,0.139,PGX_AM_BS_PDAC-sto-04,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.299000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,1,16.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgkn9,,,pgxcs-kftvmqk0,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-04,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P81Y,,,EFO:0030049,dead (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,ERBB2
5bab56c1727983b2e00ab6de,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgkof,P66Y,pgxind-kftx2b5m,pgxcs-kftvmqw4,1102861863,0.384,471612002,0.164,631249861,0.22,PGX_AM_BS_PDAC-sto-30,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.336000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,1,7.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgkof,,,pgxcs-kftvmqw4,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-30,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P66Y,,,EFO:0030049,dead (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,ERBB2
5bab56c1727983b2e00ab6df,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgkoh,P53Y,pgxind-kftx2b5o,pgxcs-kftvmqwl,1209663424,0.421,1011717945,0.352,197945479,0.069,PGX_AM_BS_PDAC-sto-31,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.337000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,1,16.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgkoh,,,pgxcs-kftvmqwl,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-31,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P53Y,,,EFO:0030049,dead (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,ERBB2
5bab56c1727983b2e00ab6e8,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgkow,P58Y,pgxind-kftx2b66,pgxcs-kftvmr0r,664654804,0.231,396732106,0.138,267922698,0.093,PGX_AM_BS_PDAC-sto-40,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.350000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,1,13.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgkow,,,pgxcs-kftvmr0r,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-40,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P58Y,,,EFO:0030049,dead (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,ERBB2
5bab56c1727983b2e00ab6f3,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgkpe,P71Y,pgxind-kftx2b6r,pgxcs-kftvmr7v,1429106309,0.497,262818701,0.091,1166287608,0.406,PGX_AM_BS_PDAC-sto-51,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.366000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,1,14.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgkpe,,,pgxcs-kftvmr7v,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-51,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P71Y,,,EFO:0030049,dead (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,ERBB2
5bab56c7727983b2e00ae061,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,adenocarcinoma [rectum],PMID:17044061,"Habermann JK, Paulsen U et al. (2007): Stage-specific alterations of the genome, transcriptome,...",NCIT:C9383,Rectal Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C20.9,"Rectum, NOS",pgxbs-kftvgycj,P78Y,pgxind-kftx2rqd,pgxcs-kftvqu1v,622456014,0.217,319470785,0.111,302985229,0.105,PGX_AM_BS_NCBISKYCGH-3716,{},-77.1,38.98,Point,USA,Bethesda,United States of America,"Bethesda, United States",38.98,-77.1,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001052,rectum,{},2020-09-10 17:44:25.126000,,,,,,,,,,,,1,45.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgycj,,,pgxcs-kftvqu1v,PMID:17044061,,,,,,,,PGX_AM_BS_NCBISKYCGH-3716,adenocarcinoma [rectum],NCIT:C9383,Rectal Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C20.9,"Rectum, NOS",NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0001052,rectum,,,,P78Y,,,EFO:0030049,dead (follow-up status),,Bethesda,United States of America,USA,-77.1::38.98,,,,,,,,,,ERBB2
5bab56c4727983b2e00aca9c,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,hepatocellular carcinoma [alcoholic cirrhosis],PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C3099,Hepatocellular Carcinoma,icdom-81703,"Hepatocellular carcinoma, NOS",icdot-C22.0,Liver,pgxbs-kftvgr1t,P67Y,pgxind-kftx2j0m,pgxcs-kftvoo3h,145138782,0.05,45200045,0.016,99938737,0.035,PGX_AM_BS_HCC-CC-hom-24,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:17.419000,T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,,,,,0,41.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgr1t,,,pgxcs-kftvoo3h,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-24,hepatocellular carcinoma [alcoholic cirrhosis],NCIT:C3099,Hepatocellular Carcinoma,pgx:icdom-81703,"Hepatocellular carcinoma, NOS",pgx:icdot-C22.0,Liver,NCIT:C27966,Stage I,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P67Y,,,EFO:0030041,alive (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,MYC
5bab56c4727983b2e00aca9f,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,hepatocellular carcinoma [hepatitis B pos.],PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C3099,Hepatocellular Carcinoma,icdom-81703,"Hepatocellular carcinoma, NOS",icdot-C22.0,Liver,pgxbs-kftvgr1y,P71Y,pgxind-kftx2j0s,pgxcs-kftvoo4x,320944782,0.112,130237368,0.045,190707414,0.066,PGX_AM_BS_HCC-CC-hom-27,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:17.423000,T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,,,,,0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr1y,,,pgxcs-kftvoo4x,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-27,hepatocellular carcinoma [hepatitis B pos.],NCIT:C3099,Hepatocellular Carcinoma,pgx:icdom-81703,"Hepatocellular carcinoma, NOS",pgx:icdot-C22.0,Liver,NCIT:C27966,Stage I,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P71Y,,,EFO:0030041,alive (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,MYC
5bab56c4727983b2e00acaa0,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,hepatocellular carcinoma [hepatitis C liver cirrhosis],PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C3099,Hepatocellular Carcinoma,icdom-81703,"Hepatocellular carcinoma, NOS",icdot-C22.0,Liver,pgxbs-kftvgr20,P59Y,pgxind-kftx2j0u,pgxcs-kftvoo5e,675635647,0.235,426803231,0.148,248832416,0.087,PGX_AM_BS_HCC-CC-hom-28,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:17.425000,T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,,,,,0,84.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr20,,,pgxcs-kftvoo5e,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-28,hepatocellular carcinoma [hepatitis C liver cirrhosis],NCIT:C3099,Hepatocellular Carcinoma,pgx:icdom-81703,"Hepatocellular carcinoma, NOS",pgx:icdot-C22.0,Liver,NCIT:C27966,Stage I,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P59Y,,,EFO:0030041,alive (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,MYC
5bab56c4727983b2e00acaa1,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,hepatocellular carcinoma [alcoholic cirrhosis],PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C3099,Hepatocellular Carcinoma,icdom-81703,"Hepatocellular carcinoma, NOS",icdot-C22.0,Liver,pgxbs-kftvgr21,P57Y,pgxind-kftx2j0w,pgxcs-kftvoo5v,531165596,0.185,337926766,0.118,193238830,0.067,PGX_AM_BS_HCC-CC-hom-29,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:17.426000,T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,,,,,0,105.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr21,,,pgxcs-kftvoo5v,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-29,hepatocellular carcinoma [alcoholic cirrhosis],NCIT:C3099,Hepatocellular Carcinoma,pgx:icdom-81703,"Hepatocellular carcinoma, NOS",pgx:icdot-C22.0,Liver,NCIT:C27966,Stage I,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P57Y,,,EFO:0030041,alive (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,MYC
5bab56c4727983b2e00acaa6,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,hepatocellular carcinoma,PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C3099,Hepatocellular Carcinoma,icdom-81703,"Hepatocellular carcinoma, NOS",icdot-C22.0,Liver,pgxbs-kftvgr29,P63Y,pgxind-kftx2j16,pgxcs-kftvoo8a,145138782,0.05,45200045,0.016,99938737,0.035,PGX_AM_BS_HCC-CC-hom-34,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:17.433000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,0,33.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr29,,,pgxcs-kftvoo8a,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-34,hepatocellular carcinoma,NCIT:C3099,Hepatocellular Carcinoma,pgx:icdom-81703,"Hepatocellular carcinoma, NOS",pgx:icdot-C22.0,Liver,NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P63Y,,,EFO:0030041,alive (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,MYC
5bab56c4727983b2e00acaa7,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,hepatocellular carcinoma [alcoholic cirrhosis],PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C3099,Hepatocellular Carcinoma,icdom-81703,"Hepatocellular carcinoma, NOS",icdot-C22.0,Liver,pgxbs-kftvgr2b,P63Y,pgxind-kftx2j18,pgxcs-kftvoo8r,145138782,0.05,45200045,0.016,99938737,0.035,PGX_AM_BS_HCC-CC-hom-35,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:17.434000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,0,7.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr2b,,,pgxcs-kftvoo8r,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-35,hepatocellular carcinoma [alcoholic cirrhosis],NCIT:C3099,Hepatocellular Carcinoma,pgx:icdom-81703,"Hepatocellular carcinoma, NOS",pgx:icdot-C22.0,Liver,NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P63Y,,,EFO:0030041,alive (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,MYC
5bab56c4727983b2e00acaaa,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,hepatocellular carcinoma [alcoholic cirrhosis],PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C3099,Hepatocellular Carcinoma,icdom-81703,"Hepatocellular carcinoma, NOS",icdot-C22.0,Liver,pgxbs-kftvgr2g,P62Y,pgxind-kftx2j1f,pgxcs-kftvooa6,319888676,0.111,97000096,0.034,222888580,0.078,PGX_AM_BS_HCC-CC-hom-38,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:17.438000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,0,64.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr2g,,,pgxcs-kftvooa6,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-38,hepatocellular carcinoma [alcoholic cirrhosis],NCIT:C3099,Hepatocellular Carcinoma,pgx:icdom-81703,"Hepatocellular carcinoma, NOS",pgx:icdot-C22.0,Liver,NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P62Y,,,EFO:0030041,alive (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,MYC
5bab56c4727983b2e00acaab,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"hepatocellular carcinoma [cirrhosis, cryptogenic]",PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C3099,Hepatocellular Carcinoma,icdom-81703,"Hepatocellular carcinoma, NOS",icdot-C22.0,Liver,pgxbs-kftvgr2h,P71Y,pgxind-kftx2j1h,pgxcs-kftvooan,560068208,0.195,45200045,0.016,514868163,0.179,PGX_AM_BS_HCC-CC-hom-39,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:17.440000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,0,17.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr2h,,,pgxcs-kftvooan,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-39,"hepatocellular carcinoma [cirrhosis, cryptogenic]",NCIT:C3099,Hepatocellular Carcinoma,pgx:icdom-81703,"Hepatocellular carcinoma, NOS",pgx:icdot-C22.0,Liver,NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P71Y,,,EFO:0030041,alive (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,MYC
5bab56c4727983b2e00acab9,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,hepatocellular carcinoma [hepatitis B pos.],PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C3099,Hepatocellular Carcinoma,icdom-81703,"Hepatocellular carcinoma, NOS",icdot-C22.0,Liver,pgxbs-kftvgr34,P56Y,pgxind-kftx2j29,pgxcs-kftvoohe,776174068,0.27,480058017,0.167,296116051,0.103,PGX_AM_BS_HCC-CC-hom-53,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:17.459000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,0,7.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgr34,,,pgxcs-kftvoohe,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-53,hepatocellular carcinoma [hepatitis B pos.],NCIT:C3099,Hepatocellular Carcinoma,pgx:icdom-81703,"Hepatocellular carcinoma, NOS",pgx:icdot-C22.0,Liver,NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P56Y,,,EFO:0030041,alive (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,MYC
5bab56c4727983b2e00acabd,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,hepatocellular carcinoma,PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C3099,Hepatocellular Carcinoma,icdom-81703,"Hepatocellular carcinoma, NOS",icdot-C22.0,Liver,pgxbs-kftvgr3b,P68Y,pgxind-kftx2j2i,pgxcs-kftvoojd,1277003911,0.444,572264163,0.199,704739748,0.245,PGX_AM_BS_HCC-CC-hom-57,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:17.465000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,0,74.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr3b,,,pgxcs-kftvoojd,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-57,hepatocellular carcinoma,NCIT:C3099,Hepatocellular Carcinoma,pgx:icdom-81703,"Hepatocellular carcinoma, NOS",pgx:icdot-C22.0,Liver,NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P68Y,,,EFO:0030041,alive (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,MYC
5bab56c4727983b2e00acaa8,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,hepatocellular carcinoma,PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C3099,Hepatocellular Carcinoma,icdom-81703,"Hepatocellular carcinoma, NOS",icdot-C22.0,Liver,pgxbs-kftvgr2c,P64Y,pgxind-kftx2j1b,pgxcs-kftvoo98,222888580,0.078,0,0.0,222888580,0.078,PGX_AM_BS_HCC-CC-hom-36,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:17.436000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,1,79.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr2c,,,pgxcs-kftvoo98,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-36,hepatocellular carcinoma,NCIT:C3099,Hepatocellular Carcinoma,pgx:icdom-81703,"Hepatocellular carcinoma, NOS",pgx:icdot-C22.0,Liver,NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P64Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,MYC
5bab56c4727983b2e00acaa9,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,hepatocellular carcinoma [alcoholic cirrhosis],PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C3099,Hepatocellular Carcinoma,icdom-81703,"Hepatocellular carcinoma, NOS",icdot-C22.0,Liver,pgxbs-kftvgr2e,P56Y,pgxind-kftx2j1d,pgxcs-kftvoo9p,226691249,0.079,126752512,0.044,99938737,0.035,PGX_AM_BS_HCC-CC-hom-37,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:17.437000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,1,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr2e,,,pgxcs-kftvoo9p,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-37,hepatocellular carcinoma [alcoholic cirrhosis],NCIT:C3099,Hepatocellular Carcinoma,pgx:icdom-81703,"Hepatocellular carcinoma, NOS",pgx:icdot-C22.0,Liver,NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P56Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,MYC
5bab56c4727983b2e00acaad,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,hepatocellular carcinoma,PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C3099,Hepatocellular Carcinoma,icdom-81703,"Hepatocellular carcinoma, NOS",icdot-C22.0,Liver,pgxbs-kftvgr2k,P67Y,pgxind-kftx2j1l,pgxcs-kftvoobm,1163283887,0.405,853453044,0.297,309830843,0.108,PGX_AM_BS_HCC-CC-hom-41,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:17.442000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,1,18.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr2k,,,pgxcs-kftvoobm,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-41,hepatocellular carcinoma,NCIT:C3099,Hepatocellular Carcinoma,pgx:icdom-81703,"Hepatocellular carcinoma, NOS",pgx:icdot-C22.0,Liver,NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P67Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,MYC
5bab56c4727983b2e00acaaf,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"hepatocellular carcinoma [cirrhosis, cryptogenic]",PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C3099,Hepatocellular Carcinoma,icdom-81703,"Hepatocellular carcinoma, NOS",icdot-C22.0,Liver,pgxbs-kftvgr2o,P78Y,pgxind-kftx2j1p,pgxcs-kftvoocl,1379385783,0.48,1000522305,0.348,378863478,0.132,PGX_AM_BS_HCC-CC-hom-43,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:17.445000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,1,3.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr2o,,,pgxcs-kftvoocl,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-43,"hepatocellular carcinoma [cirrhosis, cryptogenic]",NCIT:C3099,Hepatocellular Carcinoma,pgx:icdom-81703,"Hepatocellular carcinoma, NOS",pgx:icdot-C22.0,Liver,NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P78Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,MYC
5bab56c4727983b2e00acab5,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,hepatocellular carcinoma,PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C3099,Hepatocellular Carcinoma,icdom-81703,"Hepatocellular carcinoma, NOS",icdot-C22.0,Liver,pgxbs-kftvgr2x,P67Y,pgxind-kftx2j21,pgxcs-kftvoofg,235907459,0.082,135968722,0.047,99938737,0.035,PGX_AM_BS_HCC-CC-hom-49,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:17.453000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,1,31.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr2x,,,pgxcs-kftvoofg,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-49,hepatocellular carcinoma,NCIT:C3099,Hepatocellular Carcinoma,pgx:icdom-81703,"Hepatocellular carcinoma, NOS",pgx:icdot-C22.0,Liver,NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P67Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,MYC
5bab56c4727983b2e00acab7,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,hepatocellular carcinoma [hepatitis C pos.],PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C3099,Hepatocellular Carcinoma,icdom-81703,"Hepatocellular carcinoma, NOS",icdot-C22.0,Liver,pgxbs-kftvgr31,P68Y,pgxind-kftx2j25,pgxcs-kftvoogf,566677314,0.197,155506135,0.054,411171179,0.143,PGX_AM_BS_HCC-CC-hom-51,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:17.456000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,1,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr31,,,pgxcs-kftvoogf,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-51,hepatocellular carcinoma [hepatitis C pos.],NCIT:C3099,Hepatocellular Carcinoma,pgx:icdom-81703,"Hepatocellular carcinoma, NOS",pgx:icdot-C22.0,Liver,NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P68Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,MYC
5bab56c4727983b2e00acabe,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,hepatocellular carcinoma,PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C3099,Hepatocellular Carcinoma,icdom-81703,"Hepatocellular carcinoma, NOS",icdot-C22.0,Liver,pgxbs-kftvgr3c,P64Y,pgxind-kftx2j2k,pgxcs-kftvooju,1107365509,0.385,453075144,0.158,654290365,0.228,PGX_AM_BS_HCC-CC-hom-58,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:17.466000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,1,26.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr3c,,,pgxcs-kftvooju,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-58,hepatocellular carcinoma,NCIT:C3099,Hepatocellular Carcinoma,pgx:icdom-81703,"Hepatocellular carcinoma, NOS",pgx:icdot-C22.0,Liver,NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P64Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,MYC
5bab56c4727983b2e00acabf,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,hepatocellular carcinoma [hepatitis C liver cirrhosis],PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C3099,Hepatocellular Carcinoma,icdom-81703,"Hepatocellular carcinoma, NOS",icdot-C22.0,Liver,pgxbs-kftvgr3e,P69Y,pgxind-kftx2j2m,pgxcs-kftvookc,1218243640,0.424,963390994,0.335,254852646,0.089,PGX_AM_BS_HCC-CC-hom-59,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:17.467000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,1,27.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr3e,,,pgxcs-kftvookc,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-59,hepatocellular carcinoma [hepatitis C liver cirrhosis],NCIT:C3099,Hepatocellular Carcinoma,pgx:icdom-81703,"Hepatocellular carcinoma, NOS",pgx:icdot-C22.0,Liver,NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P69Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,MYC
5bab56c4727983b2e00acac0,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,hepatocellular carcinoma,PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C3099,Hepatocellular Carcinoma,icdom-81703,"Hepatocellular carcinoma, NOS",icdot-C22.0,Liver,pgxbs-kftvgr3g,P52Y,pgxind-kftx2j2o,pgxcs-kftvookt,1713545214,0.596,1125009313,0.391,588535901,0.205,PGX_AM_BS_HCC-CC-hom-60,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:17.469000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,1,48.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr3g,,,pgxcs-kftvookt,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-60,hepatocellular carcinoma,NCIT:C3099,Hepatocellular Carcinoma,pgx:icdom-81703,"Hepatocellular carcinoma, NOS",pgx:icdot-C22.0,Liver,NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P52Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,MYC
5bab56c4727983b2e00acac2,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,hepatocellular carcinoma [hepatitis C liver cirrhosis],PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C3099,Hepatocellular Carcinoma,icdom-81703,"Hepatocellular carcinoma, NOS",icdot-C22.0,Liver,pgxbs-kftvgr3j,P56Y,pgxind-kftx2j2s,pgxcs-kftvools,268088625,0.093,45200045,0.016,222888580,0.078,PGX_AM_BS_HCC-CC-hom-62,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:17.471000,T4,NCITstage-C27971,Stage IV,TNM-C48732,T4 Stage Finding,,,,,,,1,10.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgr3j,,,pgxcs-kftvools,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-62,hepatocellular carcinoma [hepatitis C liver cirrhosis],NCIT:C3099,Hepatocellular Carcinoma,pgx:icdom-81703,"Hepatocellular carcinoma, NOS",pgx:icdot-C22.0,Liver,NCIT:C27971,Stage IV,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P56Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,MYC
5bab56c4727983b2e00acac3,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,hepatocellular carcinoma [hemochromatosis-related cirrhosis],PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C3099,Hepatocellular Carcinoma,icdom-81703,"Hepatocellular carcinoma, NOS",icdot-C22.0,Liver,pgxbs-kftvgr3k,P70Y,pgxind-kftx2j2u,pgxcs-kftvooma,258288615,0.09,0,0.0,258288615,0.09,PGX_AM_BS_HCC-CC-hom-63,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:17.473000,T4,NCITstage-C27971,Stage IV,TNM-C48732,T4 Stage Finding,,,,,,,1,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr3k,,,pgxcs-kftvooma,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-63,hepatocellular carcinoma [hemochromatosis-related cirrhosis],NCIT:C3099,Hepatocellular Carcinoma,pgx:icdom-81703,"Hepatocellular carcinoma, NOS",pgx:icdot-C22.0,Liver,NCIT:C27971,Stage IV,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P70Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,MYC
5bab56c4727983b2e00acac4,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,hepatocellular carcinoma [hepatitis C liver cirrhosis],PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C3099,Hepatocellular Carcinoma,icdom-81703,"Hepatocellular carcinoma, NOS",icdot-C22.0,Liver,pgxbs-kftvgr3m,P63Y,pgxind-kftx2j2w,pgxcs-kftvoomr,201713581,0.07,45200045,0.016,156513536,0.054,PGX_AM_BS_HCC-CC-hom-64,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:17.474000,T4,NCITstage-C27971,Stage IV,TNM-C48732,T4 Stage Finding,,,,,,,1,35.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr3m,,,pgxcs-kftvoomr,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-64,hepatocellular carcinoma [hepatitis C liver cirrhosis],NCIT:C3099,Hepatocellular Carcinoma,pgx:icdom-81703,"Hepatocellular carcinoma, NOS",pgx:icdot-C22.0,Liver,NCIT:C27971,Stage IV,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P63Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,MYC
5bab56c4727983b2e00acac9,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,hepatocellular carcinoma [hemochromatosis-related cirrhosis],PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C3099,Hepatocellular Carcinoma,icdom-81703,"Hepatocellular carcinoma, NOS",icdot-C22.0,Liver,pgxbs-kftvgr3u,P57Y,pgxind-kftx2j36,pgxcs-kftvoop9,917772362,0.319,685581108,0.238,232191254,0.081,PGX_AM_BS_HCC-CC-hom-69,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:17.481000,T4,NCITstage-C27971,Stage IV,TNM-C48732,T4 Stage Finding,,,,,,,1,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr3u,,,pgxcs-kftvoop9,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-69,hepatocellular carcinoma [hemochromatosis-related cirrhosis],NCIT:C3099,Hepatocellular Carcinoma,pgx:icdom-81703,"Hepatocellular carcinoma, NOS",pgx:icdot-C22.0,Liver,NCIT:C27971,Stage IV,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P57Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,MYC
5bab56c4727983b2e00acaca,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,hepatocellular carcinoma,PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C3099,Hepatocellular Carcinoma,icdom-81703,"Hepatocellular carcinoma, NOS",icdot-C22.0,Liver,pgxbs-kftvgr3w,P42Y,pgxind-kftx2j38,pgxcs-kftvoopr,1263046139,0.439,605989727,0.211,657056412,0.229,PGX_AM_BS_HCC-CC-hom-70,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:17.483000,T4,NCITstage-C27971,Stage IV,TNM-C48732,T4 Stage Finding,,,,,,,1,39.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgr3w,,,pgxcs-kftvoopr,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-70,hepatocellular carcinoma,NCIT:C3099,Hepatocellular Carcinoma,pgx:icdom-81703,"Hepatocellular carcinoma, NOS",pgx:icdot-C22.0,Liver,NCIT:C27971,Stage IV,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P42Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,MYC
5bab56c4727983b2e00aca85,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,cholangiocarcinoma,PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C35417,Intrahepatic Cholangiocarcinoma,icdom-81603,Cholangiocarcinoma,icdot-C22.1,intrahepatic bile ducts,pgxbs-kftvgr0s,P71Y,pgxind-kftx2izb,pgxcs-kftvonq2,864256101,0.301,537058772,0.187,327197329,0.114,PGX_AM_BS_HCC-CC-hom-01,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,{},2020-09-10 17:44:17.386000,T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,,,,,1,7.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgr0s,,,pgxcs-kftvonq2,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-01,cholangiocarcinoma,NCIT:C35417,Intrahepatic Cholangiocarcinoma,pgx:icdom-81603,Cholangiocarcinoma,pgx:icdot-C22.1,Intrahepatic bile duct,NCIT:C27966,Stage I,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,,,,P71Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,MYC
5bab56c4727983b2e00aca88,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,cholangiocarcinoma,PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C35417,Intrahepatic Cholangiocarcinoma,icdom-81603,Cholangiocarcinoma,icdot-C22.1,intrahepatic bile ducts,pgxbs-kftvgr0x,P69Y,pgxind-kftx2izh,pgxcs-kftvonto,607158977,0.211,566858937,0.197,40300040,0.014,PGX_AM_BS_HCC-CC-hom-04,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,{},2020-09-10 17:44:17.391000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,1,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgr0x,,,pgxcs-kftvonto,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-04,cholangiocarcinoma,NCIT:C35417,Intrahepatic Cholangiocarcinoma,pgx:icdom-81603,Cholangiocarcinoma,pgx:icdot-C22.1,Intrahepatic bile duct,NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,,,,P69Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,MYC
5bab56c4727983b2e00aca8a,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,cholangiocarcinoma,PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C35417,Intrahepatic Cholangiocarcinoma,icdom-81603,Cholangiocarcinoma,icdot-C22.1,intrahepatic bile ducts,pgxbs-kftvgr10,P40Y,pgxind-kftx2izl,pgxcs-kftvonur,735130079,0.256,576308496,0.2,158821583,0.055,PGX_AM_BS_HCC-CC-hom-06,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,{},2020-09-10 17:44:17.393000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,1,44.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr10,,,pgxcs-kftvonur,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-06,cholangiocarcinoma,NCIT:C35417,Intrahepatic Cholangiocarcinoma,pgx:icdom-81603,Cholangiocarcinoma,pgx:icdot-C22.1,Intrahepatic bile duct,NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,,,,P40Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,MYC
5bab56c4727983b2e00aca8c,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,cholangiocarcinoma,PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C35417,Intrahepatic Cholangiocarcinoma,icdom-81603,Cholangiocarcinoma,icdot-C22.1,intrahepatic bile ducts,pgxbs-kftvgr14,P59Y,pgxind-kftx2izp,pgxcs-kftvonvp,1700678516,0.592,747651812,0.26,953026704,0.331,PGX_AM_BS_HCC-CC-hom-08,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,{},2020-09-10 17:44:17.396000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,1,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr14,,,pgxcs-kftvonvp,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-08,cholangiocarcinoma,NCIT:C35417,Intrahepatic Cholangiocarcinoma,pgx:icdom-81603,Cholangiocarcinoma,pgx:icdot-C22.1,Intrahepatic bile duct,NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,,,,P59Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,MYC
5bab56c4727983b2e00aca92,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,cholangiocarcinoma,PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C35417,Intrahepatic Cholangiocarcinoma,icdom-81603,Cholangiocarcinoma,icdot-C22.1,intrahepatic bile ducts,pgxbs-kftvgr1d,P78Y,pgxind-kftx2j01,pgxcs-kftvonym,1127745488,0.392,848282109,0.295,279463379,0.097,PGX_AM_BS_HCC-CC-hom-14,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,{},2020-09-10 17:44:17.405000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,1,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr1d,,,pgxcs-kftvonym,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-14,cholangiocarcinoma,NCIT:C35417,Intrahepatic Cholangiocarcinoma,pgx:icdom-81603,Cholangiocarcinoma,pgx:icdot-C22.1,Intrahepatic bile duct,NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,,,,P78Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,MYC
5bab56c4727983b2e00aca93,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,cholangiocarcinoma,PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C35417,Intrahepatic Cholangiocarcinoma,icdom-81603,Cholangiocarcinoma,icdot-C22.1,intrahepatic bile ducts,pgxbs-kftvgr1f,P65Y,pgxind-kftx2j03,pgxcs-kftvonz4,1099519139,0.382,828566477,0.288,270952662,0.094,PGX_AM_BS_HCC-CC-hom-15,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,{},2020-09-10 17:44:17.406000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,1,12.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr1f,,,pgxcs-kftvonz4,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-15,cholangiocarcinoma,NCIT:C35417,Intrahepatic Cholangiocarcinoma,pgx:icdom-81603,Cholangiocarcinoma,pgx:icdot-C22.1,Intrahepatic bile duct,NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,,,,P65Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,MYC
5bab56c4727983b2e00aca94,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,cholangiocarcinoma,PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C35417,Intrahepatic Cholangiocarcinoma,icdom-81603,Cholangiocarcinoma,icdot-C22.1,intrahepatic bile ducts,pgxbs-kftvgr1h,P76Y,pgxind-kftx2j05,pgxcs-kftvonzl,1588253500,0.552,1139715160,0.396,448538340,0.156,PGX_AM_BS_HCC-CC-hom-16,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,{},2020-09-10 17:44:17.408000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,1,18.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgr1h,,,pgxcs-kftvonzl,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-16,cholangiocarcinoma,NCIT:C35417,Intrahepatic Cholangiocarcinoma,pgx:icdom-81603,Cholangiocarcinoma,pgx:icdot-C22.1,Intrahepatic bile duct,NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,,,,P76Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,MYC
5bab56c4727983b2e00aca95,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,cholangiocarcinoma,PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C35417,Intrahepatic Cholangiocarcinoma,icdom-81603,Cholangiocarcinoma,icdot-C22.1,intrahepatic bile ducts,pgxbs-kftvgr1i,P65Y,pgxind-kftx2j07,pgxcs-kftvoo03,2034365127,0.708,988111601,0.344,1046253526,0.364,PGX_AM_BS_HCC-CC-hom-17,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,{},2020-09-10 17:44:17.409000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,1,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgr1i,,,pgxcs-kftvoo03,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-17,cholangiocarcinoma,NCIT:C35417,Intrahepatic Cholangiocarcinoma,pgx:icdom-81603,Cholangiocarcinoma,pgx:icdot-C22.1,Intrahepatic bile duct,NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,,,,P65Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,MYC
5bab56c4727983b2e00aca9a,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,cholangiocarcinoma,PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C35417,Intrahepatic Cholangiocarcinoma,icdom-81603,Cholangiocarcinoma,icdot-C22.1,intrahepatic bile ducts,pgxbs-kftvgr1q,P62Y,pgxind-kftx2j0i,pgxcs-kftvoo2j,1263444464,0.439,830611806,0.289,432832658,0.151,PGX_AM_BS_HCC-CC-hom-22,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,{},2020-09-10 17:44:17.416000,T4,NCITstage-C27971,Stage IV,TNM-C48732,T4 Stage Finding,,,,,,,1,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr1q,,,pgxcs-kftvoo2j,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-22,cholangiocarcinoma,NCIT:C35417,Intrahepatic Cholangiocarcinoma,pgx:icdom-81603,Cholangiocarcinoma,pgx:icdot-C22.1,Intrahepatic bile duct,NCIT:C27971,Stage IV,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,,,,P62Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,MYC
5bab56cc727983b2e00b07c7,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,hepatoblastoma [Fetal],PMID:11509117,"Kumon K, Kobayashi H et al. (2001): Frequent increase of DNA copy number...",NCIT:C3728,Hepatoblastoma,icdom-89703,Hepatoblastoma,icdot-C22.0,Liver,pgxbs-kftvhaze,P1Y,pgxind-kftx37i5,pgxcs-kftvur87,844788911,0.294,0,0.0,844788911,0.294,PGX_AM_BS_HepBlast-kum-1117,{},137.95,35.83,Point,JPN,Ina,Japan,"Ina, Japan",35.83,137.95,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:39.466000,,,,,,,,,,,,0,83.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvhaze,,,pgxcs-kftvur87,PMID:11509117,,,,,,,,PGX_AM_BS_HepBlast-kum-1117,hepatoblastoma [Fetal],NCIT:C3728,Hepatoblastoma,pgx:icdom-89703,Hepatoblastoma,pgx:icdot-C22.0,Liver,NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P1Y,,,EFO:0030041,alive (follow-up status),,Ina,Japan,JPN,137.95::35.83,,,,,,,,,,MYC
5bab56cc727983b2e00b07c5,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,hepatoblastoma [Embryonal],PMID:11509117,"Kumon K, Kobayashi H et al. (2001): Frequent increase of DNA copy number...",NCIT:C3728,Hepatoblastoma,icdom-89703,Hepatoblastoma,icdot-C22.0,Liver,pgxbs-kftvhaza,P2Y,pgxind-kftx37i0,pgxcs-kftvur78,461382349,0.16,0,0.0,461382349,0.16,PGX_AM_BS_HepBlast-kum-1103,{},137.95,35.83,Point,JPN,Ina,Japan,"Ina, Japan",35.83,137.95,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:39.463000,,,,,,,,,,,,1,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvhaza,,,pgxcs-kftvur78,PMID:11509117,,,,,,,,PGX_AM_BS_HepBlast-kum-1103,hepatoblastoma [Embryonal],NCIT:C3728,Hepatoblastoma,pgx:icdom-89703,Hepatoblastoma,pgx:icdot-C22.0,Liver,NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P2Y,,,EFO:0030049,dead (follow-up status),,Ina,Japan,JPN,137.95::35.83,,,,,,,,,,MYC
5bab56cc727983b2e00b07c6,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,hepatoblastoma [Unclassifiable],PMID:11509117,"Kumon K, Kobayashi H et al. (2001): Frequent increase of DNA copy number...",NCIT:C3728,Hepatoblastoma,icdom-89703,Hepatoblastoma,icdot-C22.0,Liver,pgxbs-kftvhazc,P2Y,pgxind-kftx37i3,pgxcs-kftvur7q,426516644,0.148,129017282,0.045,297499362,0.103,PGX_AM_BS_HepBlast-kum-1107,{},137.95,35.83,Point,JPN,Ina,Japan,"Ina, Japan",35.83,137.95,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:39.465000,,,,,,,,,,,,1,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvhazc,,,pgxcs-kftvur7q,PMID:11509117,,,,,,,,PGX_AM_BS_HepBlast-kum-1107,hepatoblastoma [Unclassifiable],NCIT:C3728,Hepatoblastoma,pgx:icdom-89703,Hepatoblastoma,pgx:icdot-C22.0,Liver,NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P2Y,,,EFO:0030049,dead (follow-up status),,Ina,Japan,JPN,137.95::35.83,,,,,,,,,,MYC
5bab56c4727983b2e00acacf,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,combined hepatocellular carcinoma and cholangiocarcinoma,PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C3828,Combined Hepatocellular Carcinoma and Cholangiocarcinoma,icdom-81803,Combined hepatocellular carcinoma and cholangiocarcinoma,icdot-C22.1,intrahepatic bile ducts,pgxbs-kftvgr44,P54Y,pgxind-kftx2j3i,pgxcs-kftvoos8,1740523173,0.605,927580133,0.323,812943040,0.283,PGX_AM_BS_HCC-CC-hom-75,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,{},2020-09-10 17:44:17.490000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,0,10.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr44,,,pgxcs-kftvoos8,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-75,combined hepatocellular carcinoma and cholangiocarcinoma,NCIT:C3828,Combined Hepatocellular Carcinoma and Cholangiocarcinoma,pgx:icdom-81803,Combined hepatocellular carcinoma and cholangiocarcinoma,pgx:icdot-C22.1,Intrahepatic bile duct,NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,,,,P54Y,,,EFO:0030041,alive (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,MYC
5bab56c4727983b2e00acacc,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,combined hepatocellular carcinoma and cholangiocarcinoma [Chronic cholangitis],PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C3828,Combined Hepatocellular Carcinoma and Cholangiocarcinoma,icdom-81803,Combined hepatocellular carcinoma and cholangiocarcinoma,icdot-C22.1,intrahepatic bile ducts,pgxbs-kftvgr3z,P78Y,pgxind-kftx2j3c,pgxcs-kftvooqr,392388749,0.136,169500169,0.059,222888580,0.078,PGX_AM_BS_HCC-CC-hom-72,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,{},2020-09-10 17:44:17.486000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,1,57.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgr3z,,,pgxcs-kftvooqr,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-72,combined hepatocellular carcinoma and cholangiocarcinoma [Chronic cholangitis],NCIT:C3828,Combined Hepatocellular Carcinoma and Cholangiocarcinoma,pgx:icdom-81803,Combined hepatocellular carcinoma and cholangiocarcinoma,pgx:icdot-C22.1,Intrahepatic bile duct,NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,,,,P78Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,MYC
5bab56c4727983b2e00acacd,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,combined hepatocellular carcinoma and cholangiocarcinoma,PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C3828,Combined Hepatocellular Carcinoma and Cholangiocarcinoma,icdom-81803,Combined hepatocellular carcinoma and cholangiocarcinoma,icdot-C22.1,intrahepatic bile ducts,pgxbs-kftvgr41,P65Y,pgxind-kftx2j3e,pgxcs-kftvoor8,999226216,0.348,563828115,0.196,435398101,0.151,PGX_AM_BS_HCC-CC-hom-73,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,{},2020-09-10 17:44:17.487000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,1,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr41,,,pgxcs-kftvoor8,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-73,combined hepatocellular carcinoma and cholangiocarcinoma,NCIT:C3828,Combined Hepatocellular Carcinoma and Cholangiocarcinoma,pgx:icdom-81803,Combined hepatocellular carcinoma and cholangiocarcinoma,pgx:icdot-C22.1,Intrahepatic bile duct,NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,,,,P65Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,MYC
5bab56c4727983b2e00acace,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,combined hepatocellular carcinoma and cholangiocarcinoma,PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C3828,Combined Hepatocellular Carcinoma and Cholangiocarcinoma,icdom-81803,Combined hepatocellular carcinoma and cholangiocarcinoma,icdot-C22.1,intrahepatic bile ducts,pgxbs-kftvgr42,P66Y,pgxind-kftx2j3g,pgxcs-kftvoorq,1424239767,0.495,989376094,0.344,434863673,0.151,PGX_AM_BS_HCC-CC-hom-74,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,{},2020-09-10 17:44:17.489000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,1,12.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgr42,,,pgxcs-kftvoorq,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-74,combined hepatocellular carcinoma and cholangiocarcinoma,NCIT:C3828,Combined Hepatocellular Carcinoma and Cholangiocarcinoma,pgx:icdom-81803,Combined hepatocellular carcinoma and cholangiocarcinoma,pgx:icdot-C22.1,Intrahepatic bile duct,NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,,,,P66Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,MYC
5bab56c6727983b2e00adae8,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Squamous cell carcinoma [esophagus],PMID:17470683,"Hirasaki S, Noguchi T et al. (2007): BAC clones related to prognosis in...",NCIT:C4024,Esophageal Squamous Cell Carcinoma,icdom-80703,"Squamous cell carcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvgw9u,,pgxind-kftx2pjo,pgxcs-kftvqagr,616844307,0.215,508210001,0.177,108634306,0.038,PGX_AM_BS_EsSCC-hir-17,,131.5,33.28,Point,JPN,Beppu,Japan,"Beppu, Japan",33.28,131.5,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:23.192000,T3N1M0,NCITstage-C27970,Stage III,TNM-C48706,N1 Stage Finding,TNM-C48714,N3 Stage Finding,TNM-C48728,T3 Stage Finding,,,0,56.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pgxbs-kftvgw9u,,,pgxcs-kftvqagr,PMID:17470683,,,,,,,,PGX_AM_BS_EsSCC-hir-17,Squamous cell carcinoma [esophagus],NCIT:C4024,Esophageal Squamous Cell Carcinoma,pgx:icdom-80703,"Squamous cell carcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,,,,EFO:0030041,alive (follow-up status),,Beppu,Japan,JPN,131.5::33.28,,,,,,,,,,MYC
5bab56c6727983b2e00adaf6,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Squamous cell carcinoma [esophagus],PMID:17470683,"Hirasaki S, Noguchi T et al. (2007): BAC clones related to prognosis in...",NCIT:C4024,Esophageal Squamous Cell Carcinoma,icdom-80703,"Squamous cell carcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvgwah,,pgxind-kftx2pkh,pgxcs-kftvqang,2947212661,1.0,0,0.0,2947212661,1.0,PGX_AM_BS_EsSCC-hir-5,,131.5,33.28,Point,JPN,Beppu,Japan,"Beppu, Japan",33.28,131.5,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:23.211000,T1N1M0,NCITstage-C27966,Stage I,TNM-C48706,N1 Stage Finding,TNM-C48714,N3 Stage Finding,TNM-C48720,T1 Stage Finding,,,0,60.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pgxbs-kftvgwah,,,pgxcs-kftvqang,PMID:17470683,,,,,,,,PGX_AM_BS_EsSCC-hir-5,Squamous cell carcinoma [esophagus],NCIT:C4024,Esophageal Squamous Cell Carcinoma,pgx:icdom-80703,"Squamous cell carcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27966,Stage I,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,,,,EFO:0030041,alive (follow-up status),,Beppu,Japan,JPN,131.5::33.28,,,,,,,,,,MYC
5bab56c6727983b2e00adaf8,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Squamous cell carcinoma [esophagus],PMID:17470683,"Hirasaki S, Noguchi T et al. (2007): BAC clones related to prognosis in...",NCIT:C4024,Esophageal Squamous Cell Carcinoma,icdom-80703,"Squamous cell carcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvgwak,,pgxind-kftx2pkl,pgxcs-kftvqaof,240856770,0.084,146569685,0.051,94287085,0.033,PGX_AM_BS_EsSCC-hir-7,,131.5,33.28,Point,JPN,Beppu,Japan,"Beppu, Japan",33.28,131.5,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:23.214000,T3N1M0,NCITstage-C27970,Stage III,TNM-C48706,N1 Stage Finding,TNM-C48714,N3 Stage Finding,TNM-C48728,T3 Stage Finding,,,0,60.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pgxbs-kftvgwak,,,pgxcs-kftvqaof,PMID:17470683,,,,,,,,PGX_AM_BS_EsSCC-hir-7,Squamous cell carcinoma [esophagus],NCIT:C4024,Esophageal Squamous Cell Carcinoma,pgx:icdom-80703,"Squamous cell carcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,,,,EFO:0030041,alive (follow-up status),,Beppu,Japan,JPN,131.5::33.28,,,,,,,,,,MYC
5bab56c6727983b2e00adc68,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,squamous cell carcinoma [esophagus],PMID:17298740,"Wu SS, Liu JF et al. (2007): [Analyzing chromosomal abnormality in primary esophageal...",NCIT:C4024,Esophageal Squamous Cell Carcinoma,icdom-80703,"Squamous cell carcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvgwr9,,pgxind-kftx2q5h,pgxcs-kftvqfsr,387404910,0.135,104931513,0.036,282473397,0.098,PGX_AM_BS_17298740_ESCC-wu-12,{},116.4,39.91,Point,CHN,Beijing,China,"Beijing, China",39.91,116.4,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:23.723000,,,,,,,,,,,,0,36.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pgxbs-kftvgwr9,,,pgxcs-kftvqfsr,PMID:17298740,,,,,,,,PGX_AM_BS_17298740_ESCC-wu-12,squamous cell carcinoma [esophagus],NCIT:C4024,Esophageal Squamous Cell Carcinoma,pgx:icdom-80703,"Squamous cell carcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,,,,EFO:0030041,alive (follow-up status),,Beijing,China,CHN,116.4::39.91,,,,,,,,,,MYC
5bab56c6727983b2e00adc69,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,squamous cell carcinoma [esophagus],PMID:17298740,"Wu SS, Liu JF et al. (2007): [Analyzing chromosomal abnormality in primary esophageal...",NCIT:C4024,Esophageal Squamous Cell Carcinoma,icdom-80703,"Squamous cell carcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvgwrb,,pgxind-kftx2q5j,pgxcs-kftvqft8,885343925,0.308,253694970,0.088,631648955,0.22,PGX_AM_BS_17298740_ESCC-wu-13,{},116.4,39.91,Point,CHN,Beijing,China,"Beijing, China",39.91,116.4,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:23.724000,,,,,,,,,,,,0,36.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pgxbs-kftvgwrb,,,pgxcs-kftvqft8,PMID:17298740,,,,,,,,PGX_AM_BS_17298740_ESCC-wu-13,squamous cell carcinoma [esophagus],NCIT:C4024,Esophageal Squamous Cell Carcinoma,pgx:icdom-80703,"Squamous cell carcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,,,,EFO:0030041,alive (follow-up status),,Beijing,China,CHN,116.4::39.91,,,,,,,,,,MYC
5bab56c6727983b2e00adae7,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Squamous cell carcinoma [esophagus],PMID:17470683,"Hirasaki S, Noguchi T et al. (2007): BAC clones related to prognosis in...",NCIT:C4024,Esophageal Squamous Cell Carcinoma,icdom-80703,"Squamous cell carcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvgw9s,,pgxind-kftx2pjm,pgxcs-kftvqag9,583185431,0.203,511178136,0.178,72007295,0.025,PGX_AM_BS_EsSCC-hir-16,,131.5,33.28,Point,JPN,Beppu,Japan,"Beppu, Japan",33.28,131.5,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:23.191000,T3N1M1,NCITstage-C27970,Stage III,TNM-C48700,M1 Stage Finding,TNM-C48706,N1 Stage Finding,TNM-C48714,N3 Stage Finding,,,1,9.0,TNM-C48728,T3 Stage Finding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pgxbs-kftvgw9s,,,pgxcs-kftvqag9,PMID:17470683,,,,,,,,PGX_AM_BS_EsSCC-hir-16,Squamous cell carcinoma [esophagus],NCIT:C4024,Esophageal Squamous Cell Carcinoma,pgx:icdom-80703,"Squamous cell carcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,,,,EFO:0030049,dead (follow-up status),,Beppu,Japan,JPN,131.5::33.28,,,,,,,,,,MYC
5bab56c6727983b2e00adaeb,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Squamous cell carcinoma [esophagus],PMID:17470683,"Hirasaki S, Noguchi T et al. (2007): BAC clones related to prognosis in...",NCIT:C4024,Esophageal Squamous Cell Carcinoma,icdom-80703,"Squamous cell carcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvgw9z,,pgxind-kftx2pju,pgxcs-kftvqai6,752047469,0.262,566113085,0.197,185934384,0.065,PGX_AM_BS_EsSCC-hir-2,,131.5,33.28,Point,JPN,Beppu,Japan,"Beppu, Japan",33.28,131.5,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:23.196000,T3N0M0,NCITstage-C27970,Stage III,TNM-C48705,N0 Stage Finding,TNM-C48728,T3 Stage Finding,,,,,1,34.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pgxbs-kftvgw9z,,,pgxcs-kftvqai6,PMID:17470683,,,,,,,,PGX_AM_BS_EsSCC-hir-2,Squamous cell carcinoma [esophagus],NCIT:C4024,Esophageal Squamous Cell Carcinoma,pgx:icdom-80703,"Squamous cell carcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,,,,EFO:0030049,dead (follow-up status),,Beppu,Japan,JPN,131.5::33.28,,,,,,,,,,MYC
5bab56c6727983b2e00adaee,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Squamous cell carcinoma [esophagus],PMID:17470683,"Hirasaki S, Noguchi T et al. (2007): BAC clones related to prognosis in...",NCIT:C4024,Esophageal Squamous Cell Carcinoma,icdom-80703,"Squamous cell carcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvgwa4,,pgxind-kftx2pk1,pgxcs-kftvqajl,161433515,0.056,75100075,0.026,86333440,0.03,PGX_AM_BS_EsSCC-hir-24,,131.5,33.28,Point,JPN,Beppu,Japan,"Beppu, Japan",33.28,131.5,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:23.200000,T3N1M1,NCITstage-C27970,Stage III,TNM-C48700,M1 Stage Finding,TNM-C48706,N1 Stage Finding,TNM-C48714,N3 Stage Finding,,,1,6.0,TNM-C48728,T3 Stage Finding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pgxbs-kftvgwa4,,,pgxcs-kftvqajl,PMID:17470683,,,,,,,,PGX_AM_BS_EsSCC-hir-24,Squamous cell carcinoma [esophagus],NCIT:C4024,Esophageal Squamous Cell Carcinoma,pgx:icdom-80703,"Squamous cell carcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,,,,EFO:0030049,dead (follow-up status),,Beppu,Japan,JPN,131.5::33.28,,,,,,,,,,MYC
5bab56c6727983b2e00adaf7,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Squamous cell carcinoma [esophagus],PMID:17470683,"Hirasaki S, Noguchi T et al. (2007): BAC clones related to prognosis in...",NCIT:C4024,Esophageal Squamous Cell Carcinoma,icdom-80703,"Squamous cell carcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvgwai,,pgxind-kftx2pkj,pgxcs-kftvqany,410422341,0.143,175083470,0.061,235338871,0.082,PGX_AM_BS_EsSCC-hir-6,,131.5,33.28,Point,JPN,Beppu,Japan,"Beppu, Japan",33.28,131.5,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:23.213000,T3N1M0,NCITstage-C27970,Stage III,TNM-C48706,N1 Stage Finding,TNM-C48714,N3 Stage Finding,TNM-C48728,T3 Stage Finding,,,1,7.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pgxbs-kftvgwai,,,pgxcs-kftvqany,PMID:17470683,,,,,,,,PGX_AM_BS_EsSCC-hir-6,Squamous cell carcinoma [esophagus],NCIT:C4024,Esophageal Squamous Cell Carcinoma,pgx:icdom-80703,"Squamous cell carcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,,,,EFO:0030049,dead (follow-up status),,Beppu,Japan,JPN,131.5::33.28,,,,,,,,,,MYC
5bab56c6727983b2e00adc60,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,squamous cell carcinoma [esophagus],PMID:17298740,"Wu SS, Liu JF et al. (2007): [Analyzing chromosomal abnormality in primary esophageal...",NCIT:C4024,Esophageal Squamous Cell Carcinoma,icdom-80703,"Squamous cell carcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvgwqw,,pgxind-kftx2q51,pgxcs-kftvqfox,837182526,0.291,581990054,0.202,255192472,0.089,PGX_AM_BS_17298740_ESCC-wu-04,{},116.4,39.91,Point,CHN,Beijing,China,"Beijing, China",39.91,116.4,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:23.711000,,,,,,,,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pgxbs-kftvgwqw,,,pgxcs-kftvqfox,PMID:17298740,,,,,,,,PGX_AM_BS_17298740_ESCC-wu-04,squamous cell carcinoma [esophagus],NCIT:C4024,Esophageal Squamous Cell Carcinoma,pgx:icdom-80703,"Squamous cell carcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,,,,EFO:0030049,dead (follow-up status),,Beijing,China,CHN,116.4::39.91,,,,,,,,,,MYC
5bab56c6727983b2e00adc61,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,squamous cell carcinoma [esophagus],PMID:17298740,"Wu SS, Liu JF et al. (2007): [Analyzing chromosomal abnormality in primary esophageal...",NCIT:C4024,Esophageal Squamous Cell Carcinoma,icdom-80703,"Squamous cell carcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvgwqx,,pgxind-kftx2q53,pgxcs-kftvqfpe,612223025,0.213,124817278,0.043,487405747,0.17,PGX_AM_BS_17298740_ESCC-wu-05,{},116.4,39.91,Point,CHN,Beijing,China,"Beijing, China",39.91,116.4,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:23.713000,,,,,,,,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pgxbs-kftvgwqx,,,pgxcs-kftvqfpe,PMID:17298740,,,,,,,,PGX_AM_BS_17298740_ESCC-wu-05,squamous cell carcinoma [esophagus],NCIT:C4024,Esophageal Squamous Cell Carcinoma,pgx:icdom-80703,"Squamous cell carcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,,,,EFO:0030049,dead (follow-up status),,Beijing,China,CHN,116.4::39.91,,,,,,,,,,MYC
5bab56cb727983b2e00afcb3,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Esophageal squamous cell carcinoma,PMID:12419583,"Wei F, Ni J, Wu SS et al. (2002): Cytogenetic studies of esophageal squamous cell...",NCIT:C4024,Esophageal Squamous Cell Carcinoma,icdom-80703,"Squamous cell carcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvh7fg,,pgxind-kftx3322,pgxcs-kftvtngq,287470447,0.1,0,0.0,287470447,0.1,PGX_AM_BS_EsSCC-01,,116.4,39.91,Point,CHN,Beijing,China,"Beijing, China",39.91,116.4,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:35.553000,T2N0M0,NCITstage-C28054,Stage II,TNM-C48705,N0 Stage Finding,TNM-C48724,T2 Stage Finding,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvh7fg,,,pgxcs-kftvtngq,PMID:12419583,,,,,,,,PGX_AM_BS_EsSCC-01,Esophageal squamous cell carcinoma,NCIT:C4024,Esophageal Squamous Cell Carcinoma,pgx:icdom-80703,"Squamous cell carcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,,,,EFO:0030049,dead (follow-up status),,Beijing,China,CHN,116.4::39.91,,,,,,,,,,MYC
5bab56cb727983b2e00afcb5,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Esophageal squamous cell carcinoma,PMID:12419583,"Wei F, Ni J, Wu SS et al. (2002): Cytogenetic studies of esophageal squamous cell...",NCIT:C4024,Esophageal Squamous Cell Carcinoma,icdom-80703,"Squamous cell carcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvh7fj,,pgxind-kftx3326,pgxcs-kftvtnho,456451805,0.159,216217369,0.075,240234436,0.084,PGX_AM_BS_EsSCC-03,,116.4,39.91,Point,CHN,Beijing,China,"Beijing, China",39.91,116.4,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:35.555000,T3N1M0,NCITstage-C27970,Stage III,TNM-C48706,N1 Stage Finding,TNM-C48714,N3 Stage Finding,TNM-C48728,T3 Stage Finding,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvh7fj,,,pgxcs-kftvtnho,PMID:12419583,,,,,,,,PGX_AM_BS_EsSCC-03,Esophageal squamous cell carcinoma,NCIT:C4024,Esophageal Squamous Cell Carcinoma,pgx:icdom-80703,"Squamous cell carcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,,,,EFO:0030049,dead (follow-up status),,Beijing,China,CHN,116.4::39.91,,,,,,,,,,MYC
5bab56cb727983b2e00afcbd,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Esophageal squamous cell carcinoma,PMID:12419583,"Wei F, Ni J, Wu SS et al. (2002): Cytogenetic studies of esophageal squamous cell...",NCIT:C4024,Esophageal Squamous Cell Carcinoma,icdom-80703,"Squamous cell carcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvh7fw,,pgxind-kftx332m,pgxcs-kftvtnnh,785079120,0.273,197910180,0.069,587168940,0.204,PGX_AM_BS_EsSCC-11,,116.4,39.91,Point,CHN,Beijing,China,"Beijing, China",39.91,116.4,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:35.567000,T3N1M0,NCITstage-C27970,Stage III,TNM-C48706,N1 Stage Finding,TNM-C48714,N3 Stage Finding,TNM-C48728,T3 Stage Finding,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvh7fw,,,pgxcs-kftvtnnh,PMID:12419583,,,,,,,,PGX_AM_BS_EsSCC-11,Esophageal squamous cell carcinoma,NCIT:C4024,Esophageal Squamous Cell Carcinoma,pgx:icdom-80703,"Squamous cell carcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,,,,EFO:0030049,dead (follow-up status),,Beijing,China,CHN,116.4::39.91,,,,,,,,,,MYC
5bab56cb727983b2e00afcc2,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Esophageal squamous cell carcinoma,PMID:12419583,"Wei F, Ni J, Wu SS et al. (2002): Cytogenetic studies of esophageal squamous cell...",NCIT:C4024,Esophageal Squamous Cell Carcinoma,icdom-80703,"Squamous cell carcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvh7g4,,pgxind-kftx332w,pgxcs-kftvtnpy,1275822477,0.444,425326170,0.148,850496307,0.296,PGX_AM_BS_EsSCC-16,,116.4,39.91,Point,CHN,Beijing,China,"Beijing, China",39.91,116.4,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:35.573000,T3N0M0,NCITstage-C27970,Stage III,TNM-C48705,N0 Stage Finding,TNM-C48728,T3 Stage Finding,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvh7g4,,,pgxcs-kftvtnpy,PMID:12419583,,,,,,,,PGX_AM_BS_EsSCC-16,Esophageal squamous cell carcinoma,NCIT:C4024,Esophageal Squamous Cell Carcinoma,pgx:icdom-80703,"Squamous cell carcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,,,,EFO:0030049,dead (follow-up status),,Beijing,China,CHN,116.4::39.91,,,,,,,,,,MYC
5bab56cb727983b2e00afcc3,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Esophageal squamous cell carcinoma,PMID:12419583,"Wei F, Ni J, Wu SS et al. (2002): Cytogenetic studies of esophageal squamous cell...",NCIT:C4024,Esophageal Squamous Cell Carcinoma,icdom-80703,"Squamous cell carcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvh7g6,,pgxind-kftx332y,pgxcs-kftvtnqg,1098943437,0.382,0,0.0,1098943437,0.382,PGX_AM_BS_EsSCC-17,,116.4,39.91,Point,CHN,Beijing,China,"Beijing, China",39.91,116.4,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:35.575000,T3N0M0,NCITstage-C27970,Stage III,TNM-C48705,N0 Stage Finding,TNM-C48728,T3 Stage Finding,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvh7g6,,,pgxcs-kftvtnqg,PMID:12419583,,,,,,,,PGX_AM_BS_EsSCC-17,Esophageal squamous cell carcinoma,NCIT:C4024,Esophageal Squamous Cell Carcinoma,pgx:icdom-80703,"Squamous cell carcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,,,,EFO:0030049,dead (follow-up status),,Beijing,China,CHN,116.4::39.91,,,,,,,,,,MYC
5bab56cb727983b2e00afcc8,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Esophageal squamous cell carcinoma,PMID:12419583,"Wei F, Ni J, Wu SS et al. (2002): Cytogenetic studies of esophageal squamous cell...",NCIT:C4024,Esophageal Squamous Cell Carcinoma,icdom-80703,"Squamous cell carcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvh7ge,,pgxind-kftx3338,pgxcs-kftvtnsw,754034079,0.262,143437542,0.05,610596537,0.212,PGX_AM_BS_EsSCC-22,,116.4,39.91,Point,CHN,Beijing,China,"Beijing, China",39.91,116.4,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:35.582000,T3N0M0,NCITstage-C27970,Stage III,TNM-C48705,N0 Stage Finding,TNM-C48728,T3 Stage Finding,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvh7ge,,,pgxcs-kftvtnsw,PMID:12419583,,,,,,,,PGX_AM_BS_EsSCC-22,Esophageal squamous cell carcinoma,NCIT:C4024,Esophageal Squamous Cell Carcinoma,pgx:icdom-80703,"Squamous cell carcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,,,,EFO:0030049,dead (follow-up status),,Beijing,China,CHN,116.4::39.91,,,,,,,,,,MYC
5bab56ce727983b2e00b197c,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,adenocarcinoma [esophagus],geo:GPL5711,,NCIT:C4025,Esophageal Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvhgyz,P62Y,pgxind-kftx3ekf,pgxcs-kftvwj4d,1050479893,0.365,690877763,0.24,359602130,0.125,PGX_AM_BS_GSM265808,,153.02,-27.45,Point,AUS,Herston,Australia,"Herston, Australia",-27.45,153.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:45.735000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,0,23.0,,,PMID:18519675,"Nancarrow DJ, Handoko HY et al. (2008): Genome-wide copy number analysis in esophageal...",pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),pgxcohort-2021progenetix,Version at Progenetix Update 2021,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:GSE10506,,geo:GSM265808,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvhgyz,,,pgxcs-kftvwj4d,PMID:18519675,,,,,,,,PGX_AM_BS_GSM265808,adenocarcinoma [esophagus],NCIT:C4025,Esophageal Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27968,Stage IIb,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,P62Y,,,EFO:0030041,alive (follow-up status),,Herston,Australia,AUS,153.02::-27.45,,,,,geo:GSM265808,geo:GSE10506,geo:GPL5711,,,MYC
5bab56ce727983b2e00b197e,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,adenocarcinoma [esophagus],geo:GSM266075,,NCIT:C4025,Esophageal Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvhgz2,P65Y,pgxind-kftx3ekk,pgxcs-kftvwj5d,1001163624,0.348,592904485,0.206,408259139,0.142,PGX_AM_BS_GSM266075,,153.02,-27.45,Point,AUS,Herston,Australia,"Herston, Australia",-27.45,153.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:45.738000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,0,20.0,,,geo:GSE10506,,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),pgxcohort-2021progenetix,Version at Progenetix Update 2021,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),PMID:18519675,"Nancarrow DJ, Handoko HY et al. (2008): Genome-wide copy number analysis in esophageal...",geo:GPL5711,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvhgz2,,,pgxcs-kftvwj5d,PMID:18519675,,,,,,,,PGX_AM_BS_GSM266075,adenocarcinoma [esophagus],NCIT:C4025,Esophageal Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,P65Y,,,EFO:0030041,alive (follow-up status),,Herston,Australia,AUS,153.02::-27.45,,,,,geo:GSM266075,geo:GSE10506,geo:GPL5711,,,MYC
5bab56ce727983b2e00b1983,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,adenocarcinoma [esophagus],geo:GPL5711,,NCIT:C4025,Esophageal Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvhgza,P69Y,pgxind-kftx3eku,pgxcs-kftvwj7u,830858339,0.289,480482392,0.167,350375947,0.122,PGX_AM_BS_GSM266661,,153.02,-27.45,Point,AUS,Herston,Australia,"Herston, Australia",-27.45,153.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:45.745000,T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,,,,,0,15.0,,,PMID:18519675,"Nancarrow DJ, Handoko HY et al. (2008): Genome-wide copy number analysis in esophageal...",pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),pgxcohort-2021progenetix,Version at Progenetix Update 2021,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:GSE10506,,geo:GSM266661,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvhgza,,,pgxcs-kftvwj7u,PMID:18519675,,,,,,,,PGX_AM_BS_GSM266661,adenocarcinoma [esophagus],NCIT:C4025,Esophageal Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27966,Stage I,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,P69Y,,,EFO:0030041,alive (follow-up status),,Herston,Australia,AUS,153.02::-27.45,,,,,geo:GSM266661,geo:GSE10506,geo:GPL5711,,,MYC
5bab56ce727983b2e00b1984,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,adenocarcinoma [esophagus],geo:GPL5711,,NCIT:C4025,Esophageal Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvhgzc,P70Y,pgxind-kftx3ekw,pgxcs-kftvwj8c,1320407228,0.459,779640766,0.271,540766462,0.188,PGX_AM_BS_GSM266703,,153.02,-27.45,Point,AUS,Herston,Australia,"Herston, Australia",-27.45,153.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:45.747000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,0,38.0,,,geo:GSE10506,,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),pgxcohort-2021progenetix,Version at Progenetix Update 2021,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),PMID:18519675,"Nancarrow DJ, Handoko HY et al. (2008): Genome-wide copy number analysis in esophageal...",geo:GSM266703,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvhgzc,,,pgxcs-kftvwj8c,PMID:18519675,,,,,,,,PGX_AM_BS_GSM266703,adenocarcinoma [esophagus],NCIT:C4025,Esophageal Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,P70Y,,,EFO:0030041,alive (follow-up status),,Herston,Australia,AUS,153.02::-27.45,,,,,geo:GSM266703,geo:GSE10506,geo:GPL5711,,,MYC
5bab56ce727983b2e00b1989,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,adenocarcinoma [esophagus],geo:GSE10506,,NCIT:C4025,Esophageal Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvhgzk,P52Y,pgxind-kftx3el6,pgxcs-kftvwjas,1220457045,0.425,662770209,0.231,557686836,0.194,PGX_AM_BS_GSM266715,,153.02,-27.45,Point,AUS,Herston,Australia,"Herston, Australia",-27.45,153.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:45.754000,T4,NCITstage-C27971,Stage IV,TNM-C48732,T4 Stage Finding,,,,,,,0,29.0,,,PMID:18519675,"Nancarrow DJ, Handoko HY et al. (2008): Genome-wide copy number analysis in esophageal...",pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),pgxcohort-2021progenetix,Version at Progenetix Update 2021,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:GSM266715,,geo:GPL5711,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvhgzk,,,pgxcs-kftvwjas,PMID:18519675,,,,,,,,PGX_AM_BS_GSM266715,adenocarcinoma [esophagus],NCIT:C4025,Esophageal Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27966,Stage I,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,P52Y,,,EFO:0030041,alive (follow-up status),,Herston,Australia,AUS,153.02::-27.45,,,,,geo:GSM266715,geo:GSE10506,geo:GPL5711,,,MYC
5bab56ce727983b2e00b1979,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,adenocarcinoma [esophagus],PMID:18519675,"Nancarrow DJ, Handoko HY et al. (2008): Genome-wide copy number analysis in esophageal...",NCIT:C4025,Esophageal Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvhgyu,P80Y,pgxind-kftx3ek9,pgxcs-kftvwj2w,961675959,0.334,542187873,0.189,419488086,0.146,PGX_AM_BS_GSM265500,{},153.02,-27.45,Point,AUS,Herston,Australia,"Herston, Australia",-27.45,153.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:45.731000,,,,,,,,,,,,1,12.0,,,geo:GSE10506,,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),pgxcohort-2021progenetix,Version at Progenetix Update 2021,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:GSM265500,,geo:GPL5711,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvhgyu,,,pgxcs-kftvwj2w,PMID:18519675,,,,,,,,PGX_AM_BS_GSM265500,adenocarcinoma [esophagus],NCIT:C4025,Esophageal Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,P80Y,,,EFO:0030049,dead (follow-up status),,Herston,Australia,AUS,153.02::-27.45,,,,,geo:GSM265500,geo:GSE10506,geo:GPL5711,,,MYC
5bab56ce727983b2e00b197b,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,adenocarcinoma [esophagus],PMID:18519675,"Nancarrow DJ, Handoko HY et al. (2008): Genome-wide copy number analysis in esophageal...",NCIT:C4025,Esophageal Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvhgyx,P72Y,pgxind-kftx3ekd,pgxcs-kftvwj3w,1580009098,0.55,884423576,0.308,695585522,0.242,PGX_AM_BS_GSM265787,,153.02,-27.45,Point,AUS,Herston,Australia,"Herston, Australia",-27.45,153.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:45.733000,T4,NCITstage-C27971,Stage IV,TNM-C48732,T4 Stage Finding,,,,,,,1,2.0,,,geo:GSE10506,,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),pgxcohort-2021progenetix,Version at Progenetix Update 2021,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:GSM265787,,geo:GPL5711,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvhgyx,,,pgxcs-kftvwj3w,PMID:18519675,,,,,,,,PGX_AM_BS_GSM265787,adenocarcinoma [esophagus],NCIT:C4025,Esophageal Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27980,Stage IVb,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,P72Y,,,EFO:0030049,dead (follow-up status),,Herston,Australia,AUS,153.02::-27.45,,,,,geo:GSM265787,geo:GSE10506,geo:GPL5711,,,MYC
5bab56ce727983b2e00b1988,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,adenocarcinoma [esophagus],geo:GPL5711,,NCIT:C4025,Esophageal Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvhgzj,P71Y,pgxind-kftx3el4,pgxcs-kftvwjab,1420469696,0.494,800137678,0.278,620332018,0.216,PGX_AM_BS_GSM266708,,153.02,-27.45,Point,AUS,Herston,Australia,"Herston, Australia",-27.45,153.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:45.752000,T4,NCITstage-C27971,Stage IV,TNM-C48732,T4 Stage Finding,,,,,,,1,10.0,,,PMID:18519675,"Nancarrow DJ, Handoko HY et al. (2008): Genome-wide copy number analysis in esophageal...",pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),pgxcohort-2021progenetix,Version at Progenetix Update 2021,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:GSE10506,,geo:GSM266708,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvhgzj,,,pgxcs-kftvwjab,PMID:18519675,,,,,,,,PGX_AM_BS_GSM266708,adenocarcinoma [esophagus],NCIT:C4025,Esophageal Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27979,Stage IVa,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,P71Y,,,EFO:0030049,dead (follow-up status),,Herston,Australia,AUS,153.02::-27.45,,,,,geo:GSM266708,geo:GSE10506,geo:GPL5711,,,MYC
5bab56c7727983b2e00ae062,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,adenocarcinoma [right colon flexure],PMID:17044061,"Habermann JK, Paulsen U et al. (2007): Stage-specific alterations of the genome, transcriptome,...",NCIT:C4349,Colon Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C18.9,"large intestine, excl. rectum and rectosigmoid junction",pgxbs-kftvgycl,P71Y,pgxind-kftx2rqf,pgxcs-kftvqu2c,261160604,0.091,76117230,0.026,185043374,0.064,PGX_AM_BS_NCBISKYCGH-3717,,-77.1,38.98,Point,USA,Bethesda,United States of America,"Bethesda, United States",38.98,-77.1,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001155,colon,{},2020-09-10 17:44:25.127000,T3N0M0,NCITstage-C27970,Stage III,TNM-C48705,N0 Stage Finding,TNM-C48728,T3 Stage Finding,,,,,0,48.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgycl,,,pgxcs-kftvqu2c,PMID:17044061,,,,,,,,PGX_AM_BS_NCBISKYCGH-3717,adenocarcinoma [right colon flexure],NCIT:C4349,Colon Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C18.9,"Colon, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001155,colon,,,,P71Y,,,EFO:0030041,alive (follow-up status),,Bethesda,United States of America,USA,-77.1::38.98,,,,,,,,,,MYC
5bab56c7727983b2e00ae06c,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,adenocarcinoma [right colon flexure],PMID:17044061,"Habermann JK, Paulsen U et al. (2007): Stage-specific alterations of the genome, transcriptome,...",NCIT:C4349,Colon Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C18.9,"large intestine, excl. rectum and rectosigmoid junction",pgxbs-kftvgyd1,P74Y,pgxind-kftx2rqz,pgxcs-kftvqu79,145138782,0.05,45200045,0.016,99938737,0.035,PGX_AM_BS_NCBISKYCGH-3727,,-77.1,38.98,Point,USA,Bethesda,United States of America,"Bethesda, United States",38.98,-77.1,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001155,colon,{},2020-09-10 17:44:25.141000,T3N1M0,NCITstage-C27970,Stage III,TNM-C48706,N1 Stage Finding,TNM-C48714,N3 Stage Finding,TNM-C48728,T3 Stage Finding,,,0,41.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgyd1,,,pgxcs-kftvqu79,PMID:17044061,,,,,,,,PGX_AM_BS_NCBISKYCGH-3727,adenocarcinoma [right colon flexure],NCIT:C4349,Colon Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C18.9,"Colon, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001155,colon,,,,P74Y,,,EFO:0030041,alive (follow-up status),,Bethesda,United States of America,USA,-77.1::38.98,,,,,,,,,,MYC
5bab56c7727983b2e00ae06f,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,adenocarcinoma [colorectal; liver metastasis],PMID:17044061,"Habermann JK, Paulsen U et al. (2007): Stage-specific alterations of the genome, transcriptome,...",NCIT:C4349,Colon Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C18.9,"large intestine, excl. rectum and rectosigmoid junction",pgxbs-kftvgyd6,P72Y,pgxind-kftx2rr5,pgxcs-kftvqu8q,421506733,0.147,245931956,0.086,175574777,0.061,PGX_AM_BS_NCBISKYCGH-3731,{},-77.1,38.98,Point,USA,Bethesda,United States of America,"Bethesda, United States",38.98,-77.1,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001155,colon,{},2020-09-10 17:44:25.145000,T0N0M1,,,TNM-C48699,M0 Stage Finding,TNM-C48700,M1 Stage Finding,TNM-C48705,N0 Stage Finding,,,0,60.0,TNM-C48719,T0 Stage Finding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgyd6,,,pgxcs-kftvqu8q,PMID:17044061,,,,,,,,PGX_AM_BS_NCBISKYCGH-3731,adenocarcinoma [colorectal; liver metastasis],NCIT:C4349,Colon Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C18.9,"Colon, NOS",NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0001155,colon,,,,P72Y,,,EFO:0030041,alive (follow-up status),,Bethesda,United States of America,USA,-77.1::38.98,,,,,,,,,,MYC
5bab56c7727983b2e00ae073,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,adenocarcinoma [colorectal; liver metastasis],PMID:17044061,"Habermann JK, Paulsen U et al. (2007): Stage-specific alterations of the genome, transcriptome,...",NCIT:C4349,Colon Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C18.9,"large intestine, excl. rectum and rectosigmoid junction",pgxbs-kftvgydc,P84Y,pgxind-kftx2rrd,pgxcs-kftvquas,1164222946,0.405,561494839,0.195,602728107,0.21,PGX_AM_BS_NCBISKYCGH-3736,{},-77.1,38.98,Point,USA,Bethesda,United States of America,"Bethesda, United States",38.98,-77.1,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001155,colon,{},2020-09-10 17:44:25.151000,T0N0M1,,,TNM-C48699,M0 Stage Finding,TNM-C48700,M1 Stage Finding,TNM-C48705,N0 Stage Finding,,,0,48.0,TNM-C48719,T0 Stage Finding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgydc,,,pgxcs-kftvquas,PMID:17044061,,,,,,,,PGX_AM_BS_NCBISKYCGH-3736,adenocarcinoma [colorectal; liver metastasis],NCIT:C4349,Colon Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C18.9,"Colon, NOS",NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0001155,colon,,,,P84Y,,,EFO:0030041,alive (follow-up status),,Bethesda,United States of America,USA,-77.1::38.98,,,,,,,,,,MYC
5bab56c7727983b2e00ae075,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,adenocarcinoma [colorectal; liver metastasis],PMID:17044061,"Habermann JK, Paulsen U et al. (2007): Stage-specific alterations of the genome, transcriptome,...",NCIT:C4349,Colon Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C18.9,"large intestine, excl. rectum and rectosigmoid junction",pgxbs-kftvgydf,P64Y,pgxind-kftx2rrh,pgxcs-kftvqubr,297292052,0.103,224217377,0.078,73074675,0.025,PGX_AM_BS_NCBISKYCGH-3738,{},-77.1,38.98,Point,USA,Bethesda,United States of America,"Bethesda, United States",38.98,-77.1,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001155,colon,{},2020-09-10 17:44:25.154000,T0N0M1,,,TNM-C48699,M0 Stage Finding,TNM-C48700,M1 Stage Finding,TNM-C48705,N0 Stage Finding,,,0,40.0,TNM-C48719,T0 Stage Finding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgydf,,,pgxcs-kftvqubr,PMID:17044061,,,,,,,,PGX_AM_BS_NCBISKYCGH-3738,adenocarcinoma [colorectal; liver metastasis],NCIT:C4349,Colon Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C18.9,"Colon, NOS",NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0001155,colon,,,,P64Y,,,EFO:0030041,alive (follow-up status),,Bethesda,United States of America,USA,-77.1::38.98,,,,,,,,,,MYC
5bab56c7727983b2e00ae078,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,adenocarcinoma [colorectal; liver metastasis],PMID:17044061,"Habermann JK, Paulsen U et al. (2007): Stage-specific alterations of the genome, transcriptome,...",NCIT:C4349,Colon Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C18.9,"large intestine, excl. rectum and rectosigmoid junction",pgxbs-kftvgydk,P38Y,pgxind-kftx2rro,pgxcs-kftvqud6,516349008,0.18,100917255,0.035,415431753,0.144,PGX_AM_BS_NCBISKYCGH-3741,{},-77.1,38.98,Point,USA,Bethesda,United States of America,"Bethesda, United States",38.98,-77.1,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001155,colon,{},2020-09-10 17:44:25.158000,T0N0M1,,,TNM-C48699,M0 Stage Finding,TNM-C48700,M1 Stage Finding,TNM-C48705,N0 Stage Finding,,,0,36.0,TNM-C48719,T0 Stage Finding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgydk,,,pgxcs-kftvqud6,PMID:17044061,,,,,,,,PGX_AM_BS_NCBISKYCGH-3741,adenocarcinoma [colorectal; liver metastasis],NCIT:C4349,Colon Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C18.9,"Colon, NOS",NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0001155,colon,,,,P38Y,,,EFO:0030041,alive (follow-up status),,Bethesda,United States of America,USA,-77.1::38.98,,,,,,,,,,MYC
5bab56c7727983b2e00ae060,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,adenocarcinoma [colon ascendens],PMID:17044061,"Habermann JK, Paulsen U et al. (2007): Stage-specific alterations of the genome, transcriptome,...",NCIT:C4349,Colon Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C18.9,"large intestine, excl. rectum and rectosigmoid junction",pgxbs-kftvgych,P81Y,pgxind-kftx2rqb,pgxcs-kftvqu1e,543319050,0.189,0,0.0,543319050,0.189,PGX_AM_BS_NCBISKYCGH-3715,,-77.1,38.98,Point,USA,Bethesda,United States of America,"Bethesda, United States",38.98,-77.1,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001155,colon,{},2020-09-10 17:44:25.124000,T3N1M1,NCITstage-C27970,Stage III,TNM-C48700,M1 Stage Finding,TNM-C48706,N1 Stage Finding,TNM-C48714,N3 Stage Finding,,,1,1.0,TNM-C48728,T3 Stage Finding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgych,,,pgxcs-kftvqu1e,PMID:17044061,,,,,,,,PGX_AM_BS_NCBISKYCGH-3715,adenocarcinoma [colon ascendens],NCIT:C4349,Colon Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C18.9,"Colon, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001155,colon,,,,P81Y,,,EFO:0030049,dead (follow-up status),,Bethesda,United States of America,USA,-77.1::38.98,,,,,,,,,,MYC
5bab56c7727983b2e00ae072,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,adenocarcinoma [colorectal; liver metastasis],PMID:17044061,"Habermann JK, Paulsen U et al. (2007): Stage-specific alterations of the genome, transcriptome,...",NCIT:C4349,Colon Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C18.9,"large intestine, excl. rectum and rectosigmoid junction",pgxbs-kftvgydb,P63Y,pgxind-kftx2rrb,pgxcs-kftvquaa,668859983,0.233,48100048,0.017,620759935,0.216,PGX_AM_BS_NCBISKYCGH-3735,{},-77.1,38.98,Point,USA,Bethesda,United States of America,"Bethesda, United States",38.98,-77.1,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001155,colon,{},2020-09-10 17:44:25.149000,T0N0M1,,,TNM-C48699,M0 Stage Finding,TNM-C48700,M1 Stage Finding,TNM-C48705,N0 Stage Finding,,,1,27.0,TNM-C48719,T0 Stage Finding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgydb,,,pgxcs-kftvquaa,PMID:17044061,,,,,,,,PGX_AM_BS_NCBISKYCGH-3735,adenocarcinoma [colorectal; liver metastasis],NCIT:C4349,Colon Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C18.9,"Colon, NOS",NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0001155,colon,,,,P63Y,,,EFO:0030049,dead (follow-up status),,Bethesda,United States of America,USA,-77.1::38.98,,,,,,,,,,MYC
5bab56c7727983b2e00ae076,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,adenocarcinoma [colorectal; liver metastasis],PMID:17044061,"Habermann JK, Paulsen U et al. (2007): Stage-specific alterations of the genome, transcriptome,...",NCIT:C4349,Colon Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C18.9,"large intestine, excl. rectum and rectosigmoid junction",pgxbs-kftvgydh,P63Y,pgxind-kftx2rrk,pgxcs-kftvquc8,621585079,0.216,100917255,0.035,520667824,0.181,PGX_AM_BS_NCBISKYCGH-3739,{},-77.1,38.98,Point,USA,Bethesda,United States of America,"Bethesda, United States",38.98,-77.1,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001155,colon,{},2020-09-10 17:44:25.155000,T0N0M1,,,TNM-C48699,M0 Stage Finding,TNM-C48700,M1 Stage Finding,TNM-C48705,N0 Stage Finding,,,1,10.0,TNM-C48719,T0 Stage Finding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgydh,,,pgxcs-kftvquc8,PMID:17044061,,,,,,,,PGX_AM_BS_NCBISKYCGH-3739,adenocarcinoma [colorectal; liver metastasis],NCIT:C4349,Colon Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C18.9,"Colon, NOS",NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0001155,colon,,,,P63Y,,,EFO:0030049,dead (follow-up status),,Bethesda,United States of America,USA,-77.1::38.98,,,,,,,,,,MYC
5bab56c7727983b2e00ae077,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,adenocarcinoma [colorectal; liver metastasis],PMID:17044061,"Habermann JK, Paulsen U et al. (2007): Stage-specific alterations of the genome, transcriptome,...",NCIT:C4349,Colon Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C18.9,"large intestine, excl. rectum and rectosigmoid junction",pgxbs-kftvgydi,P65Y,pgxind-kftx2rrm,pgxcs-kftvqucp,457126536,0.159,191456262,0.067,265670274,0.092,PGX_AM_BS_NCBISKYCGH-3740,,-77.1,38.98,Point,USA,Bethesda,United States of America,"Bethesda, United States",38.98,-77.1,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001155,colon,{},2020-09-10 17:44:25.156000,T3N2M1,NCITstage-C27970,Stage III,TNM-C48700,M1 Stage Finding,TNM-C48786,N2 Stage Finding,TNM-C48728,T3 Stage Finding,,,1,7.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgydi,,,pgxcs-kftvqucp,PMID:17044061,,,,,,,,PGX_AM_BS_NCBISKYCGH-3740,adenocarcinoma [colorectal; liver metastasis],NCIT:C4349,Colon Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C18.9,"Colon, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001155,colon,,,,P65Y,,,EFO:0030049,dead (follow-up status),,Bethesda,United States of America,USA,-77.1::38.98,,,,,,,,,,MYC
5c865b3a09d374f2dc2b8e0c,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,"colorectal carcinoma [right, moderately differentiated, lymph node metastasis]",geo:GSM288103,,NCIT:C4349,Colon Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C18.9,"Colon, NOS",pgxbs-kftvia4g,P83Y6M,pgxind-kftx3wvk,pgxcs-kftw5nla,849174237,0.295,385438054,0.134,463736183,0.161,PGX_AM_BS_GSM288103,,139.85,36.4,Point,JPN,Shimotsuke-shi,Japan,"Shimotsuke-shi, Japan",36.4,139.85,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001155,colon,{},2020-09-10 17:45:18.352000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,1,5.4,,,geo:GPL2005,,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),pgxcohort-2021progenetix,Version at Progenetix Update 2021,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:GSE11417,,PMID:18564138,"Kurashina K, Yamashita Y et al. (2008): Chromosome copy number analysis in screening...",geo:gsm,geo:gpl,geo:gse,,,,,,pubmed,,,,arraymap import,0.24,SNP2pop 1000 Genomes population,HANCESTRO:0027,Han Chinese,0.14,SNP2pop 1000 Genomes superpopulation,HANCESTRO:0009,East Asian,,,,,,,,,,,,M,pgxbs-kftvia4g,,,pgxcs-kftw5nla,PMID:18564138,,,,,,,,PGX_AM_BS_GSM288103,"colorectal carcinoma [right, moderately differentiated, lymph node metastasis]",NCIT:C4349,Colon Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C18.9,"Colon, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001155,colon,,,,P83Y6M,,,EFO:0030039,no followup status,,Shimotsuke-shi,Japan,JPN,139.85::36.4,,,,,geo:GSM288103,geo:GSE11417,geo:GPL2005,,,MYC
5c865b3a09d374f2dc2b8e0d,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,"colorectal carcinoma [left, well differentiated]",geo:GSM288081,,NCIT:C4349,Colon Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C18.9,"Colon, NOS",pgxbs-kftvia4h,P89Y6M,pgxind-kftx3wvm,pgxcs-kftw5n8a,610768652,0.212,382121149,0.133,228647503,0.08,PGX_AM_BS_GSM288081,,139.85,36.4,Point,JPN,Shimotsuke-shi,Japan,"Shimotsuke-shi, Japan",36.4,139.85,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001155,colon,{},2020-09-10 17:45:18.354000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,1,38.17,,,PMID:18564138,"Kurashina K, Yamashita Y et al. (2008): Chromosome copy number analysis in screening...",pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),pgxcohort-2021progenetix,Version at Progenetix Update 2021,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:GSE11417,,geo:GPL2005,,geo:gsm,pubmed,geo:gse,,,,,,geo:gpl,,,,arraymap import,0.22,SNP2pop 1000 Genomes population,HANCESTRO:0027,Han Chinese,0.16,SNP2pop 1000 Genomes superpopulation,HANCESTRO:0009,East Asian,,,,,,,,,,,,M,pgxbs-kftvia4h,,,pgxcs-kftw5n8a,PMID:18564138,,,,,,,,PGX_AM_BS_GSM288081,"colorectal carcinoma [left, well differentiated]",NCIT:C4349,Colon Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C18.9,"Colon, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001155,colon,,,,P89Y6M,,,EFO:0030039,no followup status,,Shimotsuke-shi,Japan,JPN,139.85::36.4,,,,,geo:GSM288081,geo:GSE11417,geo:GPL2005,,,MYC
5c865b3b09d374f2dc2b8e4f,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,"colorectal carcinoma [left, well differentiated, lymph node metastasis]",PMID:18564138,"Kurashina K, Yamashita Y et al. (2008): Chromosome copy number analysis in screening...",NCIT:C4349,Colon Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C18.9,"Colon, NOS",pgxbs-kftvia7j,P86Y6M,pgxind-kftx3wzb,pgxcs-kftw5o6l,883968574,0.307,546023174,0.19,337945400,0.118,PGX_AM_BS_GSM288147,,139.85,36.4,Point,JPN,Shimotsuke-shi,Japan,"Shimotsuke-shi, Japan",36.4,139.85,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001155,colon,{},2020-09-10 17:45:18.447000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,1,17.37,,,geo:GPL2005,,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),pgxcohort-2021progenetix,Version at Progenetix Update 2021,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:GSE11417,,geo:GSM288147,,pubmed,geo:gpl,geo:gse,,,,,,geo:gsm,,,,arraymap import,0.12,SNP2pop 1000 Genomes population,HANCESTRO:0027,Han Chinese,0.52,SNP2pop 1000 Genomes superpopulation,HANCESTRO:0009,East Asian,,,,,,,,,,,,F,pgxbs-kftvia7j,,,pgxcs-kftw5o6l,PMID:18564138,,,,,,,,PGX_AM_BS_GSM288147,"colorectal carcinoma [left, well differentiated, lymph node metastasis]",NCIT:C4349,Colon Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C18.9,"Colon, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001155,colon,,,,P86Y6M,,,EFO:0030039,no followup status,,Shimotsuke-shi,Japan,JPN,139.85::36.4,,,,,geo:GSM288147,geo:GSE11417,geo:GPL2005,,,MYC
5bab56c7727983b2e00ae064,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,adenocarcinoma [sigma],PMID:17044061,"Habermann JK, Paulsen U et al. (2007): Stage-specific alterations of the genome, transcriptome,...",NCIT:C43584,Rectosigmoid Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C18.7,sigmoid incl. rectosigmoid junction,pgxbs-kftvgyco,P59Y,pgxind-kftx2rqj,pgxcs-kftvqu3b,525376272,0.183,124217278,0.043,401158994,0.14,PGX_AM_BS_NCBISKYCGH-3719,,-77.1,38.98,Point,USA,Bethesda,United States of America,"Bethesda, United States",38.98,-77.1,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001155,colon,{},2020-09-10 17:44:25.130000,T3N2M1,NCITstage-C27970,Stage III,TNM-C48700,M1 Stage Finding,TNM-C48786,N2 Stage Finding,TNM-C48728,T3 Stage Finding,,,1,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgyco,,,pgxcs-kftvqu3b,PMID:17044061,,,,,,,,PGX_AM_BS_NCBISKYCGH-3719,adenocarcinoma [sigma],NCIT:C43584,Rectosigmoid Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C18.7,Sigmoid colon,NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001155,colon,,,,P59Y,,,EFO:0030049,dead (follow-up status),,Bethesda,United States of America,USA,-77.1::38.98,,,,,,,,,,MYC
5bab56c7727983b2e00ae070,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"adenocarcinoma [sigma, liver metastasis]",PMID:17044061,"Habermann JK, Paulsen U et al. (2007): Stage-specific alterations of the genome, transcriptome,...",NCIT:C43584,Rectosigmoid Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C18.7,sigmoid incl. rectosigmoid junction,pgxbs-kftvgyd7,P76Y,pgxind-kftx2rr7,pgxcs-kftvqu97,1066921802,0.371,492068466,0.171,574853336,0.2,PGX_AM_BS_NCBISKYCGH-3732,,-77.1,38.98,Point,USA,Bethesda,United States of America,"Bethesda, United States",38.98,-77.1,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001155,colon,{},2020-09-10 17:44:25.147000,T3N2M1,NCITstage-C27970,Stage III,TNM-C48700,M1 Stage Finding,TNM-C48786,N2 Stage Finding,TNM-C48728,T3 Stage Finding,,,1,42.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgyd7,,,pgxcs-kftvqu97,PMID:17044061,,,,,,,,PGX_AM_BS_NCBISKYCGH-3732,"adenocarcinoma [sigma, liver metastasis]",NCIT:C43584,Rectosigmoid Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C18.7,Sigmoid colon,NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001155,colon,,,,P76Y,,,EFO:0030049,dead (follow-up status),,Bethesda,United States of America,USA,-77.1::38.98,,,,,,,,,,MYC
5bab56c9727983b2e00aef8a,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"Mucinous colorectal carcinoma [Sigmoid colon, pT3N0M1, stage V]",PMID:15289862,"Liu XP, Sato T, Oga A et al. (2004): Two subtypes of mucinous colorectal carcinoma...",NCIT:C43592,Rectosigmoid Mucinous Adenocarcinoma,icdom-84803,Mucinous adenocarcinoma,icdot-C18.7,sigmoid incl. rectosigmoid junction,pgxbs-kftvh37p,P69Y,pgxind-kftx2xsm,pgxcs-kftvscdj,638432734,0.222,358733219,0.125,279699515,0.097,PGX_AM_BS_MucCoCa-liu-17,,131.47,34.19,Point,JPN,Yamaguchi-shi,Japan,"Yamaguchi-shi, Japan",34.19,131.47,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001155,colon,{},2020-09-10 17:44:30.893000,T3N0M1,NCITstage-C27970,Stage III,TNM-C48700,M1 Stage Finding,TNM-C48705,N0 Stage Finding,TNM-C48728,T3 Stage Finding,,,1,40.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvh37p,,,pgxcs-kftvscdj,PMID:15289862,,,,,,,,PGX_AM_BS_MucCoCa-liu-17,"Mucinous colorectal carcinoma [Sigmoid colon, pT3N0M1, stage V]",NCIT:C43592,Rectosigmoid Mucinous Adenocarcinoma,pgx:icdom-84803,Mucinous adenocarcinoma,pgx:icdot-C18.7,Sigmoid colon,NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001155,colon,,,,P69Y,,,EFO:0030049,dead (follow-up status),,Yamaguchi-shi,Japan,JPN,131.47::34.19,,,,,,,,,,MYC
5bab56c6727983b2e00adaab,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Enteropathy type T-cell lymphoma,PMID:17484883,"Deleeuw RJ, Zettl A et al. (2007): Whole-genome analysis and HLA genotyping of...",NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,icdom-97173,Intestinal T-cell lymphoma,icdot-C17.9,small intestine,pgxbs-kftvgw73,P64Y,pgxind-kftx2pg8,pgxcs-kftvq9lo,296466349,0.103,198927613,0.069,97538736,0.034,PGX_AM_BS_EntTNHL-del-02,{},-123.12,49.25,Point,CAN,Vancouver,Canada,"Vancouver, Canada",49.25,-123.12,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002108,small intestine,{},2020-09-10 17:44:23.108000,,,,,,,,,,,,0,27.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgw73,,,pgxcs-kftvq9lo,PMID:17484883,,,,,,,,PGX_AM_BS_EntTNHL-del-02,Enteropathy type T-cell lymphoma,NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,pgx:icdom-97173,Intestinal T-cell lymphoma,pgx:icdot-C17.9,"Small intestine, NOS",NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0002108,small intestine,,,,P64Y,,,EFO:0030041,alive (follow-up status),,Vancouver,Canada,CAN,-123.12::49.25,,,,,,,,,,MYC
5bab56c6727983b2e00adaad,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Enteropathy type T-cell lymphoma,PMID:17484883,"Deleeuw RJ, Zettl A et al. (2007): Whole-genome analysis and HLA genotyping of...",NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,icdom-97173,Intestinal T-cell lymphoma,icdot-C17.9,small intestine,pgxbs-kftvgw76,P73Y,pgxind-kftx2pgc,pgxcs-kftvq9mo,459360518,0.16,112800109,0.039,346560409,0.121,PGX_AM_BS_EntTNHL-del-04,{},-123.12,49.25,Point,CAN,Vancouver,Canada,"Vancouver, Canada",49.25,-123.12,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002108,small intestine,{},2020-09-10 17:44:23.111000,,,,,,,,,,,,1,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgw76,,,pgxcs-kftvq9mo,PMID:17484883,,,,,,,,PGX_AM_BS_EntTNHL-del-04,Enteropathy type T-cell lymphoma,NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,pgx:icdom-97173,Intestinal T-cell lymphoma,pgx:icdot-C17.9,"Small intestine, NOS",NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0002108,small intestine,,,,P73Y,,,EFO:0030049,dead (follow-up status),,Vancouver,Canada,CAN,-123.12::49.25,,,,,,,,,,MYC
5bab56c6727983b2e00adab3,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Enteropathy type T-cell lymphoma,PMID:17484883,"Deleeuw RJ, Zettl A et al. (2007): Whole-genome analysis and HLA genotyping of...",NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,icdom-97173,Intestinal T-cell lymphoma,icdot-C17.9,small intestine,pgxbs-kftvgw7f,P63Y,pgxind-kftx2pgo,pgxcs-kftvq9pk,460789189,0.16,168197588,0.059,292591601,0.102,PGX_AM_BS_EntTNHL-del-10,{},-123.12,49.25,Point,CAN,Vancouver,Canada,"Vancouver, Canada",49.25,-123.12,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002108,small intestine,{},2020-09-10 17:44:23.119000,,,,,,,,,,,,1,16.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgw7f,,,pgxcs-kftvq9pk,PMID:17484883,,,,,,,,PGX_AM_BS_EntTNHL-del-10,Enteropathy type T-cell lymphoma,NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,pgx:icdom-97173,Intestinal T-cell lymphoma,pgx:icdot-C17.9,"Small intestine, NOS",NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0002108,small intestine,,,,P63Y,,,EFO:0030049,dead (follow-up status),,Vancouver,Canada,CAN,-123.12::49.25,,,,,,,,,,MYC
5bab56c6727983b2e00adab4,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Enteropathy type T-cell lymphoma,PMID:17484883,"Deleeuw RJ, Zettl A et al. (2007): Whole-genome analysis and HLA genotyping of...",NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,icdom-97173,Intestinal T-cell lymphoma,icdot-C17.9,small intestine,pgxbs-kftvgw7h,P43Y,pgxind-kftx2pgq,pgxcs-kftvq9q1,590185329,0.205,309146412,0.108,281038917,0.098,PGX_AM_BS_EntTNHL-del-11,{},-123.12,49.25,Point,CAN,Vancouver,Canada,"Vancouver, Canada",49.25,-123.12,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002108,small intestine,{},2020-09-10 17:44:23.121000,,,,,,,,,,,,1,18.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgw7h,,,pgxcs-kftvq9q1,PMID:17484883,,,,,,,,PGX_AM_BS_EntTNHL-del-11,Enteropathy type T-cell lymphoma,NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,pgx:icdom-97173,Intestinal T-cell lymphoma,pgx:icdot-C17.9,"Small intestine, NOS",NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0002108,small intestine,,,,P43Y,,,EFO:0030049,dead (follow-up status),,Vancouver,Canada,CAN,-123.12::49.25,,,,,,,,,,MYC
5bab56c6727983b2e00adab5,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Enteropathy type T-cell lymphoma,PMID:17484883,"Deleeuw RJ, Zettl A et al. (2007): Whole-genome analysis and HLA genotyping of...",NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,icdom-97173,Intestinal T-cell lymphoma,icdot-C17.9,small intestine,pgxbs-kftvgw7j,P56Y,pgxind-kftx2pgs,pgxcs-kftvq9sc,220352611,0.077,4500004,0.002,215852607,0.075,PGX_AM_BS_EntTNHL-del-12,{},-123.12,49.25,Point,CAN,Vancouver,Canada,"Vancouver, Canada",49.25,-123.12,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002108,small intestine,{},2020-09-10 17:44:23.122000,,,,,,,,,,,,1,3.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgw7j,,,pgxcs-kftvq9sc,PMID:17484883,,,,,,,,PGX_AM_BS_EntTNHL-del-12,Enteropathy type T-cell lymphoma,NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,pgx:icdom-97173,Intestinal T-cell lymphoma,pgx:icdot-C17.9,"Small intestine, NOS",NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0002108,small intestine,,,,P56Y,,,EFO:0030049,dead (follow-up status),,Vancouver,Canada,CAN,-123.12::49.25,,,,,,,,,,MYC
5bab56c6727983b2e00adab6,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Enteropathy type T-cell lymphoma,PMID:17484883,"Deleeuw RJ, Zettl A et al. (2007): Whole-genome analysis and HLA genotyping of...",NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,icdom-97173,Intestinal T-cell lymphoma,icdot-C17.9,small intestine,pgxbs-kftvgw7k,P61Y,pgxind-kftx2pgu,pgxcs-kftvq9su,616433201,0.214,213509262,0.074,402923939,0.14,PGX_AM_BS_EntTNHL-del-13,{},-123.12,49.25,Point,CAN,Vancouver,Canada,"Vancouver, Canada",49.25,-123.12,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002108,small intestine,{},2020-09-10 17:44:23.123000,,,,,,,,,,,,1,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgw7k,,,pgxcs-kftvq9su,PMID:17484883,,,,,,,,PGX_AM_BS_EntTNHL-del-13,Enteropathy type T-cell lymphoma,NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,pgx:icdom-97173,Intestinal T-cell lymphoma,pgx:icdot-C17.9,"Small intestine, NOS",NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0002108,small intestine,,,,P61Y,,,EFO:0030049,dead (follow-up status),,Vancouver,Canada,CAN,-123.12::49.25,,,,,,,,,,MYC
5bab56c6727983b2e00adab7,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Enteropathy type T-cell lymphoma,PMID:17484883,"Deleeuw RJ, Zettl A et al. (2007): Whole-genome analysis and HLA genotyping of...",NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,icdom-97173,Intestinal T-cell lymphoma,icdot-C17.9,small intestine,pgxbs-kftvgw7m,P68Y,pgxind-kftx2pgw,pgxcs-kftvq9tc,412966467,0.144,222827639,0.078,190138828,0.066,PGX_AM_BS_EntTNHL-del-14,{},-123.12,49.25,Point,CAN,Vancouver,Canada,"Vancouver, Canada",49.25,-123.12,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002108,small intestine,{},2020-09-10 17:44:23.125000,,,,,,,,,,,,1,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgw7m,,,pgxcs-kftvq9tc,PMID:17484883,,,,,,,,PGX_AM_BS_EntTNHL-del-14,Enteropathy type T-cell lymphoma,NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,pgx:icdom-97173,Intestinal T-cell lymphoma,pgx:icdot-C17.9,"Small intestine, NOS",NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0002108,small intestine,,,,P68Y,,,EFO:0030049,dead (follow-up status),,Vancouver,Canada,CAN,-123.12::49.25,,,,,,,,,,MYC
5bab56c6727983b2e00adac5,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Enteropathy type T-cell lymphoma,PMID:17484883,"Deleeuw RJ, Zettl A et al. (2007): Whole-genome analysis and HLA genotyping of...",NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,icdom-97173,Intestinal T-cell lymphoma,icdot-C17.9,small intestine,pgxbs-kftvgw88,P84Y,pgxind-kftx2php,pgxcs-kftvqa03,171985161,0.06,83779885,0.029,88205276,0.031,PGX_AM_BS_EntTNHL-del-05,{},-123.12,49.25,Point,CAN,Vancouver,Canada,"Vancouver, Canada",49.25,-123.12,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002108,small intestine,{},2020-09-10 17:44:23.144000,,,,,,,,,,,,1,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgw88,,,pgxcs-kftvqa03,PMID:17484883,,,,,,,,PGX_AM_BS_EntTNHL-del-05,Enteropathy type T-cell lymphoma,NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,pgx:icdom-97173,Intestinal T-cell lymphoma,pgx:icdot-C17.9,"Small intestine, NOS",NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0002108,small intestine,,,,P84Y,,,EFO:0030049,dead (follow-up status),,Vancouver,Canada,CAN,-123.12::49.25,,,,,,,,,,MYC
5bab56c6727983b2e00adac6,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Enteropathy type T-cell lymphoma,PMID:17484883,"Deleeuw RJ, Zettl A et al. (2007): Whole-genome analysis and HLA genotyping of...",NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,icdom-97173,Intestinal T-cell lymphoma,icdot-C17.9,small intestine,pgxbs-kftvgw8a,P65Y,pgxind-kftx2phr,pgxcs-kftvqa0k,503373409,0.175,196615237,0.068,306758172,0.107,PGX_AM_BS_EntTNHL-del-29,{},-123.12,49.25,Point,CAN,Vancouver,Canada,"Vancouver, Canada",49.25,-123.12,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002108,small intestine,{},2020-09-10 17:44:23.146000,,,,,,,,,,,,1,7.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgw8a,,,pgxcs-kftvqa0k,PMID:17484883,,,,,,,,PGX_AM_BS_EntTNHL-del-29,Enteropathy type T-cell lymphoma,NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,pgx:icdom-97173,Intestinal T-cell lymphoma,pgx:icdot-C17.9,"Small intestine, NOS",NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0002108,small intestine,,,,P65Y,,,EFO:0030049,dead (follow-up status),,Vancouver,Canada,CAN,-123.12::49.25,,,,,,,,,,MYC
5bab56cb727983b2e00afce1,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"Enteropathy-Type T-Cell Lymphoma [pleomorphic, medium and large cells]",PMID:12414511,"Zettl A, Ott G, Makulik A et al. (2002): Chromosomal gains at 9q characterize enteropathy-type...",NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,icdom-97173,Intestinal T-cell lymphoma,icdot-C26.9,unspecified digest. Organs,pgxbs-kftvh7hi,P64Y,pgxind-kftx334o,pgxcs-kftvto4t,483861091,0.168,172527425,0.06,311333666,0.108,PGX_AM_BS_EP-T-NHL-05,,9.95,49.79,Point,DEU,Wuerzburg,Germany,"Wuerzburg, Germany",49.79,9.95,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001007,digestive system,{},2020-09-10 17:44:35.616000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,1,12.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvh7hi,,,pgxcs-kftvto4t,PMID:12414511,,,,,,,,PGX_AM_BS_EP-T-NHL-05,"Enteropathy-Type T-Cell Lymphoma [pleomorphic, medium and large cells]",NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,pgx:icdom-97173,Intestinal T-cell lymphoma,pgx:icdot-C26.9,"Gastrointestinal tract, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001007,digestive system,,,,P64Y,,,EFO:0030049,dead (follow-up status),,Wuerzburg,Germany,DEU,9.95::49.79,,,,,,,,,,MYC
5bab56cb727983b2e00afcee,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Enteropathy-Type T-Cell Lymphoma [ALCL],PMID:12414511,"Zettl A, Ott G, Makulik A et al. (2002): Chromosomal gains at 9q characterize enteropathy-type...",NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,icdom-97173,Intestinal T-cell lymphoma,icdot-C26.9,Unspecified digestive organs,pgxbs-kftvh7i4,P65Y,pgxind-kftx335e,pgxcs-kftvtob0,684458609,0.238,167595727,0.058,516862882,0.18,PGX_AM_BS_EP-T-NHL-17,{},9.95,49.79,Point,DEU,Wuerzburg,Germany,"Wuerzburg, Germany",49.79,9.95,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001007,digestive system,{},2020-09-10 17:44:35.634000,,,,,,,,,,,,1,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvh7i4,,,pgxcs-kftvtob0,PMID:12414511,,,,,,,,PGX_AM_BS_EP-T-NHL-17,Enteropathy-Type T-Cell Lymphoma [ALCL],NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,pgx:icdom-97173,Intestinal T-cell lymphoma,pgx:icdot-C26.9,"Gastrointestinal tract, NOS",NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0001007,digestive system,,,,P65Y,,,EFO:0030049,dead (follow-up status),,Wuerzburg,Germany,DEU,9.95::49.79,,,,,,,,,,MYC
5bab56cb727983b2e00afcf9,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Enteropathy-Type T-Cell Lymphoma [monomorphic with small- to medium-sized cells],PMID:12414511,"Zettl A, Ott G, Makulik A et al. (2002): Chromosomal gains at 9q characterize enteropathy-type...",NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,icdom-97173,Intestinal T-cell lymphoma,icdot-C26.9,unspecified digest. Organs,pgxbs-kftvh7im,P63Y,pgxind-kftx3361,pgxcs-kftvtoga,466015425,0.162,65200065,0.023,400815360,0.139,PGX_AM_BS_EP-T-NHL-27,,9.95,49.79,Point,DEU,Wuerzburg,Germany,"Wuerzburg, Germany",49.79,9.95,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001007,digestive system,{},2020-09-10 17:44:35.649000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,1,16.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvh7im,,,pgxcs-kftvtoga,PMID:12414511,,,,,,,,PGX_AM_BS_EP-T-NHL-27,Enteropathy-Type T-Cell Lymphoma [monomorphic with small- to medium-sized cells],NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,pgx:icdom-97173,Intestinal T-cell lymphoma,pgx:icdot-C26.9,"Gastrointestinal tract, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001007,digestive system,,,,P63Y,,,EFO:0030049,dead (follow-up status),,Wuerzburg,Germany,DEU,9.95::49.79,,,,,,,,,,MYC
5bab56c9727983b2e00aef7a,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"Mucinous colorectal carcinoma [Ascending colon, pT3N1M0, stage II]",PMID:15289862,"Liu XP, Sato T, Oga A et al. (2004): Two subtypes of mucinous colorectal carcinoma...",NCIT:C7966,Colon Mucinous Adenocarcinoma,icdom-84803,Mucinous adenocarcinoma,icdot-C18.9,"large intestine, excl. rectum and rectosigmoid junction",pgxbs-kftvh36y,P64Y,pgxind-kftx2xrq,pgxcs-kftvsc5u,348488704,0.121,36800036,0.013,311688668,0.108,PGX_AM_BS_MucCoCa-liu-01,,131.47,34.19,Point,JPN,Yamaguchi-shi,Japan,"Yamaguchi-shi, Japan",34.19,131.47,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001155,colon,{},2020-09-10 17:44:30.871000,T3N1M0,NCITstage-C28054,Stage II,TNM-C48706,N1 Stage Finding,TNM-C48714,N3 Stage Finding,TNM-C48728,T3 Stage Finding,,,0,115.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvh36y,,,pgxcs-kftvsc5u,PMID:15289862,,,,,,,,PGX_AM_BS_MucCoCa-liu-01,"Mucinous colorectal carcinoma [Ascending colon, pT3N1M0, stage II]",NCIT:C7966,Colon Mucinous Adenocarcinoma,pgx:icdom-84803,Mucinous adenocarcinoma,pgx:icdot-C18.9,"Colon, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001155,colon,,,,P64Y,,,EFO:0030041,alive (follow-up status),,Yamaguchi-shi,Japan,JPN,131.47::34.19,,,,,,,,,,MYC
5bab56c9727983b2e00aef89,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"Mucinous colorectal carcinoma [Rectum [above], pT3N1M0, stage II]",PMID:15289862,"Liu XP, Sato T, Oga A et al. (2004): Two subtypes of mucinous colorectal carcinoma...",NCIT:C7966,Colon Mucinous Adenocarcinoma,icdom-84803,Mucinous adenocarcinoma,icdot-C18.9,"large intestine, excl. rectum and rectosigmoid junction",pgxbs-kftvh37n,P75Y,pgxind-kftx2xsk,pgxcs-kftvscd1,1291929548,0.449,685440588,0.238,606488960,0.211,PGX_AM_BS_MucCoCa-liu-16,,131.47,34.19,Point,JPN,Yamaguchi-shi,Japan,"Yamaguchi-shi, Japan",34.19,131.47,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001155,colon,{},2020-09-10 17:44:30.892000,T3N1M0,NCITstage-C28054,Stage II,TNM-C48706,N1 Stage Finding,TNM-C48714,N3 Stage Finding,TNM-C48728,T3 Stage Finding,,,0,107.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvh37n,,,pgxcs-kftvscd1,PMID:15289862,,,,,,,,PGX_AM_BS_MucCoCa-liu-16,"Mucinous colorectal carcinoma [Rectum [above], pT3N1M0, stage II]",NCIT:C7966,Colon Mucinous Adenocarcinoma,pgx:icdom-84803,Mucinous adenocarcinoma,pgx:icdot-C18.9,"Colon, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001155,colon,,,,P75Y,,,EFO:0030041,alive (follow-up status),,Yamaguchi-shi,Japan,JPN,131.47::34.19,,,,,,,,,,MYC
5bab56c9727983b2e00aef8d,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"Mucinous colorectal carcinoma [Rectum [above], pT3N1M0, stage II]",PMID:15289862,"Liu XP, Sato T, Oga A et al. (2004): Two subtypes of mucinous colorectal carcinoma...",NCIT:C7966,Colon Mucinous Adenocarcinoma,icdom-84803,Mucinous adenocarcinoma,icdot-C18.9,"large intestine, excl. rectum and rectosigmoid junction",pgxbs-kftvh37u,P65Y,pgxind-kftx2xss,pgxcs-kftvscey,1495035193,0.52,699395763,0.243,795639430,0.277,PGX_AM_BS_MucCoCa-liu-20,,131.47,34.19,Point,JPN,Yamaguchi-shi,Japan,"Yamaguchi-shi, Japan",34.19,131.47,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001155,colon,{},2020-09-10 17:44:30.898000,T3N1M0,NCITstage-C28054,Stage II,TNM-C48706,N1 Stage Finding,TNM-C48714,N3 Stage Finding,TNM-C48728,T3 Stage Finding,,,0,100.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvh37u,,,pgxcs-kftvscey,PMID:15289862,,,,,,,,PGX_AM_BS_MucCoCa-liu-20,"Mucinous colorectal carcinoma [Rectum [above], pT3N1M0, stage II]",NCIT:C7966,Colon Mucinous Adenocarcinoma,pgx:icdom-84803,Mucinous adenocarcinoma,pgx:icdot-C18.9,"Colon, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001155,colon,,,,P65Y,,,EFO:0030041,alive (follow-up status),,Yamaguchi-shi,Japan,JPN,131.47::34.19,,,,,,,,,,MYC
5bab56c9727983b2e00aef8b,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"Mucinous colorectal carcinoma [Rectum [above], pT3N1M0, stage II]",PMID:15289862,"Liu XP, Sato T, Oga A et al. (2004): Two subtypes of mucinous colorectal carcinoma...",NCIT:C7966,Colon Mucinous Adenocarcinoma,icdom-84803,Mucinous adenocarcinoma,icdot-C18.9,"large intestine, excl. rectum and rectosigmoid junction",pgxbs-kftvh37r,P48Y,pgxind-kftx2xso,pgxcs-kftvsce0,1203222347,0.419,255219287,0.089,948003060,0.33,PGX_AM_BS_MucCoCa-liu-18,,131.47,34.19,Point,JPN,Yamaguchi-shi,Japan,"Yamaguchi-shi, Japan",34.19,131.47,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001155,colon,{},2020-09-10 17:44:30.895000,T3N1M0,NCITstage-C28054,Stage II,TNM-C48706,N1 Stage Finding,TNM-C48714,N3 Stage Finding,TNM-C48728,T3 Stage Finding,,,1,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvh37r,,,pgxcs-kftvsce0,PMID:15289862,,,,,,,,PGX_AM_BS_MucCoCa-liu-18,"Mucinous colorectal carcinoma [Rectum [above], pT3N1M0, stage II]",NCIT:C7966,Colon Mucinous Adenocarcinoma,pgx:icdom-84803,Mucinous adenocarcinoma,pgx:icdot-C18.9,"Colon, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001155,colon,,,,P48Y,,,EFO:0030049,dead (follow-up status),,Yamaguchi-shi,Japan,JPN,131.47::34.19,,,,,,,,,,MYC
5bab56c9727983b2e00aef8c,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"Mucinous colorectal carcinoma [Cecum, pT3N1M1, stage V]",PMID:15289862,"Liu XP, Sato T, Oga A et al. (2004): Two subtypes of mucinous colorectal carcinoma...",NCIT:C7966,Colon Mucinous Adenocarcinoma,icdom-84803,Mucinous adenocarcinoma,icdot-C18.0,cecum,pgxbs-kftvh37s,P57Y,pgxind-kftx2xsq,pgxcs-kftvsceh,674810044,0.235,127417281,0.044,547392763,0.19,PGX_AM_BS_MucCoCa-liu-19,,131.47,34.19,Point,JPN,Yamaguchi-shi,Japan,"Yamaguchi-shi, Japan",34.19,131.47,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000314,cecum mucosa,{},2020-09-10 17:44:30.896000,T3N1M1,NCITstage-C27970,Stage III,TNM-C48700,M1 Stage Finding,TNM-C48706,N1 Stage Finding,TNM-C48714,N3 Stage Finding,,,1,11.0,TNM-C48728,T3 Stage Finding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvh37s,,,pgxcs-kftvsceh,PMID:15289862,,,,,,,,PGX_AM_BS_MucCoCa-liu-19,"Mucinous colorectal carcinoma [Cecum, pT3N1M1, stage V]",NCIT:C7966,Colon Mucinous Adenocarcinoma,pgx:icdom-84803,Mucinous adenocarcinoma,pgx:icdot-C18.0,Cecum,NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0000314,cecum mucosa,,,,P57Y,,,EFO:0030049,dead (follow-up status),,Yamaguchi-shi,Japan,JPN,131.47::34.19,,,,,,,,,,MYC
5bab56c1727983b2e00ab6c9,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgknh,P49Y,pgxind-kftx2b4g,pgxcs-kftvmqmc,724756462,0.252,395806320,0.138,328950142,0.114,PGX_AM_BS_PDAC-sto-09,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.305000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,0,28.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgknh,,,pgxcs-kftvmqmc,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-09,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P49Y,,,EFO:0030041,alive (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,MYC
5bab56c1727983b2e00ab6cf,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgknr,P60Y,pgxind-kftx2b4s,pgxcs-kftvmqp4,1000646239,0.348,481409208,0.167,519237031,0.181,PGX_AM_BS_PDAC-sto-15,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.314000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgknr,,,pgxcs-kftvmqp4,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-15,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P60Y,,,EFO:0030041,alive (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,MYC
5bab56c1727983b2e00ab6d4,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgknz,P82Y,pgxind-kftx2b52,pgxcs-kftvmqrg,724920445,0.252,121244691,0.042,603675754,0.21,PGX_AM_BS_PDAC-sto-20,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.322000,T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,,,,,0,53.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgknz,,,pgxcs-kftvmqrg,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-20,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C27966,Stage I,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P82Y,,,EFO:0030041,alive (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,MYC
5bab56c1727983b2e00ab6d5,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgko1,P50Y,pgxind-kftx2b54,pgxcs-kftvmqrx,1235069614,0.43,541193772,0.188,693875842,0.241,PGX_AM_BS_PDAC-sto-21,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.323000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgko1,,,pgxcs-kftvmqrx,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-21,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P50Y,,,EFO:0030041,alive (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,MYC
5bab56c1727983b2e00ab6eb,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgkp1,P55Y,pgxind-kftx2b6c,pgxcs-kftvmr41,954789148,0.332,426585707,0.148,528203441,0.184,PGX_AM_BS_PDAC-sto-43,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.355000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,0,11.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgkp1,,,pgxcs-kftvmr41,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-43,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P55Y,,,EFO:0030041,alive (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,MYC
5bab56c1727983b2e00ab6ee,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgkp5,P62Y,pgxind-kftx2b6i,pgxcs-kftvmr5i,400557910,0.139,232355745,0.081,168202165,0.059,PGX_AM_BS_PDAC-sto-46,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.359000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,0,10.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgkp5,,,pgxcs-kftvmr5i,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-46,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P62Y,,,EFO:0030041,alive (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,MYC
5bab56c1727983b2e00ab6f0,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgkp9,P68Y,pgxind-kftx2b6m,pgxcs-kftvmr6h,595273564,0.207,184545216,0.064,410728348,0.143,PGX_AM_BS_PDAC-sto-48,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.362000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,0,18.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgkp9,,,pgxcs-kftvmr6h,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-48,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P68Y,,,EFO:0030041,alive (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,MYC
5bab56c1727983b2e00ab6c4,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgkn9,P81Y,pgxind-kftx2b46,pgxcs-kftvmqk0,607308745,0.211,208133603,0.072,399175142,0.139,PGX_AM_BS_PDAC-sto-04,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.299000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,1,16.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgkn9,,,pgxcs-kftvmqk0,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-04,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P81Y,,,EFO:0030049,dead (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,MYC
5bab56c1727983b2e00ab6cd,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgkno,P73Y,pgxind-kftx2b4o,pgxcs-kftvmqo7,668198778,0.232,343120899,0.119,325077879,0.113,PGX_AM_BS_PDAC-sto-13,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.311000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,1,11.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgkno,,,pgxcs-kftvmqo7,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-13,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P73Y,,,EFO:0030049,dead (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,MYC
5bab56c1727983b2e00ab6d6,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgko2,P60Y,pgxind-kftx2b56,pgxcs-kftvmqse,608243566,0.212,447781954,0.156,160461612,0.056,PGX_AM_BS_PDAC-sto-22,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.325000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,1,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgko2,,,pgxcs-kftvmqse,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-22,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P60Y,,,EFO:0030049,dead (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,MYC
5bab56c1727983b2e00ab6d7,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgko4,P45Y,pgxind-kftx2b58,pgxcs-kftvmqsv,1066992134,0.371,458952887,0.16,608039247,0.211,PGX_AM_BS_PDAC-sto-23,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.326000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,1,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgko4,,,pgxcs-kftvmqsv,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-23,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P45Y,,,EFO:0030049,dead (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,MYC
5bab56c1727983b2e00ab6d8,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgko6,P46Y,pgxind-kftx2b5a,pgxcs-kftvmqtc,863893971,0.3,390505142,0.136,473388829,0.165,PGX_AM_BS_PDAC-sto-24,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.328000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,1,14.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgko6,,,pgxcs-kftvmqtc,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-24,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P46Y,,,EFO:0030049,dead (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,MYC
5bab56c1727983b2e00ab6dd,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgkoe,P56Y,pgxind-kftx2b5k,pgxcs-kftvmqvn,938293894,0.326,528454844,0.184,409839050,0.143,PGX_AM_BS_PDAC-sto-29,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.334000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,1,18.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgkoe,,,pgxcs-kftvmqvn,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-29,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P56Y,,,EFO:0030049,dead (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,MYC
5bab56c1727983b2e00ab6e1,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgkok,P54Y,pgxind-kftx2b5s,pgxcs-kftvmqxj,918386292,0.319,446532627,0.155,471853665,0.164,PGX_AM_BS_PDAC-sto-33,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.340000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,1,11.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgkok,,,pgxcs-kftvmqxj,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-33,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P54Y,,,EFO:0030049,dead (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,MYC
5bab56c1727983b2e00ab6e5,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgkor,P56Y,pgxind-kftx2b60,pgxcs-kftvmqze,620998382,0.216,504959629,0.176,116038753,0.04,PGX_AM_BS_PDAC-sto-37,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.346000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,1,10.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgkor,,,pgxcs-kftvmqze,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-37,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P56Y,,,EFO:0030049,dead (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,MYC
5bab56c1727983b2e00ab6e6,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgkos,P43Y,pgxind-kftx2b62,pgxcs-kftvmqzu,443108326,0.154,177956247,0.062,265152079,0.092,PGX_AM_BS_PDAC-sto-38,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.347000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,1,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgkos,,,pgxcs-kftvmqzu,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-38,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P43Y,,,EFO:0030049,dead (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,MYC
5bab56c1727983b2e00ab6e8,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgkow,P58Y,pgxind-kftx2b66,pgxcs-kftvmr0r,664654804,0.231,396732106,0.138,267922698,0.093,PGX_AM_BS_PDAC-sto-40,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.350000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,1,13.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgkow,,,pgxcs-kftvmr0r,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-40,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P58Y,,,EFO:0030049,dead (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,MYC
5bab56c1727983b2e00ab6f3,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgkpe,P71Y,pgxind-kftx2b6r,pgxcs-kftvmr7v,1429106309,0.497,262818701,0.091,1166287608,0.406,PGX_AM_BS_PDAC-sto-51,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.366000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,1,14.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgkpe,,,pgxcs-kftvmr7v,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-51,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P71Y,,,EFO:0030049,dead (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,MYC
5bab56c7727983b2e00ae065,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,adenocarcinoma [rectum],PMID:17044061,"Habermann JK, Paulsen U et al. (2007): Stage-specific alterations of the genome, transcriptome,...",NCIT:C9383,Rectal Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C20.9,"Rectum, NOS",pgxbs-kftvgycq,P77Y,pgxind-kftx2rql,pgxcs-kftvqu3t,766404076,0.267,48100048,0.017,718304028,0.25,PGX_AM_BS_NCBISKYCGH-3720,,-77.1,38.98,Point,USA,Bethesda,United States of America,"Bethesda, United States",38.98,-77.1,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001052,rectum,{},2020-09-10 17:44:25.131000,T2N1M0,NCITstage-C28054,Stage II,TNM-C48706,N1 Stage Finding,TNM-C48714,N3 Stage Finding,TNM-C48724,T2 Stage Finding,,,0,42.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgycq,,,pgxcs-kftvqu3t,PMID:17044061,,,,,,,,PGX_AM_BS_NCBISKYCGH-3720,adenocarcinoma [rectum],NCIT:C9383,Rectal Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C20.9,"Rectum, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001052,rectum,,,,P77Y,,,EFO:0030041,alive (follow-up status),,Bethesda,United States of America,USA,-77.1::38.98,,,,,,,,,,MYC
5bab56c7727983b2e00ae069,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,adenocarcinoma [rectum],PMID:17044061,"Habermann JK, Paulsen U et al. (2007): Stage-specific alterations of the genome, transcriptome,...",NCIT:C9383,Rectal Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C20.9,"Rectum, NOS",pgxbs-kftvgycw,P71Y,pgxind-kftx2rqt,pgxcs-kftvqu5s,954534975,0.332,501795515,0.175,452739460,0.157,PGX_AM_BS_NCBISKYCGH-3724,,-77.1,38.98,Point,USA,Bethesda,United States of America,"Bethesda, United States",38.98,-77.1,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001052,rectum,{},2020-09-10 17:44:25.137000,T3N1M0,NCITstage-C27970,Stage III,TNM-C48706,N1 Stage Finding,TNM-C48714,N3 Stage Finding,TNM-C48728,T3 Stage Finding,,,0,52.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgycw,,,pgxcs-kftvqu5s,PMID:17044061,,,,,,,,PGX_AM_BS_NCBISKYCGH-3724,adenocarcinoma [rectum],NCIT:C9383,Rectal Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C20.9,"Rectum, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001052,rectum,,,,P71Y,,,EFO:0030041,alive (follow-up status),,Bethesda,United States of America,USA,-77.1::38.98,,,,,,,,,,MYC
5bab56c8727983b2e00aec47,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Rectal adenocarcinoma with choriocarcinomatous differentiation [adenocarcinomatous part],PMID:15668903,"Verbeek W, Schulten HJ et al. (2004): Rectal adenocarcinoma with choriocarcinomatous differentiation: clinical...",NCIT:C9383,Rectal Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C20.9,"Rectum, NOS",pgxbs-kftvh260,P54Y,pgxind-kftx2whg,pgxcs-kftvs0r2,362274961,0.126,98300097,0.034,263974864,0.092,PGX_AM_BS_RecChorCa-AD,{},10.53,52.27,Point,DEU,Braunschweig,Germany,"Braunschweig, Germany",52.27,10.53,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001052,rectum,{},2020-09-10 17:44:29.732000,,,,,,,,,,,,1,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvh260,,,pgxcs-kftvs0r2,PMID:15668903,,,,,,,,PGX_AM_BS_RecChorCa-AD,Rectal adenocarcinoma with choriocarcinomatous differentiation [adenocarcinomatous part],NCIT:C9383,Rectal Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C20.9,"Rectum, NOS",NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0001052,rectum,,,,P54Y,,,EFO:0030049,dead (follow-up status),,Braunschweig,Germany,DEU,10.53::52.27,,,,,,,,,,MYC
5bab56c4727983b2e00acaae,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,hepatocellular carcinoma,PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C3099,Hepatocellular Carcinoma,icdom-81703,"Hepatocellular carcinoma, NOS",icdot-C22.0,Liver,pgxbs-kftvgr2m,P62Y,pgxind-kftx2j1n,pgxcs-kftvooc4,1053961073,0.367,709475045,0.247,344486028,0.12,PGX_AM_BS_HCC-CC-hom-42,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:17.444000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,0,78.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr2m,,,pgxcs-kftvooc4,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-42,hepatocellular carcinoma,NCIT:C3099,Hepatocellular Carcinoma,pgx:icdom-81703,"Hepatocellular carcinoma, NOS",pgx:icdot-C22.0,Liver,NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P62Y,,,EFO:0030041,alive (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,TP53
5bab56c4727983b2e00acab9,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,hepatocellular carcinoma [hepatitis B pos.],PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C3099,Hepatocellular Carcinoma,icdom-81703,"Hepatocellular carcinoma, NOS",icdot-C22.0,Liver,pgxbs-kftvgr34,P56Y,pgxind-kftx2j29,pgxcs-kftvoohe,776174068,0.27,480058017,0.167,296116051,0.103,PGX_AM_BS_HCC-CC-hom-53,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:17.459000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,0,7.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgr34,,,pgxcs-kftvoohe,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-53,hepatocellular carcinoma [hepatitis B pos.],NCIT:C3099,Hepatocellular Carcinoma,pgx:icdom-81703,"Hepatocellular carcinoma, NOS",pgx:icdot-C22.0,Liver,NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P56Y,,,EFO:0030041,alive (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,TP53
5bab56c4727983b2e00acabc,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,hepatocellular carcinoma,PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C3099,Hepatocellular Carcinoma,icdom-81703,"Hepatocellular carcinoma, NOS",icdot-C22.0,Liver,pgxbs-kftvgr39,P73Y,pgxind-kftx2j2g,pgxcs-kftvooiv,962977633,0.335,728107938,0.253,234869695,0.082,PGX_AM_BS_HCC-CC-hom-56,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:17.463000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,0,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgr39,,,pgxcs-kftvooiv,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-56,hepatocellular carcinoma,NCIT:C3099,Hepatocellular Carcinoma,pgx:icdom-81703,"Hepatocellular carcinoma, NOS",pgx:icdot-C22.0,Liver,NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P73Y,,,EFO:0030041,alive (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,TP53
5bab56c4727983b2e00acaaf,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"hepatocellular carcinoma [cirrhosis, cryptogenic]",PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C3099,Hepatocellular Carcinoma,icdom-81703,"Hepatocellular carcinoma, NOS",icdot-C22.0,Liver,pgxbs-kftvgr2o,P78Y,pgxind-kftx2j1p,pgxcs-kftvoocl,1379385783,0.48,1000522305,0.348,378863478,0.132,PGX_AM_BS_HCC-CC-hom-43,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:17.445000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,1,3.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr2o,,,pgxcs-kftvoocl,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-43,"hepatocellular carcinoma [cirrhosis, cryptogenic]",NCIT:C3099,Hepatocellular Carcinoma,pgx:icdom-81703,"Hepatocellular carcinoma, NOS",pgx:icdot-C22.0,Liver,NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P78Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,TP53
5bab56c4727983b2e00acab8,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,hepatocellular carcinoma [alcoholic cirrhosis],PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C3099,Hepatocellular Carcinoma,icdom-81703,"Hepatocellular carcinoma, NOS",icdot-C22.0,Liver,pgxbs-kftvgr32,P61Y,pgxind-kftx2j27,pgxcs-kftvoogw,565604943,0.197,256733490,0.089,308871453,0.107,PGX_AM_BS_HCC-CC-hom-52,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:17.458000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,1,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr32,,,pgxcs-kftvoogw,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-52,hepatocellular carcinoma [alcoholic cirrhosis],NCIT:C3099,Hepatocellular Carcinoma,pgx:icdom-81703,"Hepatocellular carcinoma, NOS",pgx:icdot-C22.0,Liver,NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P61Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,TP53
5bab56c4727983b2e00acabb,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,hepatocellular carcinoma [hepatitis C liver cirrhosis],PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C3099,Hepatocellular Carcinoma,icdom-81703,"Hepatocellular carcinoma, NOS",icdot-C22.0,Liver,pgxbs-kftvgr37,P50Y,pgxind-kftx2j2e,pgxcs-kftvooic,908099431,0.316,908099431,0.316,0,0.0,PGX_AM_BS_HCC-CC-hom-55,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:17.462000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,1,45.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr37,,,pgxcs-kftvooic,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-55,hepatocellular carcinoma [hepatitis C liver cirrhosis],NCIT:C3099,Hepatocellular Carcinoma,pgx:icdom-81703,"Hepatocellular carcinoma, NOS",pgx:icdot-C22.0,Liver,NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P50Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,TP53
5bab56c4727983b2e00acabe,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,hepatocellular carcinoma,PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C3099,Hepatocellular Carcinoma,icdom-81703,"Hepatocellular carcinoma, NOS",icdot-C22.0,Liver,pgxbs-kftvgr3c,P64Y,pgxind-kftx2j2k,pgxcs-kftvooju,1107365509,0.385,453075144,0.158,654290365,0.228,PGX_AM_BS_HCC-CC-hom-58,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:17.466000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,1,26.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr3c,,,pgxcs-kftvooju,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-58,hepatocellular carcinoma,NCIT:C3099,Hepatocellular Carcinoma,pgx:icdom-81703,"Hepatocellular carcinoma, NOS",pgx:icdot-C22.0,Liver,NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P64Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,TP53
5bab56c4727983b2e00acac5,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,hepatocellular carcinoma [hepatitis C liver cirrhosis],PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C3099,Hepatocellular Carcinoma,icdom-81703,"Hepatocellular carcinoma, NOS",icdot-C22.0,Liver,pgxbs-kftvgr3o,P75Y,pgxind-kftx2j2y,pgxcs-kftvoon9,339649288,0.118,67400067,0.023,272249221,0.095,PGX_AM_BS_HCC-CC-hom-65,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:17.475000,T4,NCITstage-C27971,Stage IV,TNM-C48732,T4 Stage Finding,,,,,,,1,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgr3o,,,pgxcs-kftvoon9,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-65,hepatocellular carcinoma [hepatitis C liver cirrhosis],NCIT:C3099,Hepatocellular Carcinoma,pgx:icdom-81703,"Hepatocellular carcinoma, NOS",pgx:icdot-C22.0,Liver,NCIT:C27971,Stage IV,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P75Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,TP53
5bab56c4727983b2e00acac6,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,hepatocellular carcinoma [hepatitis B liver cirrhosis],PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C3099,Hepatocellular Carcinoma,icdom-81703,"Hepatocellular carcinoma, NOS",icdot-C22.0,Liver,pgxbs-kftvgr3p,P60Y,pgxind-kftx2j30,pgxcs-kftvoonr,536768118,0.187,351382248,0.122,185385870,0.064,PGX_AM_BS_HCC-CC-hom-66,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:17.477000,T4,NCITstage-C27971,Stage IV,TNM-C48732,T4 Stage Finding,,,,,,,1,3.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr3p,,,pgxcs-kftvoonr,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-66,hepatocellular carcinoma [hepatitis B liver cirrhosis],NCIT:C3099,Hepatocellular Carcinoma,pgx:icdom-81703,"Hepatocellular carcinoma, NOS",pgx:icdot-C22.0,Liver,NCIT:C27971,Stage IV,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P60Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,TP53
5bab56c4727983b2e00acacb,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,hepatocellular carcinoma [hepatitis B liver cirrhosis],PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C3099,Hepatocellular Carcinoma,icdom-81703,"Hepatocellular carcinoma, NOS",icdot-C22.0,Liver,pgxbs-kftvgr3x,P33Y,pgxind-kftx2j3a,pgxcs-kftvooq9,1079977303,0.376,688510039,0.239,391467264,0.136,PGX_AM_BS_HCC-CC-hom-71,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:17.484000,T4,NCITstage-C27971,Stage IV,TNM-C48732,T4 Stage Finding,,,,,,,1,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr3x,,,pgxcs-kftvooq9,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-71,hepatocellular carcinoma [hepatitis B liver cirrhosis],NCIT:C3099,Hepatocellular Carcinoma,pgx:icdom-81703,"Hepatocellular carcinoma, NOS",pgx:icdot-C22.0,Liver,NCIT:C27971,Stage IV,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P33Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,TP53
5bab56cc727983b2e00b07e8,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,hepatoblastoma [Embryonal],PMID:11509117,"Kumon K, Kobayashi H et al. (2001): Frequent increase of DNA copy number...",NCIT:C3728,Hepatoblastoma,icdom-89703,Hepatoblastoma,icdot-C22.0,Liver,pgxbs-kftvhb0v,P0Y7M,pgxind-kftx37k0,pgxcs-kftvuro9,717132114,0.249,0,0.0,717132114,0.249,PGX_AM_BS_HepBlast-kum-991,{},137.95,35.83,Point,JPN,Ina,Japan,"Ina, Japan",35.83,137.95,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:39.513000,,,,,,,,,,,,0,80.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvhb0v,,,pgxcs-kftvuro9,PMID:11509117,,,,,,,,PGX_AM_BS_HepBlast-kum-991,hepatoblastoma [Embryonal],NCIT:C3728,Hepatoblastoma,pgx:icdom-89703,Hepatoblastoma,pgx:icdot-C22.0,Liver,NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P0Y7M,,,EFO:0030041,alive (follow-up status),,Ina,Japan,JPN,137.95::35.83,,,,,,,,,,TP53
5bab56cc727983b2e00b07c6,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,hepatoblastoma [Unclassifiable],PMID:11509117,"Kumon K, Kobayashi H et al. (2001): Frequent increase of DNA copy number...",NCIT:C3728,Hepatoblastoma,icdom-89703,Hepatoblastoma,icdot-C22.0,Liver,pgxbs-kftvhazc,P2Y,pgxind-kftx37i3,pgxcs-kftvur7q,426516644,0.148,129017282,0.045,297499362,0.103,PGX_AM_BS_HepBlast-kum-1107,{},137.95,35.83,Point,JPN,Ina,Japan,"Ina, Japan",35.83,137.95,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002107,liver,{},2020-09-10 17:44:39.465000,,,,,,,,,,,,1,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvhazc,,,pgxcs-kftvur7q,PMID:11509117,,,,,,,,PGX_AM_BS_HepBlast-kum-1107,hepatoblastoma [Unclassifiable],NCIT:C3728,Hepatoblastoma,pgx:icdom-89703,Hepatoblastoma,pgx:icdot-C22.0,Liver,NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0002107,liver,,,,P2Y,,,EFO:0030049,dead (follow-up status),,Ina,Japan,JPN,137.95::35.83,,,,,,,,,,TP53
5bab56c4727983b2e00acacd,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,combined hepatocellular carcinoma and cholangiocarcinoma,PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C3828,Combined Hepatocellular Carcinoma and Cholangiocarcinoma,icdom-81803,Combined hepatocellular carcinoma and cholangiocarcinoma,icdot-C22.1,intrahepatic bile ducts,pgxbs-kftvgr41,P65Y,pgxind-kftx2j3e,pgxcs-kftvoor8,999226216,0.348,563828115,0.196,435398101,0.151,PGX_AM_BS_HCC-CC-hom-73,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,{},2020-09-10 17:44:17.487000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,1,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgr41,,,pgxcs-kftvoor8,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-73,combined hepatocellular carcinoma and cholangiocarcinoma,NCIT:C3828,Combined Hepatocellular Carcinoma and Cholangiocarcinoma,pgx:icdom-81803,Combined hepatocellular carcinoma and cholangiocarcinoma,pgx:icdot-C22.1,Intrahepatic bile duct,NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,,,,P65Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,TP53
5bab56c4727983b2e00acace,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,combined hepatocellular carcinoma and cholangiocarcinoma,PMID:19200581,"Homayounfar K, Gunawan B et al. (2009): Pattern of chromosomal aberrations in primary...",NCIT:C3828,Combined Hepatocellular Carcinoma and Cholangiocarcinoma,icdom-81803,Combined hepatocellular carcinoma and cholangiocarcinoma,icdot-C22.1,intrahepatic bile ducts,pgxbs-kftvgr42,P66Y,pgxind-kftx2j3g,pgxcs-kftvoorq,1424239767,0.495,989376094,0.344,434863673,0.151,PGX_AM_BS_HCC-CC-hom-74,,9.93,51.53,Point,DEU,Goettingen,Germany,"Goettingen, Germany",51.53,9.93,city,Feature,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,{},2020-09-10 17:44:17.489000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,1,12.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgr42,,,pgxcs-kftvoorq,PMID:19200581,,,,,,,,PGX_AM_BS_HCC-CC-hom-74,combined hepatocellular carcinoma and cholangiocarcinoma,NCIT:C3828,Combined Hepatocellular Carcinoma and Cholangiocarcinoma,pgx:icdom-81803,Combined hepatocellular carcinoma and cholangiocarcinoma,pgx:icdot-C22.1,Intrahepatic bile duct,NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0003704,intrahepatic bile duct,,,,P66Y,,,EFO:0030049,dead (follow-up status),,Goettingen,Germany,DEU,9.93::51.53,,,,,,,,,,TP53
5bab56c6727983b2e00adaf6,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Squamous cell carcinoma [esophagus],PMID:17470683,"Hirasaki S, Noguchi T et al. (2007): BAC clones related to prognosis in...",NCIT:C4024,Esophageal Squamous Cell Carcinoma,icdom-80703,"Squamous cell carcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvgwah,,pgxind-kftx2pkh,pgxcs-kftvqang,2947212661,1.0,0,0.0,2947212661,1.0,PGX_AM_BS_EsSCC-hir-5,,131.5,33.28,Point,JPN,Beppu,Japan,"Beppu, Japan",33.28,131.5,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:23.211000,T1N1M0,NCITstage-C27966,Stage I,TNM-C48706,N1 Stage Finding,TNM-C48714,N3 Stage Finding,TNM-C48720,T1 Stage Finding,,,0,60.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pgxbs-kftvgwah,,,pgxcs-kftvqang,PMID:17470683,,,,,,,,PGX_AM_BS_EsSCC-hir-5,Squamous cell carcinoma [esophagus],NCIT:C4024,Esophageal Squamous Cell Carcinoma,pgx:icdom-80703,"Squamous cell carcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27966,Stage I,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,,,,EFO:0030041,alive (follow-up status),,Beppu,Japan,JPN,131.5::33.28,,,,,,,,,,TP53
5bab56c6727983b2e00adc66,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,squamous cell carcinoma [esophagus],PMID:17298740,"Wu SS, Liu JF et al. (2007): [Analyzing chromosomal abnormality in primary esophageal...",NCIT:C4024,Esophageal Squamous Cell Carcinoma,icdom-80703,"Squamous cell carcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvgwr6,,pgxind-kftx2q5d,pgxcs-kftvqfrs,846925028,0.295,345128655,0.12,501796373,0.175,PGX_AM_BS_17298740_ESCC-wu-10,{},116.4,39.91,Point,CHN,Beijing,China,"Beijing, China",39.91,116.4,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:23.720000,,,,,,,,,,,,0,36.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pgxbs-kftvgwr6,,,pgxcs-kftvqfrs,PMID:17298740,,,,,,,,PGX_AM_BS_17298740_ESCC-wu-10,squamous cell carcinoma [esophagus],NCIT:C4024,Esophageal Squamous Cell Carcinoma,pgx:icdom-80703,"Squamous cell carcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,,,,EFO:0030041,alive (follow-up status),,Beijing,China,CHN,116.4::39.91,,,,,,,,,,TP53
5bab56c6727983b2e00adc6a,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,squamous cell carcinoma [esophagus],PMID:17298740,"Wu SS, Liu JF et al. (2007): [Analyzing chromosomal abnormality in primary esophageal...",NCIT:C4024,Esophageal Squamous Cell Carcinoma,icdom-80703,"Squamous cell carcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvgwrc,,pgxind-kftx2q5l,pgxcs-kftvqftq,1021059741,0.355,58617675,0.02,962442066,0.335,PGX_AM_BS_17298740_ESCC-wu-14,{},116.4,39.91,Point,CHN,Beijing,China,"Beijing, China",39.91,116.4,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:23.726000,,,,,,,,,,,,0,36.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pgxbs-kftvgwrc,,,pgxcs-kftvqftq,PMID:17298740,,,,,,,,PGX_AM_BS_17298740_ESCC-wu-14,squamous cell carcinoma [esophagus],NCIT:C4024,Esophageal Squamous Cell Carcinoma,pgx:icdom-80703,"Squamous cell carcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,,,,EFO:0030041,alive (follow-up status),,Beijing,China,CHN,116.4::39.91,,,,,,,,,,TP53
5bab56c6727983b2e00adc6b,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,squamous cell carcinoma [esophagus],PMID:17298740,"Wu SS, Liu JF et al. (2007): [Analyzing chromosomal abnormality in primary esophageal...",NCIT:C4024,Esophageal Squamous Cell Carcinoma,icdom-80703,"Squamous cell carcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvgwre,,pgxind-kftx2q5n,pgxcs-kftvqfu8,283513568,0.099,0,0.0,283513568,0.099,PGX_AM_BS_17298740_ESCC-wu-15,{},116.4,39.91,Point,CHN,Beijing,China,"Beijing, China",39.91,116.4,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:23.727000,,,,,,,,,,,,0,36.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pgxbs-kftvgwre,,,pgxcs-kftvqfu8,PMID:17298740,,,,,,,,PGX_AM_BS_17298740_ESCC-wu-15,squamous cell carcinoma [esophagus],NCIT:C4024,Esophageal Squamous Cell Carcinoma,pgx:icdom-80703,"Squamous cell carcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,,,,EFO:0030041,alive (follow-up status),,Beijing,China,CHN,116.4::39.91,,,,,,,,,,TP53
5bab56c6727983b2e00adaef,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Squamous cell carcinoma [esophagus],PMID:17470683,"Hirasaki S, Noguchi T et al. (2007): BAC clones related to prognosis in...",NCIT:C4024,Esophageal Squamous Cell Carcinoma,icdom-80703,"Squamous cell carcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvgwa5,,pgxind-kftx2pk3,pgxcs-kftvqak2,1185569250,0.412,1107282179,0.385,78287071,0.027,PGX_AM_BS_EsSCC-hir-25,,131.5,33.28,Point,JPN,Beppu,Japan,"Beppu, Japan",33.28,131.5,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:23.201000,T3N1M1,NCITstage-C27970,Stage III,TNM-C48700,M1 Stage Finding,TNM-C48706,N1 Stage Finding,TNM-C48714,N3 Stage Finding,,,1,9.0,TNM-C48728,T3 Stage Finding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pgxbs-kftvgwa5,,,pgxcs-kftvqak2,PMID:17470683,,,,,,,,PGX_AM_BS_EsSCC-hir-25,Squamous cell carcinoma [esophagus],NCIT:C4024,Esophageal Squamous Cell Carcinoma,pgx:icdom-80703,"Squamous cell carcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,,,,EFO:0030049,dead (follow-up status),,Beppu,Japan,JPN,131.5::33.28,,,,,,,,,,TP53
5bab56c6727983b2e00adc5d,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,squamous cell carcinoma [esophagus],PMID:17298740,"Wu SS, Liu JF et al. (2007): [Analyzing chromosomal abnormality in primary esophageal...",NCIT:C4024,Esophageal Squamous Cell Carcinoma,icdom-80703,"Squamous cell carcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvgwqr,,pgxind-kftx2q4v,pgxcs-kftvqfnh,461859299,0.161,123531834,0.043,338327465,0.118,PGX_AM_BS_17298740_ESCC-wu-01,{},116.4,39.91,Point,CHN,Beijing,China,"Beijing, China",39.91,116.4,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:23.707000,,,,,,,,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pgxbs-kftvgwqr,,,pgxcs-kftvqfnh,PMID:17298740,,,,,,,,PGX_AM_BS_17298740_ESCC-wu-01,squamous cell carcinoma [esophagus],NCIT:C4024,Esophageal Squamous Cell Carcinoma,pgx:icdom-80703,"Squamous cell carcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,,,,EFO:0030049,dead (follow-up status),,Beijing,China,CHN,116.4::39.91,,,,,,,,,,TP53
5bab56c6727983b2e00adc61,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,squamous cell carcinoma [esophagus],PMID:17298740,"Wu SS, Liu JF et al. (2007): [Analyzing chromosomal abnormality in primary esophageal...",NCIT:C4024,Esophageal Squamous Cell Carcinoma,icdom-80703,"Squamous cell carcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvgwqx,,pgxind-kftx2q53,pgxcs-kftvqfpe,612223025,0.213,124817278,0.043,487405747,0.17,PGX_AM_BS_17298740_ESCC-wu-05,{},116.4,39.91,Point,CHN,Beijing,China,"Beijing, China",39.91,116.4,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:23.713000,,,,,,,,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pgxbs-kftvgwqx,,,pgxcs-kftvqfpe,PMID:17298740,,,,,,,,PGX_AM_BS_17298740_ESCC-wu-05,squamous cell carcinoma [esophagus],NCIT:C4024,Esophageal Squamous Cell Carcinoma,pgx:icdom-80703,"Squamous cell carcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,,,,EFO:0030049,dead (follow-up status),,Beijing,China,CHN,116.4::39.91,,,,,,,,,,TP53
5bab56c6727983b2e00adc62,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,squamous cell carcinoma [esophagus],PMID:17298740,"Wu SS, Liu JF et al. (2007): [Analyzing chromosomal abnormality in primary esophageal...",NCIT:C4024,Esophageal Squamous Cell Carcinoma,icdom-80703,"Squamous cell carcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvgwqz,,pgxind-kftx2q55,pgxcs-kftvqfpw,665397116,0.231,59500059,0.021,605897057,0.211,PGX_AM_BS_17298740_ESCC-wu-06,{},116.4,39.91,Point,CHN,Beijing,China,"Beijing, China",39.91,116.4,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:23.714000,,,,,,,,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,pgxbs-kftvgwqz,,,pgxcs-kftvqfpw,PMID:17298740,,,,,,,,PGX_AM_BS_17298740_ESCC-wu-06,squamous cell carcinoma [esophagus],NCIT:C4024,Esophageal Squamous Cell Carcinoma,pgx:icdom-80703,"Squamous cell carcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,,,,EFO:0030049,dead (follow-up status),,Beijing,China,CHN,116.4::39.91,,,,,,,,,,TP53
5bab56cb727983b2e00afcc2,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Esophageal squamous cell carcinoma,PMID:12419583,"Wei F, Ni J, Wu SS et al. (2002): Cytogenetic studies of esophageal squamous cell...",NCIT:C4024,Esophageal Squamous Cell Carcinoma,icdom-80703,"Squamous cell carcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvh7g4,,pgxind-kftx332w,pgxcs-kftvtnpy,1275822477,0.444,425326170,0.148,850496307,0.296,PGX_AM_BS_EsSCC-16,,116.4,39.91,Point,CHN,Beijing,China,"Beijing, China",39.91,116.4,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:35.573000,T3N0M0,NCITstage-C27970,Stage III,TNM-C48705,N0 Stage Finding,TNM-C48728,T3 Stage Finding,,,,,1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvh7g4,,,pgxcs-kftvtnpy,PMID:12419583,,,,,,,,PGX_AM_BS_EsSCC-16,Esophageal squamous cell carcinoma,NCIT:C4024,Esophageal Squamous Cell Carcinoma,pgx:icdom-80703,"Squamous cell carcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,,,,EFO:0030049,dead (follow-up status),,Beijing,China,CHN,116.4::39.91,,,,,,,,,,TP53
5bab56ce727983b2e00b197e,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,adenocarcinoma [esophagus],geo:GSM266075,,NCIT:C4025,Esophageal Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvhgz2,P65Y,pgxind-kftx3ekk,pgxcs-kftvwj5d,1001163624,0.348,592904485,0.206,408259139,0.142,PGX_AM_BS_GSM266075,,153.02,-27.45,Point,AUS,Herston,Australia,"Herston, Australia",-27.45,153.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:45.738000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,0,20.0,,,geo:GSE10506,,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),pgxcohort-2021progenetix,Version at Progenetix Update 2021,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),PMID:18519675,"Nancarrow DJ, Handoko HY et al. (2008): Genome-wide copy number analysis in esophageal...",geo:GPL5711,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvhgz2,,,pgxcs-kftvwj5d,PMID:18519675,,,,,,,,PGX_AM_BS_GSM266075,adenocarcinoma [esophagus],NCIT:C4025,Esophageal Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,P65Y,,,EFO:0030041,alive (follow-up status),,Herston,Australia,AUS,153.02::-27.45,,,,,geo:GSM266075,geo:GSE10506,geo:GPL5711,,,TP53
5bab56ce727983b2e00b1987,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,adenocarcinoma [esophagus],geo:GSM266707,,NCIT:C4025,Esophageal Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvhgzh,P78Y,pgxind-kftx3el2,pgxcs-kftvwj9t,1586895216,0.552,736921827,0.256,849973389,0.296,PGX_AM_BS_GSM266707,,153.02,-27.45,Point,AUS,Herston,Australia,"Herston, Australia",-27.45,153.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:45.751000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,0,15.0,,,PMID:18519675,"Nancarrow DJ, Handoko HY et al. (2008): Genome-wide copy number analysis in esophageal...",pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),pgxcohort-2021progenetix,Version at Progenetix Update 2021,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:GSE10506,,geo:GPL5711,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvhgzh,,,pgxcs-kftvwj9t,PMID:18519675,,,,,,,,PGX_AM_BS_GSM266707,adenocarcinoma [esophagus],NCIT:C4025,Esophageal Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27967,Stage IIa,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,P78Y,,,EFO:0030041,alive (follow-up status),,Herston,Australia,AUS,153.02::-27.45,,,,,geo:GSM266707,geo:GSE10506,geo:GPL5711,,,TP53
5bab56ce727983b2e00b197d,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,adenocarcinoma [esophagus],PMID:18519675,"Nancarrow DJ, Handoko HY et al. (2008): Genome-wide copy number analysis in esophageal...",NCIT:C4025,Esophageal Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C15.9,esophagus,pgxbs-kftvhgz1,P62Y,pgxind-kftx3eki,pgxcs-kftvwj4v,621290996,0.216,439452456,0.153,181838540,0.063,PGX_AM_BS_GSM266074,,153.02,-27.45,Point,AUS,Herston,Australia,"Herston, Australia",-27.45,153.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,{},2020-09-10 17:44:45.736000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,1,22.0,,,geo:GSE10506,,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),pgxcohort-2021progenetix,Version at Progenetix Update 2021,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:GSM266074,,geo:GPL5711,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvhgz1,,,pgxcs-kftvwj4v,PMID:18519675,,,,,,,,PGX_AM_BS_GSM266074,adenocarcinoma [esophagus],NCIT:C4025,Esophageal Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C15.9,"Esophagus, NOS",NCIT:C27967,Stage IIa,EFO:0009656,neoplastic sample,UBERON:0001043,esophagus,,,,P62Y,,,EFO:0030049,dead (follow-up status),,Herston,Australia,AUS,153.02::-27.45,,,,,geo:GSM266074,geo:GSE10506,geo:GPL5711,,,TP53
5bab56c7727983b2e00ae073,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,adenocarcinoma [colorectal; liver metastasis],PMID:17044061,"Habermann JK, Paulsen U et al. (2007): Stage-specific alterations of the genome, transcriptome,...",NCIT:C4349,Colon Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C18.9,"large intestine, excl. rectum and rectosigmoid junction",pgxbs-kftvgydc,P84Y,pgxind-kftx2rrd,pgxcs-kftvquas,1164222946,0.405,561494839,0.195,602728107,0.21,PGX_AM_BS_NCBISKYCGH-3736,{},-77.1,38.98,Point,USA,Bethesda,United States of America,"Bethesda, United States",38.98,-77.1,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001155,colon,{},2020-09-10 17:44:25.151000,T0N0M1,,,TNM-C48699,M0 Stage Finding,TNM-C48700,M1 Stage Finding,TNM-C48705,N0 Stage Finding,,,0,48.0,TNM-C48719,T0 Stage Finding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgydc,,,pgxcs-kftvquas,PMID:17044061,,,,,,,,PGX_AM_BS_NCBISKYCGH-3736,adenocarcinoma [colorectal; liver metastasis],NCIT:C4349,Colon Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C18.9,"Colon, NOS",NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0001155,colon,,,,P84Y,,,EFO:0030041,alive (follow-up status),,Bethesda,United States of America,USA,-77.1::38.98,,,,,,,,,,TP53
5bab56c7727983b2e00ae075,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,adenocarcinoma [colorectal; liver metastasis],PMID:17044061,"Habermann JK, Paulsen U et al. (2007): Stage-specific alterations of the genome, transcriptome,...",NCIT:C4349,Colon Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C18.9,"large intestine, excl. rectum and rectosigmoid junction",pgxbs-kftvgydf,P64Y,pgxind-kftx2rrh,pgxcs-kftvqubr,297292052,0.103,224217377,0.078,73074675,0.025,PGX_AM_BS_NCBISKYCGH-3738,{},-77.1,38.98,Point,USA,Bethesda,United States of America,"Bethesda, United States",38.98,-77.1,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001155,colon,{},2020-09-10 17:44:25.154000,T0N0M1,,,TNM-C48699,M0 Stage Finding,TNM-C48700,M1 Stage Finding,TNM-C48705,N0 Stage Finding,,,0,40.0,TNM-C48719,T0 Stage Finding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgydf,,,pgxcs-kftvqubr,PMID:17044061,,,,,,,,PGX_AM_BS_NCBISKYCGH-3738,adenocarcinoma [colorectal; liver metastasis],NCIT:C4349,Colon Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C18.9,"Colon, NOS",NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0001155,colon,,,,P64Y,,,EFO:0030041,alive (follow-up status),,Bethesda,United States of America,USA,-77.1::38.98,,,,,,,,,,TP53
5bab56c7727983b2e00ae063,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,adenocarcinoma [colon ascendens],PMID:17044061,"Habermann JK, Paulsen U et al. (2007): Stage-specific alterations of the genome, transcriptome,...",NCIT:C4349,Colon Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C18.9,"large intestine, excl. rectum and rectosigmoid junction",pgxbs-kftvgycm,P65Y,pgxind-kftx2rqh,pgxcs-kftvqu2t,1465371574,0.51,762822628,0.265,702548946,0.244,PGX_AM_BS_NCBISKYCGH-3718,,-77.1,38.98,Point,USA,Bethesda,United States of America,"Bethesda, United States",38.98,-77.1,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001155,colon,{},2020-09-10 17:44:25.129000,T3N2M1,NCITstage-C27970,Stage III,TNM-C48700,M1 Stage Finding,TNM-C48786,N2 Stage Finding,TNM-C48728,T3 Stage Finding,,,1,7.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgycm,,,pgxcs-kftvqu2t,PMID:17044061,,,,,,,,PGX_AM_BS_NCBISKYCGH-3718,adenocarcinoma [colon ascendens],NCIT:C4349,Colon Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C18.9,"Colon, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001155,colon,,,,P65Y,,,EFO:0030049,dead (follow-up status),,Bethesda,United States of America,USA,-77.1::38.98,,,,,,,,,,TP53
5c865b3909d374f2dc2b8df3,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,"colorectal carcinoma [left, well differentiated, lymph node metastasis]",geo:GSM288055,,NCIT:C4349,Colon Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C18.9,"Colon, NOS",pgxbs-kftvia3a,P85Y6M,pgxind-kftx3wu5,pgxcs-kftw5mvq,996088947,0.346,621048336,0.216,375040611,0.13,PGX_AM_BS_GSM288055,,139.85,36.4,Point,JPN,Shimotsuke-shi,Japan,"Shimotsuke-shi, Japan",36.4,139.85,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001155,colon,{},2020-09-10 17:45:18.317000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,1,17.0,,,PMID:18564138,"Kurashina K, Yamashita Y et al. (2008): Chromosome copy number analysis in screening...",pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),pgxcohort-2021progenetix,Version at Progenetix Update 2021,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:GPL2005,,geo:GSE11417,,geo:gsm,pubmed,geo:gpl,,,,,,geo:gse,,,,arraymap import,0.2,SNP2pop 1000 Genomes population,HANCESTRO:0027,Han Chinese,0.16,SNP2pop 1000 Genomes superpopulation,HANCESTRO:0009,East Asian,,,,,,,,,,,,F,pgxbs-kftvia3a,,,pgxcs-kftw5mvq,PMID:18564138,,,,,,,,PGX_AM_BS_GSM288055,"colorectal carcinoma [left, well differentiated, lymph node metastasis]",NCIT:C4349,Colon Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C18.9,"Colon, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001155,colon,,,,P85Y6M,,,EFO:0030039,no followup status,,Shimotsuke-shi,Japan,JPN,139.85::36.4,,,,,geo:GSM288055,geo:GSE11417,geo:GPL2005,,,TP53
5c865b3a09d374f2dc2b8e0c,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,"colorectal carcinoma [right, moderately differentiated, lymph node metastasis]",geo:GSM288103,,NCIT:C4349,Colon Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C18.9,"Colon, NOS",pgxbs-kftvia4g,P83Y6M,pgxind-kftx3wvk,pgxcs-kftw5nla,849174237,0.295,385438054,0.134,463736183,0.161,PGX_AM_BS_GSM288103,,139.85,36.4,Point,JPN,Shimotsuke-shi,Japan,"Shimotsuke-shi, Japan",36.4,139.85,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001155,colon,{},2020-09-10 17:45:18.352000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,1,5.4,,,geo:GPL2005,,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),pgxcohort-2021progenetix,Version at Progenetix Update 2021,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:GSE11417,,PMID:18564138,"Kurashina K, Yamashita Y et al. (2008): Chromosome copy number analysis in screening...",geo:gsm,geo:gpl,geo:gse,,,,,,pubmed,,,,arraymap import,0.24,SNP2pop 1000 Genomes population,HANCESTRO:0027,Han Chinese,0.14,SNP2pop 1000 Genomes superpopulation,HANCESTRO:0009,East Asian,,,,,,,,,,,,M,pgxbs-kftvia4g,,,pgxcs-kftw5nla,PMID:18564138,,,,,,,,PGX_AM_BS_GSM288103,"colorectal carcinoma [right, moderately differentiated, lymph node metastasis]",NCIT:C4349,Colon Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C18.9,"Colon, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001155,colon,,,,P83Y6M,,,EFO:0030039,no followup status,,Shimotsuke-shi,Japan,JPN,139.85::36.4,,,,,geo:GSM288103,geo:GSE11417,geo:GPL2005,,,TP53
5c865b3a09d374f2dc2b8e0d,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,"colorectal carcinoma [left, well differentiated]",geo:GSM288081,,NCIT:C4349,Colon Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C18.9,"Colon, NOS",pgxbs-kftvia4h,P89Y6M,pgxind-kftx3wvm,pgxcs-kftw5n8a,610768652,0.212,382121149,0.133,228647503,0.08,PGX_AM_BS_GSM288081,,139.85,36.4,Point,JPN,Shimotsuke-shi,Japan,"Shimotsuke-shi, Japan",36.4,139.85,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001155,colon,{},2020-09-10 17:45:18.354000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,1,38.17,,,PMID:18564138,"Kurashina K, Yamashita Y et al. (2008): Chromosome copy number analysis in screening...",pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),pgxcohort-2021progenetix,Version at Progenetix Update 2021,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:GSE11417,,geo:GPL2005,,geo:gsm,pubmed,geo:gse,,,,,,geo:gpl,,,,arraymap import,0.22,SNP2pop 1000 Genomes population,HANCESTRO:0027,Han Chinese,0.16,SNP2pop 1000 Genomes superpopulation,HANCESTRO:0009,East Asian,,,,,,,,,,,,M,pgxbs-kftvia4h,,,pgxcs-kftw5n8a,PMID:18564138,,,,,,,,PGX_AM_BS_GSM288081,"colorectal carcinoma [left, well differentiated]",NCIT:C4349,Colon Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C18.9,"Colon, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001155,colon,,,,P89Y6M,,,EFO:0030039,no followup status,,Shimotsuke-shi,Japan,JPN,139.85::36.4,,,,,geo:GSM288081,geo:GSE11417,geo:GPL2005,,,TP53
5c865b3b09d374f2dc2b8e43,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,"colorectal carcinoma [right, mucinous, lymph node metastasis]",geo:GSM288135,,NCIT:C4349,Colon Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C18.9,"Colon, NOS",pgxbs-kftvia6y,P54Y6M,pgxind-kftx3wyp,pgxcs-kftw5o0s,693083075,0.241,423682992,0.147,269400083,0.094,PGX_AM_BS_GSM288135,,139.85,36.4,Point,JPN,Shimotsuke-shi,Japan,"Shimotsuke-shi, Japan",36.4,139.85,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001155,colon,{},2020-09-10 17:45:18.430000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,1,35.2,,,PMID:18564138,"Kurashina K, Yamashita Y et al. (2008): Chromosome copy number analysis in screening...",pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),pgxcohort-2021progenetix,Version at Progenetix Update 2021,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:GSE11417,,geo:GPL2005,,geo:gsm,pubmed,geo:gse,,,,,,geo:gpl,,,,arraymap import,0.1,SNP2pop 1000 Genomes population,HANCESTRO:0027,Han Chinese,0.56,SNP2pop 1000 Genomes superpopulation,HANCESTRO:0009,East Asian,,,,,,,,,,,,F,pgxbs-kftvia6y,,,pgxcs-kftw5o0s,PMID:18564138,,,,,,,,PGX_AM_BS_GSM288135,"colorectal carcinoma [right, mucinous, lymph node metastasis]",NCIT:C4349,Colon Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C18.9,"Colon, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001155,colon,,,,P54Y6M,,,EFO:0030039,no followup status,,Shimotsuke-shi,Japan,JPN,139.85::36.4,,,,,geo:GSM288135,geo:GSE11417,geo:GPL2005,,,TP53
5c865b3b09d374f2dc2b8e4f,pgxcohort-arraymap,arrayMap collection,DUO:0000004,no restriction,"colorectal carcinoma [left, well differentiated, lymph node metastasis]",PMID:18564138,"Kurashina K, Yamashita Y et al. (2008): Chromosome copy number analysis in screening...",NCIT:C4349,Colon Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C18.9,"Colon, NOS",pgxbs-kftvia7j,P86Y6M,pgxind-kftx3wzb,pgxcs-kftw5o6l,883968574,0.307,546023174,0.19,337945400,0.118,PGX_AM_BS_GSM288147,,139.85,36.4,Point,JPN,Shimotsuke-shi,Japan,"Shimotsuke-shi, Japan",36.4,139.85,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001155,colon,{},2020-09-10 17:45:18.447000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,1,17.37,,,geo:GPL2005,,pgxcohort-gao2021signatures,Gao and Baudis - Cancer CNV Signatures (2021),pgxcohort-2021progenetix,Version at Progenetix Update 2021,pgxcohort-carriocordo2021heterogeneity,Carrio-Cordo and Baudis - Genomic Heterogeneity in Cancer Types (2021),geo:GSE11417,,geo:GSM288147,,pubmed,geo:gpl,geo:gse,,,,,,geo:gsm,,,,arraymap import,0.12,SNP2pop 1000 Genomes population,HANCESTRO:0027,Han Chinese,0.52,SNP2pop 1000 Genomes superpopulation,HANCESTRO:0009,East Asian,,,,,,,,,,,,F,pgxbs-kftvia7j,,,pgxcs-kftw5o6l,PMID:18564138,,,,,,,,PGX_AM_BS_GSM288147,"colorectal carcinoma [left, well differentiated, lymph node metastasis]",NCIT:C4349,Colon Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C18.9,"Colon, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001155,colon,,,,P86Y6M,,,EFO:0030039,no followup status,,Shimotsuke-shi,Japan,JPN,139.85::36.4,,,,,geo:GSM288147,geo:GSE11417,geo:GPL2005,,,TP53
5bab56c7727983b2e00ae070,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"adenocarcinoma [sigma, liver metastasis]",PMID:17044061,"Habermann JK, Paulsen U et al. (2007): Stage-specific alterations of the genome, transcriptome,...",NCIT:C43584,Rectosigmoid Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C18.7,sigmoid incl. rectosigmoid junction,pgxbs-kftvgyd7,P76Y,pgxind-kftx2rr7,pgxcs-kftvqu97,1066921802,0.371,492068466,0.171,574853336,0.2,PGX_AM_BS_NCBISKYCGH-3732,,-77.1,38.98,Point,USA,Bethesda,United States of America,"Bethesda, United States",38.98,-77.1,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001155,colon,{},2020-09-10 17:44:25.147000,T3N2M1,NCITstage-C27970,Stage III,TNM-C48700,M1 Stage Finding,TNM-C48786,N2 Stage Finding,TNM-C48728,T3 Stage Finding,,,1,42.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgyd7,,,pgxcs-kftvqu97,PMID:17044061,,,,,,,,PGX_AM_BS_NCBISKYCGH-3732,"adenocarcinoma [sigma, liver metastasis]",NCIT:C43584,Rectosigmoid Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C18.7,Sigmoid colon,NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001155,colon,,,,P76Y,,,EFO:0030049,dead (follow-up status),,Bethesda,United States of America,USA,-77.1::38.98,,,,,,,,,,TP53
5bab56c9727983b2e00aef8a,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"Mucinous colorectal carcinoma [Sigmoid colon, pT3N0M1, stage V]",PMID:15289862,"Liu XP, Sato T, Oga A et al. (2004): Two subtypes of mucinous colorectal carcinoma...",NCIT:C43592,Rectosigmoid Mucinous Adenocarcinoma,icdom-84803,Mucinous adenocarcinoma,icdot-C18.7,sigmoid incl. rectosigmoid junction,pgxbs-kftvh37p,P69Y,pgxind-kftx2xsm,pgxcs-kftvscdj,638432734,0.222,358733219,0.125,279699515,0.097,PGX_AM_BS_MucCoCa-liu-17,,131.47,34.19,Point,JPN,Yamaguchi-shi,Japan,"Yamaguchi-shi, Japan",34.19,131.47,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001155,colon,{},2020-09-10 17:44:30.893000,T3N0M1,NCITstage-C27970,Stage III,TNM-C48700,M1 Stage Finding,TNM-C48705,N0 Stage Finding,TNM-C48728,T3 Stage Finding,,,1,40.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvh37p,,,pgxcs-kftvscdj,PMID:15289862,,,,,,,,PGX_AM_BS_MucCoCa-liu-17,"Mucinous colorectal carcinoma [Sigmoid colon, pT3N0M1, stage V]",NCIT:C43592,Rectosigmoid Mucinous Adenocarcinoma,pgx:icdom-84803,Mucinous adenocarcinoma,pgx:icdot-C18.7,Sigmoid colon,NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001155,colon,,,,P69Y,,,EFO:0030049,dead (follow-up status),,Yamaguchi-shi,Japan,JPN,131.47::34.19,,,,,,,,,,TP53
5bab56c6727983b2e00adaaa,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Enteropathy type T-cell lymphoma,PMID:17484883,"Deleeuw RJ, Zettl A et al. (2007): Whole-genome analysis and HLA genotyping of...",NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,icdom-97173,Intestinal T-cell lymphoma,icdot-C17.9,small intestine,pgxbs-kftvgw71,P48Y,pgxind-kftx2pg6,pgxcs-kftvq9l6,657385279,0.229,511727268,0.178,145658011,0.051,PGX_AM_BS_EntTNHL-del-01,{},-123.12,49.25,Point,CAN,Vancouver,Canada,"Vancouver, Canada",49.25,-123.12,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002108,small intestine,{},2020-09-10 17:44:23.107000,,,,,,,,,,,,1,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgw71,,,pgxcs-kftvq9l6,PMID:17484883,,,,,,,,PGX_AM_BS_EntTNHL-del-01,Enteropathy type T-cell lymphoma,NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,pgx:icdom-97173,Intestinal T-cell lymphoma,pgx:icdot-C17.9,"Small intestine, NOS",NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0002108,small intestine,,,,P48Y,,,EFO:0030049,dead (follow-up status),,Vancouver,Canada,CAN,-123.12::49.25,,,,,,,,,,TP53
5bab56c6727983b2e00adaad,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Enteropathy type T-cell lymphoma,PMID:17484883,"Deleeuw RJ, Zettl A et al. (2007): Whole-genome analysis and HLA genotyping of...",NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,icdom-97173,Intestinal T-cell lymphoma,icdot-C17.9,small intestine,pgxbs-kftvgw76,P73Y,pgxind-kftx2pgc,pgxcs-kftvq9mo,459360518,0.16,112800109,0.039,346560409,0.121,PGX_AM_BS_EntTNHL-del-04,{},-123.12,49.25,Point,CAN,Vancouver,Canada,"Vancouver, Canada",49.25,-123.12,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002108,small intestine,{},2020-09-10 17:44:23.111000,,,,,,,,,,,,1,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgw76,,,pgxcs-kftvq9mo,PMID:17484883,,,,,,,,PGX_AM_BS_EntTNHL-del-04,Enteropathy type T-cell lymphoma,NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,pgx:icdom-97173,Intestinal T-cell lymphoma,pgx:icdot-C17.9,"Small intestine, NOS",NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0002108,small intestine,,,,P73Y,,,EFO:0030049,dead (follow-up status),,Vancouver,Canada,CAN,-123.12::49.25,,,,,,,,,,TP53
5bab56c6727983b2e00adab8,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Enteropathy type T-cell lymphoma,PMID:17484883,"Deleeuw RJ, Zettl A et al. (2007): Whole-genome analysis and HLA genotyping of...",NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,icdom-97173,Intestinal T-cell lymphoma,icdot-C17.9,small intestine,pgxbs-kftvgw7n,P50Y,pgxind-kftx2pgy,pgxcs-kftvq9tu,524816259,0.183,265002246,0.092,259814013,0.09,PGX_AM_BS_EntTNHL-del-15,{},-123.12,49.25,Point,CAN,Vancouver,Canada,"Vancouver, Canada",49.25,-123.12,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002108,small intestine,{},2020-09-10 17:44:23.126000,,,,,,,,,,,,1,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgw7n,,,pgxcs-kftvq9tu,PMID:17484883,,,,,,,,PGX_AM_BS_EntTNHL-del-15,Enteropathy type T-cell lymphoma,NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,pgx:icdom-97173,Intestinal T-cell lymphoma,pgx:icdot-C17.9,"Small intestine, NOS",NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0002108,small intestine,,,,P50Y,,,EFO:0030049,dead (follow-up status),,Vancouver,Canada,CAN,-123.12::49.25,,,,,,,,,,TP53
5bab56c6727983b2e00adac0,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Enteropathy type T-cell lymphoma,PMID:17484883,"Deleeuw RJ, Zettl A et al. (2007): Whole-genome analysis and HLA genotyping of...",NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,icdom-97173,Intestinal T-cell lymphoma,icdot-C17.9,small intestine,pgxbs-kftvgw80,P85Y,pgxind-kftx2phf,pgxcs-kftvq9xp,735441988,0.256,137966470,0.048,597475518,0.208,PGX_AM_BS_EntTNHL-del-23,{},-123.12,49.25,Point,CAN,Vancouver,Canada,"Vancouver, Canada",49.25,-123.12,city,Feature,EFO:0009656,neoplastic sample,UBERON:0002108,small intestine,{},2020-09-10 17:44:23.137000,,,,,,,,,,,,1,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgw80,,,pgxcs-kftvq9xp,PMID:17484883,,,,,,,,PGX_AM_BS_EntTNHL-del-23,Enteropathy type T-cell lymphoma,NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,pgx:icdom-97173,Intestinal T-cell lymphoma,pgx:icdot-C17.9,"Small intestine, NOS",NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0002108,small intestine,,,,P85Y,,,EFO:0030049,dead (follow-up status),,Vancouver,Canada,CAN,-123.12::49.25,,,,,,,,,,TP53
5bab56cb727983b2e00afcf8,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Enteropathy-Type T-Cell Lymphoma [monomorphic with small- to medium-sized cells],PMID:12414511,"Zettl A, Ott G, Makulik A et al. (2002): Chromosomal gains at 9q characterize enteropathy-type...",NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,icdom-97173,Intestinal T-cell lymphoma,icdot-C26.9,unspecified digest. Organs,pgxbs-kftvh7ik,P39Y,pgxind-kftx335z,pgxcs-kftvtofs,372279815,0.129,82500082,0.029,289779733,0.101,PGX_AM_BS_EP-T-NHL-26,,9.95,49.79,Point,DEU,Wuerzburg,Germany,"Wuerzburg, Germany",49.79,9.95,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001007,digestive system,{},2020-09-10 17:44:35.648000,T4,NCITstage-C27971,Stage IV,TNM-C48732,T4 Stage Finding,,,,,,,1,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvh7ik,,,pgxcs-kftvtofs,PMID:12414511,,,,,,,,PGX_AM_BS_EP-T-NHL-26,Enteropathy-Type T-Cell Lymphoma [monomorphic with small- to medium-sized cells],NCIT:C4737,Enteropathy-Associated T-Cell Lymphoma,pgx:icdom-97173,Intestinal T-cell lymphoma,pgx:icdot-C26.9,"Gastrointestinal tract, NOS",NCIT:C27971,Stage IV,EFO:0009656,neoplastic sample,UBERON:0001007,digestive system,,,,P39Y,,,EFO:0030049,dead (follow-up status),,Wuerzburg,Germany,DEU,9.95::49.79,,,,,,,,,,TP53
5bab56c9727983b2e00aef7e,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"Mucinous colorectal carcinoma [Ascending colon, pT3N1M0, stage II]",PMID:15289862,"Liu XP, Sato T, Oga A et al. (2004): Two subtypes of mucinous colorectal carcinoma...",NCIT:C7966,Colon Mucinous Adenocarcinoma,icdom-84803,Mucinous adenocarcinoma,icdot-C18.9,"large intestine, excl. rectum and rectosigmoid junction",pgxbs-kftvh375,P70Y,pgxind-kftx2xry,pgxcs-kftvsc7r,42100041,0.015,22200022,0.008,19900019,0.007,PGX_AM_BS_MucCoCa-liu-05,,131.47,34.19,Point,JPN,Yamaguchi-shi,Japan,"Yamaguchi-shi, Japan",34.19,131.47,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001155,colon,{},2020-09-10 17:44:30.877000,T3N1M0,NCITstage-C28054,Stage II,TNM-C48706,N1 Stage Finding,TNM-C48714,N3 Stage Finding,TNM-C48728,T3 Stage Finding,,,0,111.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvh375,,,pgxcs-kftvsc7r,PMID:15289862,,,,,,,,PGX_AM_BS_MucCoCa-liu-05,"Mucinous colorectal carcinoma [Ascending colon, pT3N1M0, stage II]",NCIT:C7966,Colon Mucinous Adenocarcinoma,pgx:icdom-84803,Mucinous adenocarcinoma,pgx:icdot-C18.9,"Colon, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001155,colon,,,,P70Y,,,EFO:0030041,alive (follow-up status),,Yamaguchi-shi,Japan,JPN,131.47::34.19,,,,,,,,,,TP53
5bab56c9727983b2e00aef7f,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"Mucinous colorectal carcinoma [Cecum, pT3N0M0, stage I]",PMID:15289862,"Liu XP, Sato T, Oga A et al. (2004): Two subtypes of mucinous colorectal carcinoma...",NCIT:C7966,Colon Mucinous Adenocarcinoma,icdom-84803,Mucinous adenocarcinoma,icdot-C18.0,cecum,pgxbs-kftvh376,P44Y,pgxind-kftx2xs0,pgxcs-kftvsc8a,95900096,0.033,22200022,0.008,73700074,0.026,PGX_AM_BS_MucCoCa-liu-06,,131.47,34.19,Point,JPN,Yamaguchi-shi,Japan,"Yamaguchi-shi, Japan",34.19,131.47,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000314,cecum mucosa,{},2020-09-10 17:44:30.878000,T3N0M0,NCITstage-C27966,Stage I,TNM-C48705,N0 Stage Finding,TNM-C48728,T3 Stage Finding,,,,,0,80.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvh376,,,pgxcs-kftvsc8a,PMID:15289862,,,,,,,,PGX_AM_BS_MucCoCa-liu-06,"Mucinous colorectal carcinoma [Cecum, pT3N0M0, stage I]",NCIT:C7966,Colon Mucinous Adenocarcinoma,pgx:icdom-84803,Mucinous adenocarcinoma,pgx:icdot-C18.0,Cecum,NCIT:C27966,Stage I,EFO:0009656,neoplastic sample,UBERON:0000314,cecum mucosa,,,,P44Y,,,EFO:0030041,alive (follow-up status),,Yamaguchi-shi,Japan,JPN,131.47::34.19,,,,,,,,,,TP53
5bab56c9727983b2e00aef82,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"Mucinous colorectal carcinoma [Ascending colon, pT3N1M0, stage II]",PMID:15289862,"Liu XP, Sato T, Oga A et al. (2004): Two subtypes of mucinous colorectal carcinoma...",NCIT:C7966,Colon Mucinous Adenocarcinoma,icdom-84803,Mucinous adenocarcinoma,icdot-C18.9,"large intestine, excl. rectum and rectosigmoid junction",pgxbs-kftvh37c,P60Y,pgxind-kftx2xs6,pgxcs-kftvsc9p,230649192,0.08,22200022,0.008,208449170,0.073,PGX_AM_BS_MucCoCa-liu-09,,131.47,34.19,Point,JPN,Yamaguchi-shi,Japan,"Yamaguchi-shi, Japan",34.19,131.47,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001155,colon,{},2020-09-10 17:44:30.882000,T3N1M0,NCITstage-C28054,Stage II,TNM-C48706,N1 Stage Finding,TNM-C48714,N3 Stage Finding,TNM-C48728,T3 Stage Finding,,,0,86.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvh37c,,,pgxcs-kftvsc9p,PMID:15289862,,,,,,,,PGX_AM_BS_MucCoCa-liu-09,"Mucinous colorectal carcinoma [Ascending colon, pT3N1M0, stage II]",NCIT:C7966,Colon Mucinous Adenocarcinoma,pgx:icdom-84803,Mucinous adenocarcinoma,pgx:icdot-C18.9,"Colon, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001155,colon,,,,P60Y,,,EFO:0030041,alive (follow-up status),,Yamaguchi-shi,Japan,JPN,131.47::34.19,,,,,,,,,,TP53
5bab56c9727983b2e00aef84,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"Mucinous colorectal carcinoma [Rectum [below], pT3N0M0, stage I]",PMID:15289862,"Liu XP, Sato T, Oga A et al. (2004): Two subtypes of mucinous colorectal carcinoma...",NCIT:C7966,Colon Mucinous Adenocarcinoma,icdom-84803,Mucinous adenocarcinoma,icdot-C18.9,"large intestine, excl. rectum and rectosigmoid junction",pgxbs-kftvh37f,P61Y,pgxind-kftx2xsa,pgxcs-kftvscao,252309302,0.088,118709168,0.041,133600134,0.046,PGX_AM_BS_MucCoCa-liu-11,,131.47,34.19,Point,JPN,Yamaguchi-shi,Japan,"Yamaguchi-shi, Japan",34.19,131.47,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001155,colon,{},2020-09-10 17:44:30.885000,T3N0M0,NCITstage-C27966,Stage I,TNM-C48705,N0 Stage Finding,TNM-C48728,T3 Stage Finding,,,,,0,113.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvh37f,,,pgxcs-kftvscao,PMID:15289862,,,,,,,,PGX_AM_BS_MucCoCa-liu-11,"Mucinous colorectal carcinoma [Rectum [below], pT3N0M0, stage I]",NCIT:C7966,Colon Mucinous Adenocarcinoma,pgx:icdom-84803,Mucinous adenocarcinoma,pgx:icdot-C18.9,"Colon, NOS",NCIT:C27966,Stage I,EFO:0009656,neoplastic sample,UBERON:0001155,colon,,,,P61Y,,,EFO:0030041,alive (follow-up status),,Yamaguchi-shi,Japan,JPN,131.47::34.19,,,,,,,,,,TP53
5bab56c9727983b2e00aef85,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"Mucinous colorectal carcinoma [Ascending colon, pT3N1M0, stage II]",PMID:15289862,"Liu XP, Sato T, Oga A et al. (2004): Two subtypes of mucinous colorectal carcinoma...",NCIT:C7966,Colon Mucinous Adenocarcinoma,icdom-84803,Mucinous adenocarcinoma,icdot-C18.9,"large intestine, excl. rectum and rectosigmoid junction",pgxbs-kftvh37h,P71Y,pgxind-kftx2xsc,pgxcs-kftvscb5,130400130,0.045,22200022,0.008,108200108,0.038,PGX_AM_BS_MucCoCa-liu-12,,131.47,34.19,Point,JPN,Yamaguchi-shi,Japan,"Yamaguchi-shi, Japan",34.19,131.47,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001155,colon,{},2020-09-10 17:44:30.886000,T3N1M0,NCITstage-C28054,Stage II,TNM-C48706,N1 Stage Finding,TNM-C48714,N3 Stage Finding,TNM-C48728,T3 Stage Finding,,,0,80.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvh37h,,,pgxcs-kftvscb5,PMID:15289862,,,,,,,,PGX_AM_BS_MucCoCa-liu-12,"Mucinous colorectal carcinoma [Ascending colon, pT3N1M0, stage II]",NCIT:C7966,Colon Mucinous Adenocarcinoma,pgx:icdom-84803,Mucinous adenocarcinoma,pgx:icdot-C18.9,"Colon, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001155,colon,,,,P71Y,,,EFO:0030041,alive (follow-up status),,Yamaguchi-shi,Japan,JPN,131.47::34.19,,,,,,,,,,TP53
5bab56c9727983b2e00aef89,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"Mucinous colorectal carcinoma [Rectum [above], pT3N1M0, stage II]",PMID:15289862,"Liu XP, Sato T, Oga A et al. (2004): Two subtypes of mucinous colorectal carcinoma...",NCIT:C7966,Colon Mucinous Adenocarcinoma,icdom-84803,Mucinous adenocarcinoma,icdot-C18.9,"large intestine, excl. rectum and rectosigmoid junction",pgxbs-kftvh37n,P75Y,pgxind-kftx2xsk,pgxcs-kftvscd1,1291929548,0.449,685440588,0.238,606488960,0.211,PGX_AM_BS_MucCoCa-liu-16,,131.47,34.19,Point,JPN,Yamaguchi-shi,Japan,"Yamaguchi-shi, Japan",34.19,131.47,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001155,colon,{},2020-09-10 17:44:30.892000,T3N1M0,NCITstage-C28054,Stage II,TNM-C48706,N1 Stage Finding,TNM-C48714,N3 Stage Finding,TNM-C48728,T3 Stage Finding,,,0,107.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvh37n,,,pgxcs-kftvscd1,PMID:15289862,,,,,,,,PGX_AM_BS_MucCoCa-liu-16,"Mucinous colorectal carcinoma [Rectum [above], pT3N1M0, stage II]",NCIT:C7966,Colon Mucinous Adenocarcinoma,pgx:icdom-84803,Mucinous adenocarcinoma,pgx:icdot-C18.9,"Colon, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001155,colon,,,,P75Y,,,EFO:0030041,alive (follow-up status),,Yamaguchi-shi,Japan,JPN,131.47::34.19,,,,,,,,,,TP53
5bab56c9727983b2e00aef8d,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"Mucinous colorectal carcinoma [Rectum [above], pT3N1M0, stage II]",PMID:15289862,"Liu XP, Sato T, Oga A et al. (2004): Two subtypes of mucinous colorectal carcinoma...",NCIT:C7966,Colon Mucinous Adenocarcinoma,icdom-84803,Mucinous adenocarcinoma,icdot-C18.9,"large intestine, excl. rectum and rectosigmoid junction",pgxbs-kftvh37u,P65Y,pgxind-kftx2xss,pgxcs-kftvscey,1495035193,0.52,699395763,0.243,795639430,0.277,PGX_AM_BS_MucCoCa-liu-20,,131.47,34.19,Point,JPN,Yamaguchi-shi,Japan,"Yamaguchi-shi, Japan",34.19,131.47,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001155,colon,{},2020-09-10 17:44:30.898000,T3N1M0,NCITstage-C28054,Stage II,TNM-C48706,N1 Stage Finding,TNM-C48714,N3 Stage Finding,TNM-C48728,T3 Stage Finding,,,0,100.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvh37u,,,pgxcs-kftvscey,PMID:15289862,,,,,,,,PGX_AM_BS_MucCoCa-liu-20,"Mucinous colorectal carcinoma [Rectum [above], pT3N1M0, stage II]",NCIT:C7966,Colon Mucinous Adenocarcinoma,pgx:icdom-84803,Mucinous adenocarcinoma,pgx:icdot-C18.9,"Colon, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001155,colon,,,,P65Y,,,EFO:0030041,alive (follow-up status),,Yamaguchi-shi,Japan,JPN,131.47::34.19,,,,,,,,,,TP53
5bab56c9727983b2e00aef8e,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"Mucinous colorectal carcinoma [Ascending colon, pT3N0M0, stage I]",PMID:15289862,"Liu XP, Sato T, Oga A et al. (2004): Two subtypes of mucinous colorectal carcinoma...",NCIT:C7966,Colon Mucinous Adenocarcinoma,icdom-84803,Mucinous adenocarcinoma,icdot-C18.9,"large intestine, excl. rectum and rectosigmoid junction",pgxbs-kftvh37w,P91Y,pgxind-kftx2xsu,pgxcs-kftvscfg,991861570,0.345,416560996,0.145,575300574,0.2,PGX_AM_BS_MucCoCa-liu-21,,131.47,34.19,Point,JPN,Yamaguchi-shi,Japan,"Yamaguchi-shi, Japan",34.19,131.47,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001155,colon,{},2020-09-10 17:44:30.899000,T3N0M0,NCITstage-C27966,Stage I,TNM-C48705,N0 Stage Finding,TNM-C48728,T3 Stage Finding,,,,,0,101.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvh37w,,,pgxcs-kftvscfg,PMID:15289862,,,,,,,,PGX_AM_BS_MucCoCa-liu-21,"Mucinous colorectal carcinoma [Ascending colon, pT3N0M0, stage I]",NCIT:C7966,Colon Mucinous Adenocarcinoma,pgx:icdom-84803,Mucinous adenocarcinoma,pgx:icdot-C18.9,"Colon, NOS",NCIT:C27966,Stage I,EFO:0009656,neoplastic sample,UBERON:0001155,colon,,,,P91Y,,,EFO:0030041,alive (follow-up status),,Yamaguchi-shi,Japan,JPN,131.47::34.19,,,,,,,,,,TP53
5bab56c9727983b2e00aef8b,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"Mucinous colorectal carcinoma [Rectum [above], pT3N1M0, stage II]",PMID:15289862,"Liu XP, Sato T, Oga A et al. (2004): Two subtypes of mucinous colorectal carcinoma...",NCIT:C7966,Colon Mucinous Adenocarcinoma,icdom-84803,Mucinous adenocarcinoma,icdot-C18.9,"large intestine, excl. rectum and rectosigmoid junction",pgxbs-kftvh37r,P48Y,pgxind-kftx2xso,pgxcs-kftvsce0,1203222347,0.419,255219287,0.089,948003060,0.33,PGX_AM_BS_MucCoCa-liu-18,,131.47,34.19,Point,JPN,Yamaguchi-shi,Japan,"Yamaguchi-shi, Japan",34.19,131.47,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001155,colon,{},2020-09-10 17:44:30.895000,T3N1M0,NCITstage-C28054,Stage II,TNM-C48706,N1 Stage Finding,TNM-C48714,N3 Stage Finding,TNM-C48728,T3 Stage Finding,,,1,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvh37r,,,pgxcs-kftvsce0,PMID:15289862,,,,,,,,PGX_AM_BS_MucCoCa-liu-18,"Mucinous colorectal carcinoma [Rectum [above], pT3N1M0, stage II]",NCIT:C7966,Colon Mucinous Adenocarcinoma,pgx:icdom-84803,Mucinous adenocarcinoma,pgx:icdot-C18.9,"Colon, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001155,colon,,,,P48Y,,,EFO:0030049,dead (follow-up status),,Yamaguchi-shi,Japan,JPN,131.47::34.19,,,,,,,,,,TP53
5bab56c9727983b2e00aef8c,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,"Mucinous colorectal carcinoma [Cecum, pT3N1M1, stage V]",PMID:15289862,"Liu XP, Sato T, Oga A et al. (2004): Two subtypes of mucinous colorectal carcinoma...",NCIT:C7966,Colon Mucinous Adenocarcinoma,icdom-84803,Mucinous adenocarcinoma,icdot-C18.0,cecum,pgxbs-kftvh37s,P57Y,pgxind-kftx2xsq,pgxcs-kftvsceh,674810044,0.235,127417281,0.044,547392763,0.19,PGX_AM_BS_MucCoCa-liu-19,,131.47,34.19,Point,JPN,Yamaguchi-shi,Japan,"Yamaguchi-shi, Japan",34.19,131.47,city,Feature,EFO:0009656,neoplastic sample,UBERON:0000314,cecum mucosa,{},2020-09-10 17:44:30.896000,T3N1M1,NCITstage-C27970,Stage III,TNM-C48700,M1 Stage Finding,TNM-C48706,N1 Stage Finding,TNM-C48714,N3 Stage Finding,,,1,11.0,TNM-C48728,T3 Stage Finding,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvh37s,,,pgxcs-kftvsceh,PMID:15289862,,,,,,,,PGX_AM_BS_MucCoCa-liu-19,"Mucinous colorectal carcinoma [Cecum, pT3N1M1, stage V]",NCIT:C7966,Colon Mucinous Adenocarcinoma,pgx:icdom-84803,Mucinous adenocarcinoma,pgx:icdot-C18.0,Cecum,NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0000314,cecum mucosa,,,,P57Y,,,EFO:0030049,dead (follow-up status),,Yamaguchi-shi,Japan,JPN,131.47::34.19,,,,,,,,,,TP53
5bab56c1727983b2e00ab6c9,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgknh,P49Y,pgxind-kftx2b4g,pgxcs-kftvmqmc,724756462,0.252,395806320,0.138,328950142,0.114,PGX_AM_BS_PDAC-sto-09,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.305000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,0,28.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgknh,,,pgxcs-kftvmqmc,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-09,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P49Y,,,EFO:0030041,alive (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,TP53
5bab56c1727983b2e00ab6ce,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgknp,P57Y,pgxind-kftx2b4q,pgxcs-kftvmqoo,375113607,0.13,261513494,0.091,113600113,0.04,PGX_AM_BS_PDAC-sto-14,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.313000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,0,23.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgknp,,,pgxcs-kftvmqoo,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-14,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P57Y,,,EFO:0030041,alive (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,TP53
5bab56c1727983b2e00ab6cf,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgknr,P60Y,pgxind-kftx2b4s,pgxcs-kftvmqp4,1000646239,0.348,481409208,0.167,519237031,0.181,PGX_AM_BS_PDAC-sto-15,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.314000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,0,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgknr,,,pgxcs-kftvmqp4,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-15,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P60Y,,,EFO:0030041,alive (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,TP53
5bab56c1727983b2e00ab6d4,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgknz,P82Y,pgxind-kftx2b52,pgxcs-kftvmqrg,724920445,0.252,121244691,0.042,603675754,0.21,PGX_AM_BS_PDAC-sto-20,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.322000,T1,NCITstage-C27966,Stage I,TNM-C48720,T1 Stage Finding,,,,,,,0,53.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgknz,,,pgxcs-kftvmqrg,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-20,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C27966,Stage I,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P82Y,,,EFO:0030041,alive (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,TP53
5bab56c1727983b2e00ab6d5,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgko1,P50Y,pgxind-kftx2b54,pgxcs-kftvmqrx,1235069614,0.43,541193772,0.188,693875842,0.241,PGX_AM_BS_PDAC-sto-21,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.323000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,0,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgko1,,,pgxcs-kftvmqrx,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-21,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P50Y,,,EFO:0030041,alive (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,TP53
5bab56c1727983b2e00ab6da,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgko9,P69Y,pgxind-kftx2b5e,pgxcs-kftvmqu9,98286250,0.034,35991469,0.013,62294781,0.022,PGX_AM_BS_PDAC-sto-26,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.330000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,0,52.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgko9,,,pgxcs-kftvmqu9,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-26,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P69Y,,,EFO:0030041,alive (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,TP53
5bab56c1727983b2e00ab6db,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgkoa,P66Y,pgxind-kftx2b5g,pgxcs-kftvmquq,868983507,0.302,295636758,0.103,573346749,0.199,PGX_AM_BS_PDAC-sto-27,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.332000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,0,51.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgkoa,,,pgxcs-kftvmquq,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-27,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P66Y,,,EFO:0030041,alive (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,TP53
5bab56c1727983b2e00ab6e3,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgkon,P72Y,pgxind-kftx2b5w,pgxcs-kftvmqyg,769921162,0.268,387606224,0.135,382314938,0.133,PGX_AM_BS_PDAC-sto-35,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.343000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,0,34.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgkon,,,pgxcs-kftvmqyg,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-35,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P72Y,,,EFO:0030041,alive (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,TP53
5bab56c1727983b2e00ab6eb,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgkp1,P55Y,pgxind-kftx2b6c,pgxcs-kftvmr41,954789148,0.332,426585707,0.148,528203441,0.184,PGX_AM_BS_PDAC-sto-43,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.355000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,0,11.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgkp1,,,pgxcs-kftvmr41,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-43,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P55Y,,,EFO:0030041,alive (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,TP53
5bab56c1727983b2e00ab6ec,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgkp2,P75Y,pgxind-kftx2b6e,pgxcs-kftvmr4j,857952241,0.298,456263490,0.159,401688751,0.14,PGX_AM_BS_PDAC-sto-44,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.356000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,0,12.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgkp2,,,pgxcs-kftvmr4j,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-44,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P75Y,,,EFO:0030041,alive (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,TP53
5bab56c1727983b2e00ab6ee,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgkp5,P62Y,pgxind-kftx2b6i,pgxcs-kftvmr5i,400557910,0.139,232355745,0.081,168202165,0.059,PGX_AM_BS_PDAC-sto-46,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.359000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,0,10.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgkp5,,,pgxcs-kftvmr5i,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-46,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P62Y,,,EFO:0030041,alive (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,TP53
5bab56c1727983b2e00ab6ef,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgkp7,P50Y,pgxind-kftx2b6k,pgxcs-kftvmr5z,454995441,0.158,202745470,0.071,252249971,0.088,PGX_AM_BS_PDAC-sto-47,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.360000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,0,17.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgkp7,,,pgxcs-kftvmr5z,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-47,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P50Y,,,EFO:0030041,alive (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,TP53
5bab56c1727983b2e00ab6f0,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgkp9,P68Y,pgxind-kftx2b6m,pgxcs-kftvmr6h,595273564,0.207,184545216,0.064,410728348,0.143,PGX_AM_BS_PDAC-sto-48,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.362000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,0,18.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgkp9,,,pgxcs-kftvmr6h,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-48,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P68Y,,,EFO:0030041,alive (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,TP53
5bab56c1727983b2e00ab6f1,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgkpa,P64Y,pgxind-kftx2b6o,pgxcs-kftvmr6x,1028256992,0.358,594551142,0.207,433705850,0.151,PGX_AM_BS_PDAC-sto-49,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.363000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,0,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgkpa,,,pgxcs-kftvmr6x,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-49,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P64Y,,,EFO:0030041,alive (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,TP53
5bab56c1727983b2e00ab6f2,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgkpc,P60Y,pgxind-kftx2b6p,pgxcs-kftvmr7e,468361000,0.163,435560967,0.151,32800033,0.011,PGX_AM_BS_PDAC-sto-50,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.364000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,0,8.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgkpc,,,pgxcs-kftvmr7e,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-50,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P60Y,,,EFO:0030041,alive (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,TP53
5bab56c1727983b2e00ab6c3,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgkn7,P53Y,pgxind-kftx2b44,pgxcs-kftvmqjk,285300282,0.099,112300110,0.039,173000172,0.06,PGX_AM_BS_PDAC-sto-03,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.297000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,1,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgkn7,,,pgxcs-kftvmqjk,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-03,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P53Y,,,EFO:0030049,dead (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,TP53
5bab56c1727983b2e00ab6c5,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgknb,P47Y,pgxind-kftx2b48,pgxcs-kftvmqkh,441223582,0.153,244808829,0.085,196414753,0.068,PGX_AM_BS_PDAC-sto-05,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.300000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,1,3.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgknb,,,pgxcs-kftvmqkh,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-05,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P47Y,,,EFO:0030049,dead (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,TP53
5bab56c1727983b2e00ab6c6,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgknc,P64Y,pgxind-kftx2b4a,pgxcs-kftvmqky,250841852,0.087,127853092,0.044,122988760,0.043,PGX_AM_BS_PDAC-sto-06,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.301000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,1,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgknc,,,pgxcs-kftvmqky,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-06,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P64Y,,,EFO:0030049,dead (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,TP53
5bab56c1727983b2e00ab6c8,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgkng,P67Y,pgxind-kftx2b4e,pgxcs-kftvmqlv,1035974486,0.36,488551666,0.17,547422820,0.19,PGX_AM_BS_PDAC-sto-08,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.304000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,1,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgkng,,,pgxcs-kftvmqlv,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-08,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P67Y,,,EFO:0030049,dead (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,TP53
5bab56c1727983b2e00ab6cd,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgkno,P73Y,pgxind-kftx2b4o,pgxcs-kftvmqo7,668198778,0.232,343120899,0.119,325077879,0.113,PGX_AM_BS_PDAC-sto-13,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.311000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,1,11.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgkno,,,pgxcs-kftvmqo7,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-13,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P73Y,,,EFO:0030049,dead (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,TP53
5bab56c1727983b2e00ab6d1,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgknu,P33Y,pgxind-kftx2b4w,pgxcs-kftvmqq2,930201938,0.324,353048690,0.123,577153248,0.201,PGX_AM_BS_PDAC-sto-17,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.317000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,1,10.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgknu,,,pgxcs-kftvmqq2,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-17,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P33Y,,,EFO:0030049,dead (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,TP53
5bab56c1727983b2e00ab6d6,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgko2,P60Y,pgxind-kftx2b56,pgxcs-kftvmqse,608243566,0.212,447781954,0.156,160461612,0.056,PGX_AM_BS_PDAC-sto-22,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.325000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,1,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgko2,,,pgxcs-kftvmqse,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-22,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P60Y,,,EFO:0030049,dead (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,TP53
5bab56c1727983b2e00ab6d7,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgko4,P45Y,pgxind-kftx2b58,pgxcs-kftvmqsv,1066992134,0.371,458952887,0.16,608039247,0.211,PGX_AM_BS_PDAC-sto-23,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.326000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,1,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgko4,,,pgxcs-kftvmqsv,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-23,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P45Y,,,EFO:0030049,dead (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,TP53
5bab56c1727983b2e00ab6d8,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgko6,P46Y,pgxind-kftx2b5a,pgxcs-kftvmqtc,863893971,0.3,390505142,0.136,473388829,0.165,PGX_AM_BS_PDAC-sto-24,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.328000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,1,14.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgko6,,,pgxcs-kftvmqtc,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-24,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P46Y,,,EFO:0030049,dead (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,TP53
5bab56c1727983b2e00ab6d9,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgko7,P63Y,pgxind-kftx2b5c,pgxcs-kftvmqts,494276606,0.172,249359376,0.087,244917230,0.085,PGX_AM_BS_PDAC-sto-25,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.329000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,1,13.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgko7,,,pgxcs-kftvmqts,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-25,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P63Y,,,EFO:0030049,dead (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,TP53
5bab56c1727983b2e00ab6dd,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgkoe,P56Y,pgxind-kftx2b5k,pgxcs-kftvmqvn,938293894,0.326,528454844,0.184,409839050,0.143,PGX_AM_BS_PDAC-sto-29,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.334000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,1,18.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgkoe,,,pgxcs-kftvmqvn,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-29,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P56Y,,,EFO:0030049,dead (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,TP53
5bab56c1727983b2e00ab6de,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgkof,P66Y,pgxind-kftx2b5m,pgxcs-kftvmqw4,1102861863,0.384,471612002,0.164,631249861,0.22,PGX_AM_BS_PDAC-sto-30,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.336000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,1,7.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgkof,,,pgxcs-kftvmqw4,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-30,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P66Y,,,EFO:0030049,dead (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,TP53
5bab56c1727983b2e00ab6df,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgkoh,P53Y,pgxind-kftx2b5o,pgxcs-kftvmqwl,1209663424,0.421,1011717945,0.352,197945479,0.069,PGX_AM_BS_PDAC-sto-31,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.337000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,1,16.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgkoh,,,pgxcs-kftvmqwl,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-31,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P53Y,,,EFO:0030049,dead (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,TP53
5bab56c1727983b2e00ab6e0,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgkoj,P33Y,pgxind-kftx2b5q,pgxcs-kftvmqx2,843773840,0.293,397858835,0.138,445915005,0.155,PGX_AM_BS_PDAC-sto-32,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.338000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,1,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgkoj,,,pgxcs-kftvmqx2,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-32,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P33Y,,,EFO:0030049,dead (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,TP53
5bab56c1727983b2e00ab6e1,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgkok,P54Y,pgxind-kftx2b5s,pgxcs-kftvmqxj,918386292,0.319,446532627,0.155,471853665,0.164,PGX_AM_BS_PDAC-sto-33,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.340000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,1,11.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgkok,,,pgxcs-kftvmqxj,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-33,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P54Y,,,EFO:0030049,dead (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,TP53
5bab56c1727983b2e00ab6e4,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgkop,P49Y,pgxind-kftx2b5y,pgxcs-kftvmqyx,388864561,0.135,252010997,0.088,136853564,0.048,PGX_AM_BS_PDAC-sto-36,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.344000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,1,12.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgkop,,,pgxcs-kftvmqyx,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-36,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P49Y,,,EFO:0030049,dead (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,TP53
5bab56c1727983b2e00ab6e5,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgkor,P56Y,pgxind-kftx2b60,pgxcs-kftvmqze,620998382,0.216,504959629,0.176,116038753,0.04,PGX_AM_BS_PDAC-sto-37,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.346000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,1,10.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgkor,,,pgxcs-kftvmqze,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-37,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P56Y,,,EFO:0030049,dead (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,TP53
5bab56c1727983b2e00ab6e6,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgkos,P43Y,pgxind-kftx2b62,pgxcs-kftvmqzu,443108326,0.154,177956247,0.062,265152079,0.092,PGX_AM_BS_PDAC-sto-38,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.347000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,1,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgkos,,,pgxcs-kftvmqzu,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-38,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P43Y,,,EFO:0030049,dead (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,TP53
5bab56c1727983b2e00ab6e8,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgkow,P58Y,pgxind-kftx2b66,pgxcs-kftvmr0r,664654804,0.231,396732106,0.138,267922698,0.093,PGX_AM_BS_PDAC-sto-40,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.350000,T2,NCITstage-C28054,Stage II,TNM-C48724,T2 Stage Finding,,,,,,,1,13.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgkow,,,pgxcs-kftvmr0r,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-40,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C28054,Stage II,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P58Y,,,EFO:0030049,dead (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,TP53
5bab56c1727983b2e00ab6ed,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,Pancreatic ductal Adenocarcinoma,PMID:22487468,"Luebke AM, Baudis M et al. (2012): Losses at chromosome 4q are associated...",NCIT:C8294,Pancreatic Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C25.9,"Pancreas, NOS",pgxbs-kftvgkp4,P63Y,pgxind-kftx2b6g,pgxcs-kftvmr51,658419457,0.229,530633644,0.185,127785813,0.044,PGX_AM_BS_PDAC-sto-45,,10.02,53.58,Point,DEU,Hamburg,Germany,"Hamburg, Germany",53.58,10.02,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,{},2020-09-10 17:44:10.357000,T3,NCITstage-C27970,Stage III,TNM-C48728,T3 Stage Finding,,,,,,,1,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgkp4,,,pgxcs-kftvmr51,PMID:22487468,,,,,,,,PGX_AM_BS_PDAC-sto-45,Pancreatic ductal Adenocarcinoma,NCIT:C8294,Pancreatic Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C25.9,"Pancreas, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001264,pancreas,,,,P63Y,,,EFO:0030049,dead (follow-up status),,Hamburg,Germany,DEU,10.02::53.58,,,,,,,,,,TP53
5bab56c7727983b2e00ae069,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,adenocarcinoma [rectum],PMID:17044061,"Habermann JK, Paulsen U et al. (2007): Stage-specific alterations of the genome, transcriptome,...",NCIT:C9383,Rectal Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C20.9,"Rectum, NOS",pgxbs-kftvgycw,P71Y,pgxind-kftx2rqt,pgxcs-kftvqu5s,954534975,0.332,501795515,0.175,452739460,0.157,PGX_AM_BS_NCBISKYCGH-3724,,-77.1,38.98,Point,USA,Bethesda,United States of America,"Bethesda, United States",38.98,-77.1,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001052,rectum,{},2020-09-10 17:44:25.137000,T3N1M0,NCITstage-C27970,Stage III,TNM-C48706,N1 Stage Finding,TNM-C48714,N3 Stage Finding,TNM-C48728,T3 Stage Finding,,,0,52.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,M,pgxbs-kftvgycw,,,pgxcs-kftvqu5s,PMID:17044061,,,,,,,,PGX_AM_BS_NCBISKYCGH-3724,adenocarcinoma [rectum],NCIT:C9383,Rectal Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C20.9,"Rectum, NOS",NCIT:C27970,Stage III,EFO:0009656,neoplastic sample,UBERON:0001052,rectum,,,,P71Y,,,EFO:0030041,alive (follow-up status),,Bethesda,United States of America,USA,-77.1::38.98,,,,,,,,,,TP53
5bab56c7727983b2e00ae061,pgxcohort-2021progenetix,Version at Progenetix Update 2021,DUO:0000004,no restriction,adenocarcinoma [rectum],PMID:17044061,"Habermann JK, Paulsen U et al. (2007): Stage-specific alterations of the genome, transcriptome,...",NCIT:C9383,Rectal Adenocarcinoma,icdom-81403,"Adenocarcinoma, NOS",icdot-C20.9,"Rectum, NOS",pgxbs-kftvgycj,P78Y,pgxind-kftx2rqd,pgxcs-kftvqu1v,622456014,0.217,319470785,0.111,302985229,0.105,PGX_AM_BS_NCBISKYCGH-3716,{},-77.1,38.98,Point,USA,Bethesda,United States of America,"Bethesda, United States",38.98,-77.1,city,Feature,EFO:0009656,neoplastic sample,UBERON:0001052,rectum,{},2020-09-10 17:44:25.126000,,,,,,,,,,,,1,45.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,F,pgxbs-kftvgycj,,,pgxcs-kftvqu1v,PMID:17044061,,,,,,,,PGX_AM_BS_NCBISKYCGH-3716,adenocarcinoma [rectum],NCIT:C9383,Rectal Adenocarcinoma,pgx:icdom-81403,"Adenocarcinoma, NOS",pgx:icdot-C20.9,"Rectum, NOS",NCIT:C92207,Stage Unknown,EFO:0009656,neoplastic sample,UBERON:0001052,rectum,,,,P78Y,,,EFO:0030049,dead (follow-up status),,Bethesda,United States of America,USA,-77.1::38.98,,,,,,,,,,TP53
